Investigating the interaction between PDE4D7 and DHX9 in the progression of prostate cancer by Busiau, Tara Simone
 
 
 
 
 
 
Busiau, Tara Simone (2021) Investigating the interaction between PDE4D7 
and DHX9 in the progression of prostate cancer. PhD thesis. 
 
http://theses.gla.ac.uk/81899/  
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
   1 
 
 
 
 
Investigating the interaction 
between PDE4D7 and DHX9 in 
the progression of prostate 
cancer  
 
 
Tara Simone Busiau 
BSc (Hons) Biomedical Sciences  
 
 
Submitted in fulfilment of the requirements for the Degree 
of Philosophy 
 
Institute of Cardiovascular and Medical Sciences 
College of Medical, Veterinary and Life Sciences 
 
 
University of Glasgow  
June 2020
   2 
Abstract 
Prostate cancer (PC) is the most commonly diagnosed disease in men, and is 
considered the second most likely cause of cancer-related death in the Western 
male population behind lung cancer. In recent years, the rate of disease 
detection has significantly increased in part due to the successful 
implementation of the prostate specific antigen (PSA) testing in clinics. 
Currently, PC is positively diagnosed when PSA levels are detected to be over 4.0 
ng/mL in the blood plasma. However, increasing evidence has shown that this 
number is often misleading and inaccurate. The prostate is known to have a very 
good blood supply, therefore small amounts of PSA can always be detected. 
Furthermore, the PSA reflects the state of the whole gland itself rather than 
indicating the presence of a tumour at this site. As the availability of PSA testing 
increases, this has also resulted in the detection of false positives as some men 
have naturally higher levels of PSA than others. On the other hand, some cancers 
can go undetected as it may have progressed so far that it no longer expresses 
PSA. Following a positive diagnosis, the most common course of treatment 
prescribed is androgen deprivation therapy (ADT). ADT refers to the treatments 
that aim to reduce the effects of testosterone and other androgens by surgically 
or chemically preventing their production. Although ADT is known as the gold 
standard in PC treatment, approximately 15% of men fail to respond to this form 
of therapy. Furthermore, after a mean time of 13-19 months, some men become 
castration resistant and no longer respond to ADT.  
There is currently a need to identify novel biomarkers in order to accurately 
diagnose and stage the disease. Furthermore, new drug targets need to be 
identified in order to provide the best course of treatment. Previous work by the 
Baillie laboratory, in collaboration with Philips Diagnostics, recently identified 
phosphodiesterase 4D7 (PDE4D7) to be a novel prognostic marker for disease. 
PDE4D7 expression was shown to be decreased in PC cell lines and primary 
tumours as the disease progressed to the hormone independent state. The 3',5'-
cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) are known to 
play a role in disease progression as they mediate downstream signalling 
pathways that can promote cell growth and disease progression. PDE enzymes 
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are the only known enzyme family to hydrolyse cAMP, and loss of PDE4D7 
expression, in particular, during PC correlates with disease progression. 
Interestingly, DHX9 has recently been identified as a novel interacting partner 
for PDE4D7. Work by Dr Ashleigh Byrne identified DHX9 as a novel interactor by 
using mass spectrometry, and since then DHX9 has become a subject of 
increased interest in the area of cancer research. DHX9 is an RNA/DNA helicase 
that is involved in multiple cellular processes, including transcription and 
maintaining genome stability. DHX9 expression is known to increase as cancers, 
such as lung and colorectal, progress towards their metastatic stages. Previous 
work by other lab groups have demonstrated that DHX9 is linked to multiple 
signalling pathways that are involved in cancer development, such as the mTOR 
and p53 pathway. Interestingly, DHX9 maps to the PC susceptibility locus, 
making it an interesting protein to study in the context of PC disease progression 
and metastasis.  
Work in this thesis provides further evidence that PDE4D7 and DHX9 proteins are 
novel interactors in PC. By using a series of biochemical techniques, PDE4D7 was 
shown to interact with DHX9 in androgen sensitive PC cell line. By using peptide 
array technology, I was able to map where this interaction took place and define 
docking sites on both protein partners. DHX9 was found to bind within the newly 
identified FLY multi docking site within the upstream conserved region-1 (UCR1) 
of PDE4D7. Furthermore, PDE4D7 was found to bind within DHX9’s helicase core 
domain, suggesting that it may play a role in regulating its activity. I was able to 
further validate these binding sites by designing cell permeable peptides 
designed to disrupt protein binding in vitro.  
Considering that many PKA substrates are found in complex with PDEs, DHX9 was 
found to be a PKA substrate in vitro. By using biochemical techniques, such as 
immunoprecipitations and proximity ligations assay, DHX9 was found to be 
readily phosphorylated by PKA, and this was significantly increased when cells 
were pre-treated with the adenylate cyclase activator forskolin and the general 
PDE inhibitor IBMX. By using peptide array technology and bioinformatic 
predictions, serine 449 within the helicase core of DHX9 was found to be in a 
PKA motif and phosphorylated by PKA. Interestingly, this serine can be found 
upstream of the PDE4D7 binding site. Disruption of the interaction between 
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PDE4D7 and DHX9 led to a significant increase in DHX9 phosphorylation, 
supporting the idea that PDE4D7 binding regulated DHX9 phosphorylation. Using 
the information gained in the peptide arrays, a phospho-specific antibody 
against DHX9 was raised. The newly synthesised antibody was able to detect 
phosphorylated DHX9 by western blotting and immunofluorescence with confocal 
microscopy. 
Although DHX9 is known to be differentially expressed in multiple cancers, little 
is known about its function in PC. Silencing of DHX9 expression using siRNA 
technology significantly inhibited PC cell growth. Interestingly, previous work by 
Erzikhan et al (2009) demonstrated that inhibiting DHX9’s oncogenic activity, by 
disrupting DHX9’s interaction with EWS-FL1 using YK-4-279, significantly 
decreased growth when assessed by xCELLigence technology. Unfortunately, 
disruption of this interaction between PDE4D7 and DHX9 did not alter the growth 
of PC cells following treatment with the cell permeable disruptor peptide. 
However, the disruption of the interaction between PDE4D7 and DHX9 
significantly decreased DHX9’s ability to promote R-loop formation when 
assessed by immunofluorescence and confocal microscopy. Using RPPA analysis, I 
was also able to show that the loss of DHX9 expression in PC cells can potentially 
affect the mTOR signalling pathway.  
To conclude, this thesis provides further evidence that PDE4D7 and DHX9 form a 
signalling complex that may be relevant in PC. I was able to map where these 
interactions took place and design cell permeable peptides that were able to 
disrupt this interaction. I was also able to show that DHX9 can be readily 
phosphorylated in vitro, and its phosphorylation is partly regulated by its 
interaction with PDE4D7. Loss of DHX9 expression, and interaction with EWS-FL1, 
significantly decreases cell growth, and this may partly be due to changes in 
mTOR pathways. However, future work on this topic is still needed. 
Unfortunately, due to time constraints, the functional implications of DHX9 
phosphorylation was not studied in this thesis and I was not able to use relevant 
human samples to further validate the relevance of my findings.
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Chapter 1 Introduction 
1.1 Advances in cancer research and treatment 
Since the 1970s, a dramatic reduction in the mortality rates of certain cancers 
has been observed, thanks to the use of classic therapeutic strategies such as 
chemotherapy, radiotherapy, and surgery (Alvarez and Besa, 2000). Despite this 
detection and treatment of cancer is increase in almost every country, becoming 
the most significant public health challenge in the 21st century (Bray et al., 
2018). Although cancer is the second leading cause of death in high income 
counties, the 5 year survival rate following treatment has increased to 70 % in 
2020, compared to 49 % in the 1970s (Schilsky et al., 2020). The complexity of 
cancer at a cellular and molecular level is often considered an obstacle to 
achieve important changes in the understanding of basic cellular and molecular 
changes that allow a cell to become cancerous (Alvarez and Besa, 2000). 
However, in the past decade, many researchers have focused on finding new 
drug targets and therapeutic strategies to overcome these obstacles (Pucci, 
Martinelli and Ciofani, 2019). 
1.1.1 Precision medicine 
Ove the past decade, it has become widely accepted that traditional cancer 
therapies are ineffective and expensive, often leading to unnecessary side 
effects. Current therapies do not take into the fact that no two patient cancers 
are the same, leading to different responses to treatments such as 
chemotherapy or radiation (Krzyszczyk et al., 2018). Recently, a shift from 
organ-centric treatment to a more personalised approach for treatment has 
greatly modernized the field. Tools such as next generation sequencing and RNA 
sequence has helped to identify novel druggable target for the treatment of 
different cancers (Gambardella et al., 2020). In recent years, RNA sequencing 
has become one of the most important tools for transcriptomic profiling. The 
revolutions from bulk RNA sequencing to single-cell sequencing has enabled 
researchers to identify novel biomarkers and characterise different types of 
cancer (Hong et al., 2020). To date, precision medicine has been proved to be 
highly successful in the identification of new targets in breast, and lung cancer, 
and in melanoma (Gambardella et al., 2020). Identifying specific molecular 
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changes, somatic or germline mutations, or gene fusions using these next 
generations techniques would allow doctors to tailor treatment to their specific 
cancer, resulting in better patient outcome (Kimmelman and Tannock, 2018). 
Precision medicine provides the best personalised therapies for cancer patients 
(Pucci, Martinelli and Ciofani, 2019). 
1.1.2 Novel Cancer Therapies 
During the last decade, traditional cancer therapy mainly consisted of 
chemotherapy which maximised damaged to the rapidly dividing cells. But this 
would often come at the expense of normal cells, leading to a poor quality of 
life to the patient. The development of new anticancer drugs has rapidly 
changed this, thanks to a greater understanding of tumour biology and cancer 
cells (Ramaswami, Harding and Newsom-Davis, 2013). These novel approaches 
aim to limit the damage to healthy normal cells, while enhacing tumour 
destruction (Shariff et al., 2019). 
One of these novel therapies aims to inhibit the epidermal growth factor 
receptor (EGFR). EGFR’s role in the body is to regulate epithelial tissue 
development and homeostasis. However, in cancer, EGFR is a driver of 
tumorigenesis, often caused by mutations, transcriptional upregulation, or ligand 
overproduction. (Sigismund, Avanzato and Lanzetti, 2018). EGFR is a tyrosine 
kinase receptor consisting of an extracellular ligand-binding domain, a 
transmembrane anchoring region, and an intracellular tyrosine kinase. Upon 
ligand binding, the receptor dimerises, leading to its phosphorylation. This in 
turn creates a docking site for numerous effector proteins such as PI3K (Gerber, 
2008). In recent years, EGFR has increasingly been recognised as a biomarker of 
resistance in tumours. Mutations and amplification of this receptor has been 
found to increase under drug pressure (Sigismund, Avanzato and Lanzetti, 2018). 
The identification of this novel biomarker has greatly impacted the treatment of 
non-small cell lung cancer (NSCLC). However, the introduction of EGFR inhibitors 
has greatly improved disease outcome (Gerber, 2008). First generation EGFR 
inhibitors, such as gefitinib and erlotinib, binds reversibly to the MgATP binding 
site within the EGFR tyrosine kinase catalytic domain. Studies have shown that 
binding of these drugs results in reduced cellular proliferation, increased 
apoptosis, and inhibition of cell migration (Lenz, 2006). Inhibition of the tyrosine 
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kinase region of EGFR leads to the greatest duration of disease control, the 
longest overall survival, and the best quality of life (Le and Gerber, 2019).  
In addition to inhibiting EGFR, immunotherapy has revolutionised the 
management of metastatic cancers (Le Saux et al., 2020). Immunotherapies 
against existing cancers include various approaches, ranging from stimulating the 
immune system to counteracting inhibitory and suppressive mechanisms 
(Farkona, Diamandis and Blasutig, 2016). Over the last decade, the primary 
approach to activate host T-cells against tumour antigens has been through 
therapeutic cancer vaccination, such as the vaccination against human 
papillomavirus (Mellman, Coukos and Dranoff, 2011). Alternatively, oncolytic 
viruses can be engineered in order to selectively replicate in and kill cancer cells 
(Kaufman, Kohlhapp and Zloza, 2015). These viruses can reduced tumour sizes 
by causing tumour cell infections, promoting cell lysis, or by inducing the 
antitumour immunity (Farkona, Diamandis and Blasutig, 2016). However, the 
most promising of the immunotherapies is the use of chimeric antigen receptor 
(CAR) engineered T-cells. CAR T-cell therapy involves genetically modifying a T-
cell to specifically express a chimeric antigen for a specific tumour antigen, the 
re-infused back into the patient. These engineered cells are then re-infused 
back into the patient (Miliotou and Papadopoulou, 2018). CAR T-cells has largely 
been successful in the treatment of haematological malignancies. Over the last 
10 years, clinical trial involving CAR T-cells engineered to express CD19 have 
shown high and durable response rate in patients suffering from acute 
lymphoblastic leukaemia and aggressive B-cell non-Hodgkin lymphomas (Leon, 
Ranganathan and Savoldo, 2020).  
1.1.3 Peptide mimetics for the treatment of cancer 
In addition to precisions medicine and immunotherapy, peptide therapeutic has 
become a promising field for emerging anti-cancer agents (Boohaker et al., 
2012). Protein-protein interaction have been recognised as key mediators of 
biological processes and the progression of certain cancers. So far, over 650 000 
disease relevant interactions have been identified, and the large majority of 
these have been deemed “undruggable” due to their highly dynamic nature. 
However, due to technological improvement, these interactions have slowly 
emerged as highly interesting drug targets (Mabonga and Kappo, 2020). By 
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identifying interacting regions that contain hot spots, defined as the residues 
which are crucial for interaction, researchers have been able to develop novel 
small molecule inhibitors to block interactions that are known to drive disease 
(Ma and Nussinov, 2014). Currently, there are over 60 approved peptide drugs 
for the treatment of different diseases, four of which have been approved for 
the treatment of cancer (Thundimadathil, 2012). Use of peptide in the 
treatment of cancer will be discussed in section 3.4.3. 
1.2 The human male prostate gland 
The prostate gland plays an important role in male reproduction. It contains a 
system of branching ducts composed of pseudo-stratified epithelium surrounded 
by a fibromuscular stroma. This gland secretes lipids, enzymes, amines, and 
metal ions that are essential in the normal function of spermatozoa. The gland 
itself is the source of some of the most common medical problems of men over 
the age of 40 (Toivanen and Shen, 2017). Benign inflammation of the prostate 
occurs in more than 50% of men within this age group, and post-mortem 
autopsies revealed that 31% of Caucasians and 51 % of African-American men 
between the age of 70-79 were found to have tumours within their prostate 
(Jahn, Giovannucci and Stampfer, 2015). Due to high occurrence of benign 
inflammation, the prostate is susceptible to oncogenic transformation at a 
significantly higher frequency than that of other accessory glands (Toivanen and 
Shen, 2017). 
The prostate surrounds the urethra at the neck of the urinary bladder. It is the 
size of a large walnut with a wide base on top. The gland is located underneath 
the floor of the bladder, and it’s narrow apex is directed towards the urogenital 
diaphragm (Aschoff et al., 2011). The prostatic gland is composed of two 
distinctive compartments: the epithelium and the stroma. These two 
compartments interact with each other via androgen receptors (AR) and this 
interplay is important in the development and differentiation of the prostate 
(Krušlin, Ulamec and Tomas, 2015). Structurally, it is organised anatomically 
into four zones: the peripheral (70%), central (25%), transition (5%), and anterior 
fibromuscular zones (Sidelsky, Setia and Vourganti, 2017) (Figure 1.1).  
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Figure 1.1 Structural organization of the prostate. The prostate is distributed into the peripheral, 
central, transition, and anterior fibromuscular zones. (Image adapted from Marzo et al. 2007). 
The main function of the stromal compartment of the prostate gland is to ensure 
an appropriate microenvironment for the epithelial compartment. It provides 
many supportive signals to retain or restore gland homeostasis in healthy 
conditions or during regeneration processes. In addition, the prostate epithelium 
has a glandular function as it secretes prostatic fluid that constitutes 
approximately one fifth to one third of the volume of the entire ejaculate. 
Prostatic fluid contains a number of factors that control the ejaculation process 
and regulate the proteins required to activate sperm maturation (Verze, Cai and 
Lorenzetti, 2016). 
1.3 Modelling human prostate cancer using mice 
Over the years, mouse models have been used for human cancer research as 
they have proven to be a useful tool due to their similar genomic and 
physiological characteristics of tumour biology between mice and humans 
(Lampreht Tratar, Horvat and Cemazar, 2018). These mouse models have played 
a central role in the study of disease aetiology, prevention, and treatment of 
PC. Although multiple cell models have been developed, they do not take into 
account the numerous cellular interactions within the tumour environment that 
play a key role in disease initiation and progression (Ittmann et al., 2013). 
Although the gross anatomy of the mouse prostate is different to that of 
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humans, the prostate of both species is composed of glands and ducts of similar 
organisation (Parisotto and Metzger, 2013). Mouse models for PC can be divide 
into two categories: xenograft models or genetically engineered models (GEM). 
In xenograft models, PC cell lines are directly implanted into 
immunocompromised host mice either subcutaneously or injected orthotopically 
into the prostate (Ittmann et al., 2013). Different PC cell lines have been used 
to perform various xenograft models that exhibit different features of PC, 
therefore creating models for different stages of disease (Rea et al., 2016). 
Although these models have been used in the past, they are faced with 
significant limitations for the establishment of PC models. In order for PC cell 
lines to adapt to in vitro growth environment, these cells lose their ability to 
grow in a three-dimensional structure, hence losing their inter- and intra-tumour 
heterogeneity and unable to accurately reflect major features of human PC (Shi, 
Chen and Tan, 2019). Furthermore, it has been reported that these xenografts 
models cannot provide reliable data to support drug development, efficacy and 
prognosis. Many anticancer drugs have been shown to be potent in xenograft 
models, only a few of these drugs have been shown to have the same potency 
when used as a therapy in humans (Sharpless and DePinho, 2006).  
The development of genome editing tools over the last three decades have 
allowed scientists to generate a number of PC mouse models (Parisotto and 
Metzger, 2013). These genetically modified mouse models can help define the 
molecular events of prostate tumorigenesis, and can be grouped into two types: 
those engineered to increase the expression of a specific promoter and those 
with target deletion of genes (Pienta et al., 2008). These two types of GEM have 
enabled researchers to validate the biological importance of different molecular 
changes that occurs during PC tumorigenesis (Ittmann et al., 2013). One of the 
most well-known GEM mouse model for PC is the transgenic adenocarcinoma of 
the mouse prostate (TRAMP) model generated and characterized in 1995-1997 
(Valkenburg and Williams, 2011). TRAMP mice are known to display high grade 
prostatic intraepithelial neoplasia (PIN) or prostate cancer by 10-12 weeks of age 
due to the overexpression of SV-40 T-antigen (TAG) by rat probasin gene 
promoter (Gelman, 2016). Since its characterization, this model has been used 
to investigate the roles of specific pathway mediators, transcription factors, or 
metabolic pathways in PC progression (Gelman, 2016). With over 400 
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publications to date, the TRAMP model has been extensively used in PC research 
and drug discovery (Ittmann et al., 2013). 
1.4 Development of prostate cancer 
Prostate cancer (PC) is the most commonly diagnosed malignancy and the second 
leading cause of cancer-related deaths in the Western male population (Rawla, 
2019). The high incidence can be attributed to modern day increased life 
expectancy as well as the implementation of prostate specific antigen (PSA) 
testing (Hessels et al., 2007). Many PC are diagnosed based on the elevated 
levels of PSA in the plasma (>4.0 ng/mL) (Rawla, 2019). However, in recent 
years, this test has been found to have problems with specificity and sensitivity. 
Although the screening of PC allows for early diagnosis and better management 
of disease, the use of the PSA testing has slowly become controversial (Stavridis 
et al., 2010). The prostate gland is known to have a very good blood supply, 
therefore small amounts of PSA is constantly present in the bloodstream. Rather 
than only being expressed at the point of disease, levels of PSA reflects the 
whole gland instead of the presence of a tumour specifically (Reynard, Peters 
and Gillatt, 1995). When using the 4.0 ng/mL cut off, over 91% of men are 
positively diagnosed with PC, but this also leads to the increase in morbidity and 
the prescription of unnecessary procedures because their PSA may have been 
elevated due to benign conditions (David and Gopal, 2020). As the availability of 
the PSA testing has increased, this has also resulted in the increased in the 
detection of false positive PC as some men have naturally increased levels of 
PSA without cancer. This in turn leads to performing unnecessary biopsies as 
well as overtreatment. On the other hand, certain cancers can go undetected as 
they are either asymptomatic or do not show the typical elevated levels of PSA 
(Wilt, 2003; Rawla, 2019). There is currently a need to overcome these 
sensitivity and specificity issues in order to provide a more accurate diagnosis.  
1.4.1 Steroid signalling in prostate cancer 
1.4.1.1  Androgen biosynthesis 
The two most important endogenous androgens are testosterone and 
dihydrotestosterone (DHT). Androgens are traditionally considered male sex 
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steroids responsible for the maintenance of male characteristics via the 
activation of the AR and its downstream signalling pathway (Freeman, Bloom and 
McGuire, 2001). Under normal physiological conditions, about 60% of circulating 
androgens are produced in the testicles. The remaining 40% derives from 
dehydroepiandrosterone (DHEA) synthesised in the zona reticularis of the 
adrenal glands (Pippione et al., 2017).  
The overall rate of steroidogenesis is controlled by peptide hormones, such as 
adrenocorticotropin hormone (ACTH), follicle stimulating hormone (FSH), and 
luteinizing hormone (LH). Binding of these peptide hormones to it’s appropriate 
G-protein couple receptor (GPCR) leads to the activation of the cAMP dependent 
PKA signalling pathway. Stimulation of the cAMP-PKA cascade promotes the 
increased delivery of circulating cholesterol into the mitochondria of the Leydig 
cells or the adrenal gland (Hu et al., 2010; Prough, Clark and Klinge, 2016). All 
steroid hormones are produced from cholesterol through a cascade of enzymes 
(Figure 1.2). In the mitochondria, cholesterol is converted to pregnenolone by 
P450scc, which is then further converted to DHEA by 17α-hydroxylase and 17,20 
lyase. DHEA is then rapidly converted to testosterone by 3β-hydroxysteroid 
dehydrogenasetype II or 17 β -hydroxysteroid dehydrogenase III enzymes. 
Testosterone can be further processed into DHT by 5α-reductase (Miller, 2002; Singh 
et al., 2005; Flück and Pandey, 2014; Miller and Auchus, 2019). The majority of 
circulating testosterone exists bound to carrier protein sex hormone binding 
globulin (SHBG) or albumin. (Heemers and Tindall, 2007). 
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Figure 1.2: Androgen biosynthesis in Leydig cells. G-protein coupled receptor (GPCR) 
activation by binding of a tropic hormone (TH) leads to the activation of adenylyl cyclase (AC) 
leading to an increase level of PKA in the cytoplasm. Activation of the cAMP-PKA signalling 
pathway increases the delivery cholesterol into the mitochondria of the cell. Cholesterol is then 
sequentially enzymatically cleaved in order to produce testosterone.  
1.4.1.2 Androgen receptor and signalling 
The AR is a member of the steroid and nuclear receptor superfamily (Bennett et 
al., 2010). The gene encoding this receptor can be found on the long arm of the 
X chromosome, more precisely at position Xq11-Xq12 (Tan et al., 2015). 
Structurally, the AR compromises three main functional domains: The N-terminal 
transcriptional regulation domain (NTD), the DNA binding domain (DBD), and the 
ligand binding domain (LBD) (Figure 1.3). While the DBD remains highly 
conserved between the different members of the steroid hormone nuclear 
receptor family, the N-terminal region is highly variable (Davey and Grossmann, 
2016). The LBD of the AR is only moderately conserved among the receptors, and 
contains activation function-2 (AF2) which is important for the ligand-dependent 
activation of the receptor (Culig et al., 2003; Tan et al., 2015). The activation 
function-1 (AF1) domain, located in the NTD, plays a pivotal role in AR function 
GPCR A
C 
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and significant loss in AR’s transcriptional activity can be seen when AF-1 is 
deleted (Culig et al., 2003). The lysine rich hinge region between the DBD and 
LBD regions are important for the nuclear localization of the receptor. Deletion 
of this hinge region eliminates nuclear localization and transcriptional activity of 
the AR in the presence of a ligand (Culig et al., 2003). All three domains are 
important for receptor function. The DBD region tethers the AR to a promoter 
and enhancer regions of AR regulated genes, or androgen responsive elements, 
by direct DNA binding to allow the activation functions of the NTD and LBD to 
stimulate transcription of these genes (Tan et al., 2015, Green, Mostaghel and 
Nelson, 2012). 
 
Figure 1.3 Functional domains of the AR. The N-terminal domain contains the activation 
function-1 domain (AF-1). The N-terminal domain is then followed by the DNA binding domain 
(DBD), the hinge region (H). The Ligand binding domain contains the activation function-2 
domain (AF-2). Nuclear localization signal (NLS) and nuclear export signal (NES) are responsible 
for transporting the AR in and out of the nucleus.  
 
In the absence of a ligand, the AR resides primarily in the cytoplasm in 
association with heat shock proteins (HSPs) as a monomer in an inactivate but 
highly responsive state. Nuclear import of the AR is crucial for its function. Upon 
ligand binding, the nuclear localization signal (NLS) is recognised in the 
cytoplasm by the importin-a/b complex allowing the receptor to move through 
the nuclear pore and into the nucleus (Cutress et al., 2008). Alternatively, AR 
can be activated via phosphorylation at multiple sites along the protein. 
Phosphorylation at these different sites has been implicated in a number of 
different cellular responses, including AR transcriptional activity, regulation of 
AR expression, cell growth, and AR degradation (Daniels et al., 2013). In 
response to androgen binding, Ser81 within the N-terminal transactivation 
domain is the most highly phosphorylated site within the AR (Russo et al., 2018). 
AR can be phosphorylated by multiple kinases at this site, including cyclin-
dependent kinase CDK1, CDK5, and CDK9, all of which are able to increase the 
transcriptional activity of AR as well as promoting its translocation into the 
nucleus (Daniels et al., 2013).Translocation of the androgen/AR complex into 
the nucleus leads to the dimerization of the receptor, where it can then bind to 
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androgen response elements (ARE) target genes and modulate gene transcription 
(Davey and Grossmann, 2016). AR dimers recruit an array of factors, including 
co-activators and mediators of proteins whose enzymatic activities promote 
chromatic remodelling and transcriptional regulation of target genes, leading to 
cell differentiation, survival and proliferation (Figure 1.4) (Burnstein, 2005).  
 
Figure 1.4 Classical androgen receptor signalling pathway. Binding of androgen or DHT, AR 
dimerizes and translocate to the nucleus where it can then bind to DNA. When bound to DNA, the 
AR forms a complex with co-activators, co-regulatory proteins, or ARE. Figure taken from Davey 
and Grossmann, 2016. 
1.4.2 Initial development of prostate cancer 
Although the prostate depends on androgens for normal prostate development, 
alone it does not promote the development of disease. Instead, PC development 
involves the accumulation of cancerous epithelial cells (Knudsen and Vasioukhin, 
2010). The AR signalling pathway is vital for the normal functioning of the 
prostate. However, it also plays a pivotal role in prostate carcinogenesis and the 
progression to androgen-independent disease (Lonergan and Donald, 2011). In 
the normal prostate, the rate of cell death is 1-2% per day, which is balanced by 
a 1-2% rate of proliferation (Heinlein and Chang, 2002). Both healthy and 
malignant prostate growth depends on the ratio of cells proliferating to those 
dying. Androgens are the main regulator of this ratio by both stimulating 
proliferation and inhibiting apoptosis (Feldman and Feldman, 2001). However, 
this balance is disrupted in prostate cancer, with the rate of proliferation 
overtaking the rate of cell death (Kim et al., 2017). The initiation of PC can be 
attributed to the activation of a distinct growth-promoting pathway. In a study 
Nucleus 
Cytoplasm 
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analysing 11 early-onset PC cases, an increase in the prevalence of structural 
rearrangements enriched in the AR binding sites was identified with 10 out of 11 
cases having the androgen driven Erythroblast Transformation Specific (ETS) 
gene fusions (Russo and Balk, 2018). Most of these fusions were the 
Transmembrane Serine Protease 2 (TMPRSS2):ETS related gene (ERG) fusions 
found in approximately 50% of PC. The presence of this rearrangement is a 
critical event in the development of disease (Hägglöf et al., 2014), with the 
fusions only been identified only in clinically localised and hormone-refractory 
metastatic PC (Tomlins et al., 2009).  
TMPRSS2 is a serine protease that is highly expressed in the epithelium of the 
human prostate gland and depends on the binding to an ARE for its expression 
(Chen et al., 2010). ERG is a member of the ETS family of transcription factor, 
with a role in the development and differentiation of a wide range of tissue and 
cell types (Adamo and Ladomery, 2016). This gene translocation occurs early 
during disease formation as it can be detected in precursor prostatic 
intraepithelial neoplasia lesions (PIN) (Cai et al., 2009). In PC, ERG can recruit 
the AR to novel genomic loci as well as co-bind to AR binding sites across the 
chromatin. This interaction leads to an alteration in the transcriptional output 
induced by the activation of the AR signalling pathway (Kron et al., 2017). The 
TMPRSS2:ERG gene fusion leads to an overexpression of a N-terminal truncated 
ERG protein that is still transcriptionally active (Zhou et al., 2019). This leads to 
an increase in ERG mRNA expression in 62% of PC (J. Wang et al., 2006), which 
may lead to the activation of pathways related to the initiation and progression 
of PC via the cGMP-PKG pathway (Zhou et al., 2019). 
Although AR activation most commonly stimulates growth through the 
TMPRSS2:ERG gene translocation (Sharifi, 2013), the ability of AR to activate and 
cross talk with other signalling pathways is known to contribute to disease 
initiation and progression (Kaarbø, Klokk and Saatcioglu, 2007). One such 
pathways is the phosphoinositide 3-kinase (PI3K)/Akt/ mammalian target of 
rapamycin (mTOR) pathway (Kaarbø et al., 2010). Activation of PI3K leads to the 
generation of the secondary messenger phosphatidylinositol 3,5-triphosphate 
(PIP3). This in turn leads to the recruitment and activation of the Akt kinase, 
which is then able to translocate to the nucleus to promote cell growth and 
proliferation. Akt is negatively regulated by tumour suppressor phosphatase and 
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tensin homolog deleted on chromosome 10 (PTEN) (Lonergan and Donald, 2011). 
Activation of this pathways leads to PC progression due to its ability to integrate 
intra- and extracellular growth factors which are critical to cellular processes. 
This pathway is frequently overactive in advanced PC due to the loss of the 
tumour suppressor PTEN (D. E. Butler et al., 2017). 30% of PC tumours are known 
to no longer express PTEN, which in turn leads to the constitutive activation of 
the PI3K/AKT/mTOR signalling pathway (Crumbaker, Khoja and Joshua, 2017). 
Interestingly, the AR and PI3K/AKT/mTOR signalling pathways are known to be 
activated in androgen sensitive (AS) cell line LNCaP. Combined inhibition of 
these two pathways using small molecular inhibitors results in an enhanced 
antitumoral activity in this cell line, indicating that these two pathways work 
synergistically in order to promote the progression of disease (Thomas et al., 
2013). 
In addition to its transcriptional activity, AR is known to play a role in regulating 
the cell cycle machinery (Schiewer, Augello and Knudsen, 2012). While in the G1 
phase, mammalian cells evaluate growth-promoting or growth inhibitory cues 
within their environment in order to progress through the mitotic cycle of enter 
quiescence. These cells depend on the cyclin-dependent kinases (Cdk) in order 
to regulate its transition through the mitotic cycle by promoting or inhibiting 
phosphorylation, binding to cyclins, and binding to CDK inhibitors (Knudsen, 
Arden and Cavenee, 1998). Studies have shown that androgen deprivation causes 
G0-G1 cell cycle arrest, while androgen stimulates cellular proliferation (Xu et 
al., 2006). Androgens have been shown to increase Cdk activity and stimulate 
cells to enter the S-phase of the cell cycles, which in turn promotes cellular 
proliferation (Lu, Tsai and Tsai, 1997). Not only is AR and androgens able to 
stimulate disease via its transcriptional activity, but its interaction with multiple 
signalling pathways and its ability to contribute to their activation plays an 
important role in disease initiation and progression.  
1.4.3 Progression into castration resistant prostate cancer 
Androgen deprivation therapy (ADT) has been the primary standard of care in 
patients with locally advance PC. ADT generally leads to a decrease in PSA level 
and disease remissions in about 90 % of patients (Huang et al., 2018). 
Unfortunately, after an average time of 2-3 years, the disease progresses despite 
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continuous hormone therapy. This PC is known as castrate-resistant PC (CRPC) 
(Karantanos, Corn and Thompson, 2013). CRPC is defined as disease progression 
following initial ADT and may present with an increased rise in serum PSA, 
progression of pre-existing disease, androgen insensitivity (AI), or the 
appearance of new metastases (Hotte and Saad, 2010). It has been shown that 
CRPC is characterised by the overexpression or hyperactivation of the AR 
(Nadiminty and Gao, 2012), despite being in an environment of serum 
testosterone below 50 ng/dL in the blood (Gomella, 2003). It is thought that the 
mechanisms involved in CRPC development include AR gene amplification and 
mutation, overexpression of co-activators, activation of growth factors, and 
cross-talk with other transcription factors and signalling pathways (Figure 1.5) 
(Nadiminty and Gao, 2012).  
 
Figure 1.5 Known mechanism that leads to metastatic prostate cancer, including immune 
evasion. Although ADT is successful in most patients, they often progress to the more aggressive 
CRPC phenotype. CRPC is known to be androgen insensitive and unresponsive to AR inhibitors. 
Multiple mechanisms have been identified and illustrated above (A-G). These mechanisms are 
known to be resistant to ADT and associated with complex molecular alterations, all leading to the 
increase in PSA expression, increased growth and PC cell survival. A. Crosstalk with other 
activated receptors leads to the phosphorylation of the androgen receptor. B. Amplification of AR. 
C. Chronic IFN1 pathway activation. D. Loss of MHC Class I expression. E. Decreased chemotaxis 
of inflammatory immune cells. F. Autocrine hormone production and AR mutations. G. Altered 
expression or activity of co-activators and co-repressors. (Mills, 2014; Vitkin et al., 2019).  
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1.4.3.1  Increased expression and amplification of AR 
Increased AR expression is one of the most frequent changes in CRPC and is 
highly associated with resistance to anti-androgen. Using fluorescent in situ 
hybridization staining (FISH), Visakorpi et al. (1995) and Koivisto et al (1997) 
have seen an amplification in the AR gene in 30% and 28 % of recurrent tumours 
respectively (Visakorpi et al., 1995; Koivisto et al., 1997). Interestingly, 
Visakorpi et al. reports that this gene amplification was not observed in primary 
tumours (Visakorpi et al., 1995) suggesting that AR amplification is an adaptive 
response to ADT (Jernberg, Bergh and Wikström, 2017). It has been suggested 
that AR gene amplification can lead to an increase in AR expression due to a 
gene dosing effect, which in turn can contribute to androgen resistance. The 
addition of even one gene copy of AR has been shown to increase AR expression, 
suggesting that even a small change gene dosage can dictate disease and therapy 
outcome (Edwards et al., 2003). Furthermore, the amplification of the AR gene 
sensitizes PC cells to castration levels of androgens. Research lead by Fujimoto 
et al (2007) has shown that stimulation with DHT lead to a 4-fold increase in 
nuclear AR expression in late stage androgen insensitive (AI) cells when 
compared to early stage androgen sensitive (AS) cells. It is thought that the 
increase in AR protein can contribute to androgen hypersensitivity as well as 
disease progression (Fujimoto et al., 2007). However, work by Edwards et al 
(2001), has suggested that AR gene amplification is not solely to blame for the 
development of antiandrogen-resistance PC. By studying paired tumours (early vs 
late-stage tumours) from 20 different patients, Edwards et al (2001) were able 
to investigate if AR gene amplification alone heavily contributes to CRPC 
progression. Of the 20 patients, only three patients were shown to have AR gene 
amplification after hormone relapse (Edwards et al., 2001).  
1.4.3.2  AR mutations 
To date, 159 AR mutations have been identified in PC tissues, and most of these 
mutations are single-base substitutions (Eisermann et al., 2013). Approximately 
45% of these mutations occurs in the LBD, while 30% of mutations occurs in exon 
1 (Gottlieb et al., 2012). The most frequently detected AR mutation is T878A, 
which is a gain of function mutation that can be activated by both steroid 
hormones and first-generation antiandrogens (Jernberg, Bergh and Wikström, 
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2017). This mutation is also associated with resistance to abiraterone (Rathkopf 
et al., 2017). A study by Romanel et al (2015) has shown that men who have this 
mutation in circulating tumour DNA (ctDNA) have a lower PSA response rate and 
shorter survival time following abiraterone treatment when compared with men 
with a wild-type AR gene (Romanel et al., 2015).  
1.4.3.3  AR splice variants 
AR-variants have recently emerged as important players in PC progression as 
well as drug resistance. More than a dozen variants lacking the ligand binding 
domain have been identified from human PC cell lines and xenografts (Xu and 
Qiu, 2016). Increased expression of these variants has been associated with 
persistent AR activity after ADT (He et al., 2018), as well as resistance to 
enzalutamide and abiraterone (Armstrong and Gao, 2019). AR-variant 7 (AR-V7) 
is the most widely studied of these variants, and its expression is known to be 
increased in patients that have progressed to CRPC. Expression of this variant 
has only been detected in response to primary ADT (Sharp et al., 2019). It has 
been shown that in AR-V7 dependent CRPC, full-length AR binds to AR-V7 to 
repress transcription of growth-suppressive genes. Silencing of either full length 
AR or AR-V7 significantly decreases cell growth in CRPC cell models (Cato et al., 
2019). Work by Guo (2009) showed that not only does the expression of this 
splice variant increase between early and late stage disease, but AR-V7 
expression is found to increase within the nuclear region in hormone-refractory 
tumours. Immunohistochemical staining of over 429 human tissue microarrays 
showed that ARV7 expression was significantly increased during PC progression. 
Interestingly, these stains also revealed that 44 % of AR-V7 in hormone resistant 
tumours samples was localised in the nucleus. In contrast, only 9% of AR-V7 was 
found in the nucleus when compared to their pair hormone-naïve tumours. AR-V7 
expression significantly increases within the nuclear regions of hormone-
resistant tumours, suggesting that the expression of this splice variant can drive 
PC progression (Guo et al., 2009) 
1.4.3.4  Alterations in cofactor recruitment 
Due to its direct interaction with the receptor, AR cofactors have the ability to 
stimulate or repress the transcriptional activity of AR function (Heinlein and 
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Chang, 2002; Fujita and Nonomura, 2018). It has recently been shown that 
multiple AR-associated cofactors are able to modulate and reprogram AR binding 
events (Augello, Den and Knudsen, 2014). In recent years, researchers have 
observed diverse expression patterns of co-factors involved in human PC. 
Increased expression of some co-factors, such as SRC1, and decreased expression 
of others, such as ARA70 and ART27, are found in PC tissue when compared with 
benign tissue. Changes in concentration of AR cofactors can influence the 
selective expression of AR target genes and this in turn can determine the switch 
between proliferation and growth inhibition (Peng et al., 2008).  
1.4.3.5  Ligand-independent activation via cross talk with signal transduction 
pathways.  
AR ligand independent activation is one of the key signalling mechanism under 
low androgen conditions (Lyons et al., 2008). Increasing evidence has shown that 
PC cells have acquired the ability to survive and grow in low androgen 
environments by activating the AR pathway using growth factors, cytokines, and 
steroids. In the absence of androgens, growth factors such as epidermal growth 
factor (EGF), interleukin-6 (IL-6) or insulin-like growth factor I (IGF-I), can 
increase AR transcriptional activity despite not binding to normal ligand. This is 
mediated through protein kinases which are able to inhibit or activate AR 
transcription (Jenster, 2000). Increasing evidence has implicated cyclic 
adenosine monophosphate (cAMP) and the protein kinase A (PKA) pathway in the 
activation of AR. The activation of the cAMP signalling pathway will be further 
discussed in section 1.5.1. A study by Nazareth and Weigel (1996) has shown that 
PKA activation using forskolin, an adenylyl cyclase (AC) activator, lead to the 
activation of AR in the absence of androgens in AI PC3 cells, and this activation 
was blocked in the presence of a PKA inhibitor (Nazareth and Weigel, 1996).  
In addition to the cAMP-PKA pathway, PI3K/Akt/mTOR pathway is known to 
contribute to disease progression by activating AR in absence of its ligand. This is 
most commonly mediated by the loss or mutation in PTEN, which in turn leads to 
an increased activation of Akt (Fang et al., 2007). Work by McCall et al (2008) 
examined how deletion of PTEN gene and lower PTEN protein expression can 
contribute to PC progression in matched tumour samples. By using fluorescent in 
situ hybridisation and immunohistochemistry analysis, 23% of hormone sensitive 
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tumours were found to harbour PTEN gene deletions. This significantly increased 
to 52% when compared to their matched hormone refractory tumours (McCall et 
al., 2008). PTEN is a key regulator of growth factor signalling and is able to 
regulate different cellular processes, including cell growth (Conley-LaComb et 
al., 2013). Loss of PTEN expression leads to an activation in the PI3K/Akt/mTOR 
pathway, and is strongly associated with negative oncological outcomes 
(Jamaspishvili et al., 2018). However, loss of PTEN expression also lead to an 
increase in AR activity as these two proteins have been shown to be direct 
interactors in LNCaP cells (El Sheikh et al., 2008). The interaction between PTEN 
and AR has been shown to inhibit AR’s ability to translocate into the nucleus, 
thus acting as a negative regulator of the AR pathway (Lin et al., 2004). 
Additionally, loss of PTEN expression is known to increase Akt activity (D. E. 
Butler et al., 2017), which in turn can increase AR phosphorylation in vitro and 
can increase AR activation (Edwards and Bartlett, 2005).  
1.4.4 Detection and diagnosis of prostate cancer. 
The main diagnostic tools for PC include the digital rectal examination (DRE), 
serum concentrations of PSA, and transrectal ultrasound (Gaudreau et al., 2016). 
In 18% of patients, prostate cancer can be detected by DRE alone, highlighting 
the technique’s importance in disease detection (Heidenreich et al., 2014). 
Initial patient evaluation and treatment decisions are currently based on a risk 
stratification scheme that incorporates three important prognostic biomarkers at 
diagnosis: clinical stage, biopsy Gleason grade/score, and serum PSA (Gaudreau 
et al., 2016).  
1.4.4.1  PSA as a biomarker for PC 
Although biomarkers, such as PSA, reflect the state of the whole gland, early 
screening for PC biomarkers may predict the likelihood of disease during a man’s 
asymptomatic state of cancer progression. Diagnostic biomarkers can predict 
cancer in patients suspected of having disease, while prognostic biomarkers 
predict the course of disease progression. Many prostate cancer biomarkers have 
been identified, however only a few have been approved by the FDA, including 
the PSA protein. PSA is the most commonly used oncological biomarker and 
screening method to detect prostate cancer (Kohaar, Petrovics and Srivastava, 
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2019). PSA is a serine protease secreted exclusively by the prostate epithelial 
cells (Marshall and Kelch, 1986). PSA screening for PC has been associated with a 
substantial increase in the diagnosis of prostate cancer. In general, total serum 
PSA levels are less than 4ng/mL in healthy patients (Gao et al., 2019). PC causes 
PSA to be released into the circulatory system, increasing the level in blood up 
to 105 fold. An increased PSA level of above 4 ng/mL prompts a recommendation 
that the man undergo prostate biopsy (Lilja, Ulmert and Vickers, 2008). The 
concentration of PSA is related to the size and the amount of glandular 
epithelium. However, other factors are known to increase normal PSA levels, 
such as race, body mass index, drugs, and age. (Pérez-Ibave, Burciaga-Flores and 
Elizondo-Riojas, 2018).  
1.4.4.2  Disease staging and scoring 
The tissue diagnosis of the adenocarcinoma is essential for establishing a positive 
diagnosis of prostate cancer (Humphrey, 2017). Samples are obtained via a 
prostate biopsy under ultrasound guidance and local anaesthesia (Heidenreich et 
al., 2014). Currently, light microscopic examination by haematoxylin and eosin 
(H&E) staining of the tissue is most commonly used for patient diagnosis 
(Humphrey, 2017). The Gleason histopathologic grading is one of three 
determinants of prostate cancer staging and is an important indicator of the 
biologic behaviour. The classical Gleason system defines the tumour into one of 
five histological growth patterns. A Gleason grade of 1 indicates that the gland is 
well differentiated and is correlated with a favourable prognosis. While a grade 
of 5 indicates that the gland is least differentiated and correlate with poor 
prognosis (Chen and Zhou, 2016). The Gleason score is then the sum of the two 
most prevalent grades found within the gland, with values ranging between 2 
and 10 (Gordetsky and Epstein, 2016). This method specifically looks at the 
extent of glandular differentiations and the pattern of growth of the prostatic 
stroma by using haematoxylin and eosin (H&E) staining (Humphrey, 2004). Since 
the initial study published by Gleason in 1966, there have been revisions in the 
guidelines of pathological reporting. Modification in the grading system in recent 
years has made it more complex for clinicians to grade the cancer (Gordetsky 
and Epstein, 2016). The new grading system has been proposed to increase 
grading accuracy and simplify the grading system into 5 grades, rather than the 
original 10. Under this new system. The lowest grade a patient can receive is 1 
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instead of 6, reducing the overtreatment of patients (Epstein et al., 2016). 
Higher grades are associated with a greater likelihood of having metastasised 
disease and a worse outcome after treatment of localized disease (Figure 1.6) 
(Gaudreau et al., 2016).  
 
Figure 1.6 Five-year biochemical recurrence free progression probabilities in patients after 
radical prostatectomy. Patient in Gleason Grade group 5 have a 25% chance of being disease 
free 10 years after the removal of the prostate. On the other hand, patients in Gleason Grade 1 
have a 90 % of being disease free within this same time frame (Figure taken from Sunassee, Al 
Sannaa and Ro, 2019). 
 
1.4.5 Current courses of treatment 
1.4.5.1  Active surveillance and watchful waiting 
Active surveillance and watchful waiting are two non-invasive treatment options 
for patients with low-risk PC (Herden and Weissbach, 2018). However, they 
include two different strategies. Watchful waiting is used as a palliative option 
for patients who are asymptomatic but with reduced life expectancy and is 
currently considered the least aggressive course of treatment. It does not 
involve regular biopsies or frequent blood tests. Treatment is only provided 
when symptoms appear (Malinowski et al., 2019). On the other hand, active 
surveillance is a curative option for patients with low risk of PC progression. In 
effect, the intention is to provide delayed treatment (Loeb et al., 2017). This 
method of treatment mainly focuses on preventing overtreatment by selecting 
patients based on their low-risk features and strictly monitoring them overtime. 
This close follow up of the patients enables rapid re-classification of disease that 
would alter the course of treatment (Bul et al., 2013; Kinsella et al., 2018). 
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Patients undergo regular examinations with a yearly DRE, PSA check every six 
months, MRI and biopsy every one to three years (Malinowski et al., 2019). 
1.4.5.2  Androgen deprivation therapy (ADT) 
ADT refers to treatments that act by reducing the effects of testosterone and 
other androgens and this can be achieved either surgically or chemically, but 
both methods aim to inhibit the progression of PC (Thomas and Neal, 2013). 
Surgical castration is the simplest and the most effective method to reduced 
levels of circulating testosterone and involves surgical removal of the testicles, 
reducing levels of androgens by over 90% within the first 24 hours, making this 
the most effective method to achieve a castrate state (Singer et al., 2008). 
Androgen homeostasis in the normal adult male is maintained through the 
release of gonadotropin-releasing hormone (GnRH) by the hypothalamus 
(Gomella, 2003). GnRH is secreted in a pulsatile manner, which then induces the 
anterior pituitary gland to release LH (Gomella, 2003; Choi and Lee, 2011). ADT 
can achieve castration levels of androgens via the administration of GnRH 
agonist or antagonists. GnRH agonists are the most prescribed medication for 
ADT, with the two most commonly used being leuprolide and goserelin. GnRH 
agonists produce an intense stimulation of GnRH receptors, causing a rise in LH 
and FSH. This in turn results in a rapid release of testosterone, often referred to 
as a “surge”, during the first two weeks of treatment (Thompson, 2001). The 
continuous stimulation leads to receptor desensitization which suppresses LH 
and FSH secretion, reducing testosterone to castrate levels (Boccon-Gibod, Van 
Der Meulen and Persson, 2011; Choi and Lee, 2011; Mason et al., 2013). GnRH 
antagonists act by competitively binding to receptors in the pituitary gland, 
leading to reduced amounts of LH and FSH. Such compounds are able to 
decrease levels of testosterone immediately to castration levels, as well as 
avoiding the surge seen with the agonists (Kunath et al., 2015; Crawford et al., 
2018).  
1.4.5.3  Radiotherapy 
Radiotherapy for prostate cancer can be separated into two types: external 
beam radiotherapy (EBRT) and brachytherapy (BT). BT is recommended to 
patients with low-intermediate stage PC, while EBRT can be used for any PC 
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stages (Heidenreich et al., 2014).BT currently involves the permanent 
implantation of free or stranded iodine, called low-dose BT, as well as 
temporary placement of iridium, called high-dose BT. Low-dose BT has been 
shown to be one of the strategies that is recommended for the curative 
treatment as the implanted radioactive source is left within the prostate. (Stish 
et al., 2018). In a follow up study of 757 men who underwent low-dose BT, 2.3% 
of patients developed distant metastasis following treatment. There was an 
overall survival rate of 97% in patients highlighting the curative effects of BT 
(Lazarev et al., 2018). EBRT is a non-invasive treatment that delivers high-dose 
radiation to the region of interest (Kovacs and Pinkawa, 2019). The prescribed 
dose of radiation is delivered directly to the tumour to destroy the cancerous 
cells. The beams are arranged in a way that the tumour receives the maximum 
dose, sparing the normal tissue and surrounding organs (Podder, Fredman and 
Ellis, 2018). EBRT is recommended for patients with tumours that extend 
through the prostate capsule or that has invaded into the seminal vesicles 
(Kamran and D’Amico, 2018).  
1.4.5.4  Enzalutamide, Abiraterone and Casodex in CRPC 
Hormone therapies are currently considered the gold standard for PC treatment 
as they are safe and highly effective but their biggest downfall is the lack of 
sustained anti-tumour effects (Hara et al., 2018). As previously mentioned, CRPC 
is an advanced form of PC that is resistant to lower levels of testosterone and 
has metastasised to other parts of the body. It has been shown that 80% of men 
with CRPC will progress to metastatic CRPC (mCRPC), with this progression being 
rapid in half of these patients (Albala, 2017). Abiraterone and enzalutamide are 
currently the first-line treatment in patients with mCRPC as both improve 
patient survival, but after a median of ~18 months resistance develops (Attard et 
al., 2018). Abiraterone is an androgen biosynthesis inhibitor that irreversibly 
inhibits the enzymatic activity of cytochrome P45 17 (CYP17) (Rehman and 
Rosenberg, 2012). Administration of abiraterone supresses androgen production 
in the testes and adrenal glands, returning them to castrate levels (Altavilla et 
al., 2012). Enzalutamide, also referred to as MDV3100, was the first second-
generation anti-androgen to be characterised. This compound directly binds to 
AR and inhibits its androgen binding, AR translocation to the nucleus, and ARE 
mediated DNA-binding (Hussain et al., 2018). In this situation, AR is no longer 
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able to activate the expression of its downstream genes or recruit any co-
activators (Rice, Malhotra and Stoyanova, 2019). In addition to enzalutamide and 
abiraterone, casodex has also been used in the treatment of CRPC. Casodex, also 
known as bicalutamide, is a non-steroidal, first generation anti-androgen which 
has been approved for use in combination with LHRH analogue (Beebe-Dimmer 
et al., 2018). Casodex binds competitively to the AR in the cell, which in turn 
causes it to alter its co-activator binding sites so that the receptor can no longer 
initiate gene transcription (Osguthorpe and Hagler, 2011; Waller and Sampson, 
2018).  
1.4.6 Novel PC therapies 
Although ADT and other therapies are regarded as the first treatment of choice 
for PC, hormone resistant PC will eventually develop and will become CRPC. 
Although metastatic CRPC currently benefit from a wide range of treatment 
options, it remains incurable and the prognosis of these patients remain poor 
(He et al., 2020). In the last few years, novel therapies have been approved in 
order to improve CRPC patient outcome. Most recently, polyadenosine 
diphosphate [ADP]-ribose polymerase (PARP) inhibitors have been approved for 
the treatment of CRPC (Powers et al., 2020). Recent studies into CRPC have 
shown that mutations in DNA repair genes are associated with highly aggressive 
PC and CRPC. As such, these cancers are susceptible to PARP inhibitors. PARP 
are highly conserved enzymes that bind to DNA breaks and recruit DNA repair 
proteins to the damaged site (Virtanen et al., 2019). Data from the phase 3 
clinical trial PROfound has shown that PARP inhibitors are highly effective in the 
treatment of CRPC. In this trial, CRPC patients receiving PARP inhibitors had 
lower levels of PSA and an increase in overall survival following treatment. This 
inhibitor has been approved for the treatment of CRPC in May 2020 owing to its 
success in clinical trials (Powers et al., 2020). 
Furthermore, radium-223 is currently the only radiopharmaceutical treatment 
for metastatic CRPC.Radium-223 emits high energy alpha particles over a short 
range, results in a localised anti-tumour effect and the inhibition of tumour-
induced osteoblastic activity (Heidenreich et al., 2019). This radioactive isotope 
induces irreversible DNA double stranded breaks, leading to tumour and cell 
death. Treatment with radium-223 is known to increase the overall survival of 
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patients and a better biological response when compared to conventional CRPC 
treatments (Deshayes et al., 2017). 
As previously mentioned, cancer immunotherapy has made a huge impact on 
treatment of different cancers, and PC is not exempt from this. PC is often 
described as a cold tumour, with a immunosuppressive microenvironment. As 
such, current therapies are designed to enhance the presence of antigen-
presenting cells and effector T-cells in the PC tumour environment (Fay and 
Graff, 2020). One of these strategies is by designing monoclonal antibodies 
raised against a tumour-associated antigen (TAA). This method marks the tumour 
cell for destruction via multiple pathways: activation of the complement system; 
antibody-dependent cytotoxic T-cell activation; or enhancing the uptake of 
phagocytes, followed by the presentation to an immature T-cell (Powers et al., 
2020). This method has been used to develop the Sipuleucel-T vaccine for the 
treatment of PC. When administered, Sipuleucel-T induces cytotoxic T-cells to 
recognise and kill prostate tumour cells due to the presence of the prostatic acid 
phosphatase antigen (Fay and Graff, 2020). In late-stage clinical trials, 
Sipuleucel-T significantly increased the survival by at least 4.1 months and 
increase the overall survival by 20 months when compared to placebo. Men 
receiving Sipuleucel-T experience a 22.5% reduction in risk of death following 
treatment (Anassi and Ndefo, 2011). 
1.5  cAMP signalling  
1.5.1 cAMP signalling pathway 
Extracellular signalling cues, such as hormones, cannot enter the cell directly 
and rely on secondary messenger proteins that are produced inside cells 
following activation of cell surface receptors. cAMP was the first second 
messenger to be found and it remains the best characterised. cAMP is used by a 
range of Gs-coupled receptors to transduce extracellular signals into a 
compartmentalised signalling pathway in the target cell (Yan et al., 2016; 
Rinaldi et al., 2019). The levels of cAMP in any intracellular location are 
influenced by two key enzymes: adenylyl cyclase (AC) (the cAMP producer) and 
cyclic nucleotide phosphodiesterases (PDEs), the only family of enzymes capable 
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of degrading the cyclic-nucleotide. (Sassone-Corsi, 2012; Baillie, Tejeda and 
Kelly, 2019a) (Figure 1.7).  
The classical model of activation of the cAMP pathway involves the 
heterotrimeric G-protein coupled receptor (GPCR). GPCRs are the largest of 
membrane proteins and mediates most cellular responses that involve an 
extracellular cue. These receptors are characterised by seven α-helical 
transmembrane domains separated by alternating intracellular and extracellular 
loop regions (Rosenbaum, Rasmussen and Kobilka, 2009). Heterotrimeric G 
proteins are made up of three subunits: Gα, Gβ, Gγ. In the inactive state, Gα is 
bound to Gβγ dimer and guanosine diphosphate (GDP) (Tuteja, 2009). Binding of 
a ligand to the extracellular domain of the receptor leads to a conformational 
change of the receptor to accommodate the association of the G-protein 
complex (Latorraca, Venkatakrishnan and Dror, 2017). G-protein association 
triggers the guanylyl nucleotide exchange, from GDP to guanosine triphosphate 
(GTP), which leads to the dissociation of Gα from Gβγ as a free active subunit. 
GTP-bound Gα binds and activates AC, which can then in turn hydrolyse ATP to 
form cAMP (Ferre, 2015). The hydrolysis of GTP to GDP terminates the AC 
signalling and promotes the dissociation of Gα from AC and the reassembly of 
the free heterotrimer (Ferre, 2015). Four main cAMP effector proteins have been 
identified that transduce the cAMP signal: PKA, exchange protein directly 
activated by cAMP (EPAC), cyclic-nucleotide-gated ion (CNG) channels, and the 
Popeye domain containing protein family (POPDC) (Sassone-Corsi, 2012; 
Schindler and Brand, 2016) (Figure 1.7).  
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Figure 1.7 Cyclic nucleotide signalling pathways. Ligand binding to a G-protein coupled 
receptor (GPCR) leads to the activation of adenylyl cyclase (AC) by the Gαs subunit. AC is then 
able to synthesise the production of cAMP from ATP. cAMP can activate exchange protein 
activated by cAMP (EPAC), protein kinase A (PKA), popeye-domain containing protein (POPDC) 
and cyclic nucleotide gated channels (CNGs). Activation of proteins downstream of cAMP leads to 
the phosphorylation of multiple target, including the transcription factor cAMP response element 
binding protein (CREB). Phosphodiesterase (PDE) are currently known to be the only proteins 
known to hydrolyse cAMP to 5’AMP. PDEs in black only hydrolyse cAMP. On the other hand PDEs 
highlighted in red are known to also hydrolyse cGMP. (Baillie, Tejeda and Kelly, 2019). 
1.5.2 Protein Kinase A  
The 3’, 5’-cyclic adenosine monophosphate (cAMP)-dependent protein kinase A 
(PKA) is considered essential for mediating a wide range of biological effects 
that are initiated by cAMP (Figure 1.7) (Chung et al., 2009). The cAMP-PKA 
pathway is one of the major signalling pathways that is implicated in PC 
progression (Sarwar et al., 2014). PKA is a hetero tetramer consisting of two 
catalytic subunits that bind to a pair of regulatory subunits and it is ubiquitously 
expressed and involved in multiple cellular processes. Four genes encode the 
regulatory (R) subunit (RIα, RIIα, Riβ, RIIβ), and three encodes the catalytic (C) 
subunit (Cα, Cβ, Cγ) (Schächterle et al., 2015). PKA can phosphorylate multiple 
targets in each individual cell following binding of two cAMP molecules to each R 
subunit that induce a conformational change that serves to release and activates 
the C subunit (Koschinski and Zaccolo, 2017). In order to maintain the normal 
functioning of PKA signalling, its activity is tightly controlled in space and time 
by scaffolding proteins known as A-kinase anchoring proteins (AKAPs) (Søberg et 
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al., 2017). Although PKA phosphorylation plays an important part in disease 
progression, changes in expression of PKA and its subunits is also known to be 
important in PC. Initial work by Cho et al (2000) demonstrated that PKA-I 
expression was increased in multiple cancers, including PC (Cho et al., 2000). 
PKA-I is known to contribute to tumour growth and progression, as well as 
suppress the innate and adaptive arms of anti-tumour surveillance (Hussain et 
al., 2015). Overexpression of PKA-I is often associated with poor disease 
outcome due to its ability to increase cell growth and neoplastic transformation 
(Khor et al., 2008). Further details about PKA phosphorylation, and its role in 
PC, will be discussed in chapter 4. 
1.5.3 Other cAMP effector proteins 
EPAC proteins act as guanine nucleotide exchange factor (GEF) and activates the 
small GTP-binding proteins Rap1 and Rap2 (Tsalkova et al., 2009). An important 
downstream effect of EPAC activation is the induction of integrin-mediated cell 
adhesion and E-cadherin mediated cell-junction formation (Rehmann, de Rooij 
and Bos, 2010). Cyclic-nucleotide-gated ion channels (CNG) are opened by the 
binding of cAMP (Kaupp and Seifert, 2002). These channels play an important 
role in the transduction olfactory signals in olfactory receptor neurones. 
Stimulation of odorant receptors leads to an increase in the intracellular levels 
of cAMP, which in turn activates CNG, leading to an influx of sodium and calcium 
ions (Brown et al., 2006). There are currently three know isoforms of the 
membrane-bound POPDC proteins, POPDC1-3. Although their biochemical 
activity is poorly understood, some of their functions have been determined 
using genetically modified animal models (Amunjela and Tucker, 2016; Brand, 
2018) (Figure 1.7). Interestingly, the loss of POPDC expression correlates with 
enhanced cellular proliferation, migration, invasion, metastasis, drug resistance, 
and poor patient prognosis in various human cancers (Amunjela and Tucker, 
2016). 
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1.6  Phosphodiesterase 
1.6.1 Overview of the PDE family 
PDEs are currently the only known superfamily of enzymes that can hydrolyse 
cAMP to influence the spatial and temporal aspects of receptor-driven cAMP 
signalling and prevent the inappropriate activation of downstream signalling 
pathways under basal conditions (Fertig and Baillie, 2018). There are eleven 
known families of PDEs that exists in mammals, with multiple genes, alternative 
splicing and promoter diversity giving rise to many unique isoforms per family. 
Each isoform has different affinities for cAMP, cGMP or both and they are 
constrained within tight spatial localizations in order to sculpt the local cAMP or 
cGMP gradients formed by specific receptors (Formosa and Vassallo, 2014). All 
PDEs contain three functional domains: a conserved catalytic core, a regulatory 
N-terminus and a less well-defined C-terminus. The catalytic and C-terminal end 
of all PDEs share 18-46% sequence homology overall (Halpin, 2008). PDEs are 
categorised on their catalytic domain homology, however each isoform possesses 
a subfamily specific N-terminus containing differing lengths and complexity of 
regulatory domains. The role of PDEs is not only to control the total cellular 
content of cAMP but create nanodomains for compartmentalised cAMP signalling 
mechanisms that underpin receptor function that produced the cAMP in the first 
place. The precise subcellular location of a cornucopia of different PDEs within 
the cell allows a single cell to respond to multiple extracellular and intracellular 
signals. PDEs maintain the correct levels of cAMP in the correct place at the 
correct time and in doing so they regulate multiple physiological processes and 
their dysfunction is known to be a factor in many diseases (Baillie, Tejeda and 
Kelly, 2019a).  
1.6.2 Structure of PDE4 isoforms 
PDE4 was the first PDE to be characterised biochemically and can exclusively 
hydrolyse cAMP (Houslay and Adams, 2003). There are currently four genes (A, B, 
C, and D) that are able to generate approximately 25 different isoforms each 
containing a unique N-terminal targeting domain, and they are currently 
considered the largest of the 11 families of PDEs (Klussmann, 2016). The 
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regulatory region contains the upstream conserved regions 1 and 2 (UCR1 and 
UCR2), which is then followed by the catalytic domain (Figure 1.8). 
 
Figure 1.8 Schematic representation of PDE4A, B, C, and D. Each isoform distinguishes 
themselves from its unique N-terminal region. PDE4 isoforms are categorised based on their 
regulatory UCR1 and UCR2 region. All PDE4 isoforms share a highly conserved catalytic domain 
and a C-terminal region. (Figure taken from Tibbo, Tejeda and Baillie, 2019). 
The UCR1/2 region is connected to the catalytic domain by the linker region 1 
and 2 (LR1 and 2) respectively (Fertig and Baillie, 2018a). The unique N-terminal 
of each PDEs often mediates protein-protein or protein-lipid interactions in 
order to target each enzyme to the appropriate subcellular compartment or 
signalling complex. Each individual PDE4 isoform controls one or more distinct 
pools of cAMP and has unique physiological functions that do not overlap with 
another PDE4 isoform (Xie et al., 2014). Interestingly, the expression of PDE4 
isoforms has been shown to increase following prolonged, raised intracellular 
levels of cAMP. The long-term elevation in cAMP levels leads to the increase in 
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mRNA and protein expression of multiple PDE4 isoforms, particularly PDE4D1 and 
PDE4D2 (MacKenzie et al., 2002). 
PDE4s can be further divided into three categories: long, short and super short. 
Long isoforms contain both UCR1 and UCR2 regions, whereas short isoforms only 
express the UCR2 region and super short isoforms have a truncated UCR2 region 
(Houslay and Adams, 2003). It has also been demonstrated that PDE4s can form 
dimers via the UCR1 region. In general, long isoforms exist as dimers, whereas 
short isoforms are only able to behave as monomers as they lack components 
which facilitate interaction of the monomers. Specifically, the UCR1 region has 
been shown to mediate intermolecular interactions that allow the dimerization 
of long isoforms and deletions of this region leads to the ablation of this 
interaction and the formation of monomeric proteins. Furthermore, the isolation 
the UCR1 regions results in its oligomerization (Xie et al., 2014). It has been 
shown that C-terminal end of the UCR1 region of a long-isoforms is able to bind 
to the N-terminal end of UCR2 and that this interaction can be inhibited by the 
PKA phosphorylation of a serine within the UCR1 domain (Beard et al., 2000). 
 
1.6.3 PDE4 activation and regulation 
PDE4 isoforms are important in the cross talk between cAMP and other signalling 
pathways. Therefore, tight control of their catalytic activity is necessary in 
order to maintain normal cell homeostasis. In addition to aiding the dimerization 
of PDE4 long isoforms, the UCR1/2 region has been shown to be important in the 
regulation of its catalytic activity. Using structural analysis, it has been shown 
that the UCR2 region of one of the subunit of the dimers crosses over to the 
catalytic region of the other dimer (Cedervall et al., 2015). This conformational 
change regulates the autoinhibition of PDE4 activity. The evidence shows that 
the crossing over of the UCR1/2 region regulates the catalytic activity (Francis, 
Blount and Corbin, 2011) in a trans-capping modality whereby one member of 
the dimer has its catalytic pocket occluded by the other’s UCR2 . 
Phosphorylation of the UCR1 by PKA disrupts the UCR2’s ability to block the 
catalytic domain, activating the enzyme. Increased levels of intracellular cAMP 
are known to increase the cellular activity of long PDE4 isoforms in this manner 
(Figure 1.9) (MacKenzie et al., 2002).  
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Figure 1.9 Phosphorylation of PDE4s by PKA regulates its activation. Phosphorylation of long 
PDE4 isoforms leads to the phosphorylation of UCR1 region. This in turn leads to the binding of 
UCR1 to bind to its own UCR2 domain instead of the catalytic domain. Thin in turn leads to the 
activation of the catalytic activity of PDEs (figure taken from Baillie, Tejeda and Kelly, 2019). 
PDE4 activity can be further regulated by the phosphorylation via the ERK MAP 
kinase pathway. This pathway is a key route by which various growth factors and 
hormones exert their effects on cell growth and survival. All PDE4 isoforms, 
apart from PDE4A, contain a single ERK phosphorylation site within its catalytic 
domain (Houslay and Adams, 2003). In cells expressing long PDE4 isoforms, 
phosphorylation by ERK leads to the inhibition of its enzymatic activity leading 
to an increase in cellular levels of cAMP. This in turn allows for the activation of 
PKA and the phosphorylation of UCR1, leading to the ablation of the inhibitory 
effects of ERK phosphorylation. This provides a regulatory system, with the 
effects of ERK phosphorylation only being transient and rapidly overturned 
(Baillie et al., 2000).  
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Figure 1.10 Overview of PDE post-translational modifications. The intracellular concentration 
of cyclic nucleotides is highly dependent on the addition of different functional groups to PDEs. 
Phosphorylation of PDEs is the most common mechanism by PDE activity is regulated. Some PDE 
isoforms, such as PDE10A2, can be palmitoylated, enabling its translocation to the membrane. 
Ubiquitination, s-nitrosylation, and hydroxylation of PDE can all lead to the enzymes’ degradation 
by increasing their detection by an E3 ligase. SUMOylation of a PDE isoform can lead to an 
increase in its activity. Figure taken from Baillie, Tejeda and Kelly, 2019. 
1.6.4 PDE4D involvement in prostate cancer 
In the last 10 years, there has been increasing evidence indicating that PDE4D 
has a role in the progression in PC. First identified by Rahrmann et al (2009), the 
expression of PDE4D isoforms was found to be overexpressed in human PC 
patient samples and cell lines. Changes in PDE4D mRNA isoform expression was 
also observed in patient samples and this was verified when experimentation 
showed that knockdown of PDE4D lead to reduced growth and migration of PC 
xenografts in vivo. This study was the first indication that PDE4D promotes the 
proliferation of PC (Rahrmann et al., 2009). Since then, expression levels of 
various PDE4D isoforms have been determined. Using quantitative polymerase 
chain reaction (qPCR) technology, the mRNA expression levels of PDE4D was 
evaluated in 19 different PC cells lines and xenografts and led to the 
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identification that the overall levels of PDE4D mRNA was decreased during the 
transition between the AS to AI state (Henderson et al., 2014). Further 
investigation revealed that a significant proportion of this decrease was due to 
the decrease in PDE4D7 expression (Figure 1.11). This was observed at both 
mRNA and protein level. Decreased expression of PDE4D7 in AI samples lead to 
the reduced ability of PC cells to hydrolyse cAMP. In addition, it was noted that 
selective knockdown of PDE4D7 using small interfering RNA (siRNA) in an AS cell 
line (VCaP) resulted in increases in cellular proliferation. On the other hand, re-
expression of PDE4D7 in an AI cell line (PC3) by transfection impeded cellular 
proliferation, indicating that PDE4D7 mediated cAMP signalling processes within 
the AI cell results in the inhibition of proliferation. This same trend was 
observed when increases in cell cAMP were mimicked when PC3 cells were 
stimulated with the AC activator forskolin (Henderson et al., 2014). 
 
Figure 1.11 PDE4D1-9 expression in PC cell lines and xenografts. Expression of various 
PDE4D isoforms was assessed using Real Time qPCR. PDE4D7 expression was shown to have 
the highest expression in PDE4D transcripts in PC cells and is significantly downregulated in AI 
samples. (Henderson et al., 2014). 
The need for more accurate biomarkers to reflect molecular pathologies lead to 
the further characterisation of PDE4D7 in PC. In order to understand whether in 
vitro data can be translated to patient samples, over 1045 patient samples were 
screened for PDE4D7 expression. The TMPRSS2-ERG gene rearrangement status 
was also examined. PDE4D7 expression has been shown to positively correlate 
with disease progression and expression of this isoform significantly decreased 
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between primary PC tumours and CRPC samples. Interestingly, the expression of 
PDE4D7 was highest in primary PC samples indicating PDE4D7 may have a role 
with initial tumorigenesis. PDE4D7 was significantly highly expressed in tumour 
samples containing the TMPRSS2-ERG gene fusions when compared to TMPRSS2-
ERG negative samples (Böttcher et al., 2015).  
It has been proposed that the changes in PDE4D7 expression can be used as a 
novel prognostic marker for PC. This would then allow clinicians to provide 
patients with a “PDE4D7 score” that may reflect their stage of disease 
progression. Henderson et al (2019) propose that by determining the levels of 
PDE4D7 mRNA transcript, they could potentially predict post-surgical disease 
outcome (Henderson et al., 2019). For example, the risks of post-surgical 
progression would significantly increase in patients with a low PDE4D7 score. On 
the other hand, patients with a very high score are much less at risk of disease 
progression. In such a manner, the “PDE4D7 score” has the potential to be a 
more accurate and effective prognostic tool to clinicians (Böttcher et al., 2016; 
Henderson et al., 2019). Recent work by van Strijp et al (2018) further validated 
the prognostic power of PDE4D7 as a new biomarker for PC. The correlation 
between PDE4D7 scores were studied in pre-surgical and post-surgical samples. 
mRNA from patient and biopsy samples were extracted, and a Cox regression 
was applied to combine the clinical score with PDE4D7. Once again, results 
showed that PDE4D7 expression was highly associated with PSA recurrence after 
surgery and the expression of PDE4D7 was shown to provide risk information for 
pre-treatment risk stratification. Combinations of clinical scores with PDE4D7 
status significantly improved the clinical risk stratification before surgery (van 
Strijp et al., 2018). This combination allows a more accurate definition of the 
disease as well as suggesting the most appropriate course of treatment (Figure 
1.12). 
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Figure 1.12 Kaplan-Meier survival analysis of the biochemical recurrence free survival (BCR) 
in the patient diagnostic biopsy. A cohort of patient biopsies were given a PDE4D7 score, and 
this was plotted against BCR progression and survival probability. Patients with a lower PDE4D7 
score (brown) were less more to show disease progression. However, patients with a higher score 
(blue) were less likely to show signs of disease reoccurrence. Figure taken from van Strijp et al., 
2018. 
1.7  DExH-Box Helicase 9 (DHX9) and cancer 
1.7.1 Structure and function of DHX9  
DHX9, also referred to as RNA helicase A (RHA) or nuclear DNA helicase II, is a 
nucleoside triphosphate (NTP)-dependent helicase that has been shown to 
unwind both DNA and RNA, as well as aberrant polynucleotide structures (Lee 
and Pelletier, 2016). DHX9 is a protein that is approximately 140 kDa in size and 
it contains eight domains (Fidaleo, De Paola and Paronetto, 2016). The N-
terminal region of DHX9 is characterised by two copies of double stranded RNA 
binding domain (dsRBD), then followed by the minimal transactivation domain 
(MTAD). The dsRBD region has the ability to bind to the post-transcriptional 
control elements (PCEs) in the 5’ untranslated region (UTRs) of specific mRNAs 
to modulate their translation (Fidaleo, De Paola and Paronetto, 2016). The core 
helicase domain consists of 8 motifs that are subdivided into two Rec-A like 
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domains, with motifs 1-3 residing in the first domain while motifs 4-6 reside in 
domain 2 (Lee and Pelletier, 2016). The helicase region contains an ATP binding 
site with the consensus sequence GCGKT (A site) and FILDD (B site) in the first 
motif of the helicase domain (Zhang and Grosse, 1997). The C-terminal domain 
contains the helicase-associated domain 2 (HA2) followed by the 
oligonucleotide/oligosaccharide-binding fold (OB-fold) overlapping the nuclear 
localization/export signal (NLS/NES). Also of note is the arginine and glycine 
(RG) rich domain at the very end of the C-terminal end of the protein is able to 
bind to single-stranded nucleic acids (Lee and Pelletier, 2016) (Figure 1.12) 
 
Figure 1.13 Schematic representation of functional domains of DHX9. DHX9 is a 140kDa 
protein formed of eight distinct domains. The N-terminal region is composed of the dsRBD and 
MTAD regions. The helicase core domain contains the conserved ATP-dependent helicase 
domain. Finally, the C-terminal domain contains the HA2, OB-fold, NLS/NES, and RGG-box 
(Figure taken from Lee and Pelletier, 2016). 
DHX9 is a protein that is known to have diverse functions in the cell. The 
function of DHX9 includes regulating DNA replication, transcription, translation, 
microRNA biogenesis, RNA processing and transport, and maintenance of 
genomic stability (Lee and Pelletier, 2016). DHX9 is part of the DExD/H-box 
superfamily of helicases that form a large superfamily of proteins which are 
conserved from bacteria, viruses and humans (Tanner and Linder, 2001). DHX9, 
like other members of the family, has the ability to bind to both DNA and RNA 
via its dsRBD regions (Figure 1.14). DHX9 unwinds double stranded DNA and RNA, 
as well as aberrant structures such as DNA/RNA hybrids, R-loops, intramolecular 
triplex DNA, and G-quadruplexes (Figure 1.14) (Fidaleo, De Paola and Paronetto, 
2016). Although DHX9 is able to bind to both DNA and RNA, the dsRBD has a 
higher affinity for double stranded RNA (dsRNA) and a weaker affinity for single 
stranded DNA (ssDNA) (Zhang and Grosse, 2004). DHX9 moves in a 3’ to 5’ 
direction and can use ATP for its unwinding activity. In order for this enzyme to 
work efficiently, DHX9 binds to a 3’ single-stranded tail that serves as an anchor 
for enzyme binding (Lee and Pelletier, 2016). 
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Figure 1.14 DHX9 nucleic acid substrates. DNA is coloured in red, and RNA strands in blue. 
DHX9 binds to the 3’ single stranded tail that can be found on multiple substrates (Lee and 
Pelletier, 2016). 
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1.7.2 DHX9 in cancer  
The expression of multiple DNA helicases, including DHX9, are upregulated in 
cancer cells/tissues and is required for cancer cell proliferation or resistance to 
DNA damage in response to DNA damage acquired during chemotherapy (Figure 
1.15). This reflects the need to respond to increased replicative lesions that 
arise in highly proliferative states (Brosh, 2013). Multiple missense mutations in 
human helicase genes have been identified and linked strongly with cancer, 
highlighting the importance of this protein in maintaining genomic stability 
(Suhasini and Brosh Jr, 2013). Dysregulation of this functionally diverse 
superfamily can have disastrous effects on normal cellular homeostasis and 
contribute to cancer development and progression (Cai et al., 2017). 
 
Figure 1.15 DExD/H helicases in adult cancers. DExD/H helicases have been reported to be 
involved in multiple solid and blood cancers. DHX9 has is known to be involved in prostate, lung, 
breast and testicular cancers. Figure taken from Cai et al., 2017. 
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One cancer where the expression of DHX9 has been shown to be increased is in 
lung cancer. Using RT-PCR, DHX9 mRNA expression is increased in tumour 
samples when compared to normal lung tissue, however, there is no correlation 
between DHX9 expression and disease stage and survival (Wei et al., 2004). As 
well as being overexpressed, DHX9 has been shown to inhibit the effects of 
enoxacin in lung cancer cell lines. Enoxacin has been used as an anti-tumoral 
agent due to its ability to induce microRNA biogenesis (Sousa et al., 2013).  
 
In recent years, DHX9 has slowly become an interesting new target to slow the 
progression of different cancers. It has been reported that the inhibition of DHX9 
expression reduces the fitness of different cancer cell types. Cells lines derived 
from multiple myeloma, osteosarcoma, breast, lung, and cervical cancer were 
transfected with shRNA targeting DHX9 and suppression of DHX9 in all cell lines 
lead to an increase in the rate of cellular apoptosis and growth arrest. 
Interestingly, when this same experiment was repeated in murine lymphoma 
models, the prolonged suppression of DHX9 did not result in negative off-target 
effects being recorded and as body weight, blood biochemistry, and histology 
were similar to that of control mice. The suppressed expression of DHX9 was 
tolerated in vivo, suggesting that DHX9 can be a new chemotherapeutic target 
with tolerable side effects (Lee et al., 2016). Using FISH, Southern blotting and 
PCR analysis, the DHX9 gene was shown to locate to chromosome 1q25. This is 
known to be a major susceptibility locus for hereditary PC supporting the 
suggestion that potential mutation at this site can lead to dysfunctional 
regulation of transcription as well as increase cellular proliferation in the 
prostate (Lee et al., 1999). This observation is highly relevant to the direction of 
travel within my thesis and how will this impact the field. 
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1.8 PDE4D7 and DHX9 – Potential interactors in prostate 
cancer 
Recent work in the Baillie lab has identified DHX9 as a potential interacting 
partner for PDE4D7 in PC (unpublished work funded by Prostate Cancer UK). In 
recent years, DHX9 has emerged as an important protein in multiple cancers by 
either acting as an oncogene or as a tumour suppressor (Yan et al., 2019) and it 
has a large number of interacting partners, involving it in multiple biological 
processes (Lee and Pelletier, 2016). The function and molecular mechanisms 
surrounding the PDE4D7-DHX9 signalosome have not been characterised. To 
date, DHX9 and PDE4D7 has only been suggested to be novel interactors by the 
Baillie, and this can only be speculated as both proteins are expressed in the 
prostate (Figure 1.16).  
 
Figure 1.16 Expression of DHX9 and PDE4D in different tissues. Expression of DHX9 (B.) and 
PDE4D7 (A.) was investigated in multiple tissues sections, then analysed. Both proteins are 
expressed in the prostate, highlighted with an asterisk. Data obtained from The Human Protein 
Atlas (http://www.proteinatlas.org).  
Although PDE4D is highly expressed in the prostate, DHX9 is moderately 
expressed in the prostate. However, these two proteins are expressed in 
different compartments. Data from the Human Protein Atlas has shown that 
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DHX9 is highly expressed in the nucleus, whereas PDE4D is expressed in the 
plasma membrane and the cytosol (Uhlen et al., 2017). However, recent work by 
multiple groups have shown that DHX9 is able to shuttle in and out of the 
nucleus thanks to a NLS/NES signal in its C-terminal region (Lee and Pelletier, 
2016). Interestingly, PDE4D is able to mediate reactions within the nucleus 
(Robinson et al., 2020), indicating that these two proteins can exist in the same 
cellular compartment. In addition to looking at the expression of these two 
proteins in healthy tissues, the expression of PDE4D and DHX9 was expression 
was investigated in diseased prostate tissue (Figure 1.17). Interestingly, these 
two proteins have opposite expression patterns in prostate cancer. Higher 
expression of DHX9 (figure 1.17 B) is associated with low survivability, while 
higher expression of PDE4D7 is associated with high survivability (figure 1.17 A).  
 
Figure 1.17 PDE4D and DHX9 expression in PC. The expression of PDE4D7 (A) and DHX9 (B) 
was investigated in multiple PC tissues. Protein expression was related to survival probability. Data 
taken from The Human Protein Atlas (Uhlen et al., 2017) 
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Data collected from the Human Protein Atlas, as well as from the Baillie lab, 
highly suggests that these two proteins are important in PC pathogenesis and 
progression. While the expression of PDE4D7, more specifically PDE4D7, 
decreases as the disease progresses, DHX9 expression increases, suggesting the 
expression and function of these two proteins are linked to one another.  
1.9 Thesis Aims 
The literature reviewed above has highlighted the importance of PDE4D7 in the 
development and progression of PC and has indicated that DHX9 is also involved 
in cancer, including PC. In this light, the fact that PDE4D7 and DHX9 form a 
signalling complex in PC cells suggests that they may coordinate cancer related 
signalling mechanisms. If true, the DHX9-PDE4D7 signalling axis could represent 
a novel target for therapeutic intervention in PC. My thesis seeks to verify the 
existence of the DHX9-PDE4D7 complex and to use novel biochemical tools and 
assays to gain some understanding of the molecular mechanisms that underpin 
the influence of the complex on PC cell growth. The thesis is divided into three 
sections with the following aims: 
AIM 1: To confirm the interaction between PDE4D7 and DHX9. Biochemical 
techniques were used to show the direct interaction between DHX9-PDE4D7 
and data was supported by complementary imaging techniques that 
visualised co-localisation of the proteins in a cellular context. Peptide array 
technology was used to map the DHX9-PDE4D7 protein-protein interaction 
domains and this information used to develop cell penetrating disruptor 
peptides that acted to specifically disassemble the complex. These novel 
bio-tools were used in “functional” assays as part of AIM 3. 
AIM 2: To determine whether DHX9 is a substrate for PKA phosphorylation. 
As many PDE4 containing protein complexes contain PKA substrates, I was 
keen to find out if DHX9 could be modified in this way. Using peptide array 
technology, a putative PKA phosphorylation site was identified on the 
helicase. Using sequence information, I developed novel custom phospho-
DHX9 to the site. Such a tool could be used to gauge the influence of 
PDE4D7 on putative PKA phosphorylation of DHX9. DHX9 phosphorylation 
was studied in vitro using biochemical and imaging techniques.  
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AIM 3: To characterise the role of DHX9 in PC cells. By using Real Time Cell 
Analyzer (RTCA) xCELLigence technology, the effects of DHX9 silencing via 
siRNA knockdown or treatment with a DHX9 inhibitor was studied. The 
functional implication of the disruption of the PDE4D7-DHX9 complex (using 
DHX9-PDE4D7 peptide from AIM1) was examined by measuring the levels of 
R-loops and monitoring PC cell growth. Finally, changes in downstream PC 
signalling pathways influenced by DHX9 were evaluated using Reverse Phase 
Protein Array (RPPA) following treatment of PC cell lines with DHX9-
specific siRNA .  
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Chapter 2 Material and Methods 
2.1  Molecular Biology 
2.1.1 Constructs 
 
Table 2.1 List of plasmids used for this thesis 
Construct Antibiotic Resistance Source 
pcDNA3.1 PDE4D7-VSV Ampicilin (Sigma, A9393) I. Gall 
pCMV3 DHX9-FLAG Kanamycin ( Thermo 
Fisher, 11815032) 
Sino Biological 
pGEX-6P-1 DHX9-GST Ampicilin (Sigma, A9393)  
 
Dr J. Capitanio and Prof 
R. Wozniak, University of 
Alberta, Canada 
 
 
pGEX-6P-1 GST-DHX9 1-
380 
Ampicilin (Sigma, A9393) 
pGEX-6P-1 GST-DHX9 
381-820 
Ampicilin (Sigma, A9393) 
pGEX-6P-1 GST-DHX9 
821-1270 
Ampicilin 
pGEX-5X-1 4D UCR1-GST Ampicilin (Sigma, A9393) Dr G. Bolger, University 
of Alabama, USA 
pGEX-4X-1 GST Ampicilin (Sigma, A9393) Dr Y.Y Sin, University of 
Glasgow, UK 
  
2.1.2 Transformation of plasmid DNA into competent cells 
DH5a (Agilent, 200231) and BL21(DE3) Codon Plus (Agilent, 230245) were stored 
at -80°C and thawed on ice prior to use. 1-10 ng of plasmid DNA (Error! R
eference source not found.) was added to 50 µL competent cells, mixed gently 
by pipetting, and incubated on ice for 30 minutes. After incubation, the cells 
were heat shocked for 45 seconds at 42°C and placed on ice for a further 2 
minutes. 450 µL of Luria broth (LB) (10g/L tryptone, 10g/L NaCl, 5 g/L yeast 
extract) was added to the transformant, then grown for an hour at 37°C, 300 
RPM. 50 - 150 µL of the transformation mixture was then spread onto a LB Agar 
plate (10g/L tryptone, 10g/L NaCl, 5 g/L yeast extract, 20 g/L agar) containing 
the appropriate antibiotic and incubated overnight at 37°C.  
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2.1.3 Isolation and quantification of plasmid DNA 
Single colonies from the transformation plate were picked and grown overnight 
in 5 mL of LB containing 50 µg/mL of kanamycin at 37°C, 220 RPM. Isolation of 2 
mL of the overnight culture was conducted using the QIAprep Miniprep kit 
(Qiagen, 27106) according to manufacturer’s instructions. For an overnight 250 
mL bacterial culture, plasmid DNA was purified using PureLink HiPure Plasmid 
Maxiprep kit (Invitrogen, K210007) according to manufacturer’s instruction. The 
purified DNA was resuspended in ultra-pure nuclease free H2O and stored at -
20°C.  
2.1.4 Quantification  
A NanoDrop 3300 spectrophotometer (Thermo Fisher Scientific) was used to 
determine the concentration and purity of the plasmid DNA. The absorbance of 
the sample was measured at 260 nm and 280 nm. Absorbance at 260 nm was 
used to quantify the concentration of dsDNA in the sample, whereas the 
A260/280nm ratio was used to determine the purity of the sample.  
2.1.5 Storage of plasmid DNA 
For plasmid storage, 1 mL of the overnight culture grown in 2.1.3 was mixed 
with 1 mL of 50% glycerol / 50% LB in a sterile cryovial. The glycerol stock was 
snap frozen on dry ice and stored at -80°C until needed. For future DNA 
preparations, a sterile pipette tip was used to scrape cells from the frozen vial 
an inoculate 250 mL of LB with the appropriate antibiotic. The culture was 
incubated overnight at 37°C, 220 RPM. Plasmid DNA was purified as described in 
2.1.3. 
2.1.6  Analysis of plasmid DNA  
In order to check the correct identity of purified plasmid DNA, 50 ng of plasmid 
DNA was incubated with 1 unit of restriction enzyme. Plasmid DNA was digested 
using the following reaction composition: 
 Enzyme 1: 1 µL 
 Enzyme 2: 1 µL 
 10 x reaction buffer: 5 µL  
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 Plasmid DNA: 50 ng 
 Nuclease free water: up to 50 µL 
6 x Purple Loading Dye: 10 µL 
 
The restriction enzymes used to cut each plasmid is included in table Table 2.2 
Restriction enzymes used for each plasmid 
Table 2.2 Restriction enzymes used for each plasmid 
Plasmids Restriction enzymes Fraction sizes 
pGEX-6-P-1 DHX9 BglII + BamHI 5 364bp + 3 424bp 
pGEX-6-P-1 DHX9 1-380 
aa 
BamHI + HindIII 5 334bp + 784bp 
pGEX-6-P-1 DHX9 381 - 
820 aa 
BamHI + NotI 4 955bp + 1 163bp 
pGEX-6-P-1 DHX9 821 - 
1270 aa 
BglII + BamHI 5 364bp + 967bp 
 
The digestion was allowed to incubate for one hour at 37°C. The reaction was 
stopped by adding 10 µL of 6 x Purple Loading Dye. Agarose gel electrophoresis 
was used to analyse 20 µL of the restriction enzyme digest. 1% agarose (w/v) 
was dissolved in Tris-acetate EDTA (TAE) buffer (40mM Tris, 20mM Acetate and 
1mM EDTA). The solution was allowed to cool slightly, and SybrSafe (Invitrogen, 
S33102) was added to visualise the DNA fragments under UV light. The gel was 
cast in the Bio-Rad SubCell GT Agarose gel system with a comb inserted to 
create wells and allowed to cool. Once set, the comb was removed, and the gel 
placed in gel tank containing TAE buffer. A 1kb DNA ladder (NEB) was used as a 
marker. The gel was run for an hour at 100 V, or until the dye front migrated 
two thirds of the gel. The gel was then removed from the tank and imaged using 
the Gel Doc XR+ system (Bio-Rad). If the digest suggested that the correct 
plasmid was purified, 100 ng plasmid DNA, in a final volume of 20 µL, was sent 
to GATC (Eurofins) for sequencing.  
2.2  Mammalian Cell Culture 
2.2.1 Culture of human cell lines 
All cell culture procedures were performed in class II hoods using aseptic 
technique with sterile plastics and instruments. All cell culture reagents were 
purchased from Sigma. Culture flasks were purchased from Corning. The cells 
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were observed using a phase contrast inverted microscope in order to ensure 
that the cells were healthy and free of any contaminants. Cells were maintained 
at 37°C with 5% CO2 and 95% air. DU145, VCaP, and HEK293 cells were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (SAFC, D5671) 
supplemented with 10% foetal bovine serum, 100 units/mL penicillin and 
streptomycin, and 2mM L-glutamine. HEK293 media was further supplemented 
with 1 x non-essential amino acids (Invitrogen, 11140050). VCaP media was 
further supplemented with 1 mM sodium pyruvate. LNCaP cells were maintained 
in RPMI-1640 (SAFC, R8758) supplemented with 10 % FBS and 100 units/mL of 
penicillin and streptomycin. All cells were sub-cultured when 80% confluent. 
Cells were passaged when 80% confluent. All culture medium, phosphate 
buffered saline (PBS), and trypsin was pre-warmed to 37°C. Conditioned VCaP 
media was set aside for future use. However, for all other cell lines, culture 
medium was aspirated from flasks. Cells were washed with 5 mL PBS. Cells were 
removed from the culture flasks with the addition of 5 mL of 0.25% trypsin-EDTA 
solution. The flask was placed back in the 37°C incubator for five minutes or 
until the monolayer has detached from the flask. An equal volume of growth 
medium was added to the flask to neutralise the trypsin, and the cell were 
collected by centrifugation at 700 RPM for three minutes at room temperature. 
The cell pellet was resuspended in fresh growth medium, or conditioned medium 
for VCaPs, and seeded as required.  
2.2.2 Cryopreservation of cells 
In order to freeze cells for future use, pelleted cells were resuspended in 1 mL 
freezing medium containing complete growth medium supplemented with 10% 
sterile DMSO. Cells were transferred to a sterile 1.8 mL cryovial and stored in a 
freezing container with 100 % isopropanol at -80°C for 24 hours. Frozen cells 
were transferred to liquid nitrogen for long term storage the following day. In 
order to revive cells, cryovials containing the cells was thawed by incubated in a 
water bath at 37°C. Cells were added to a 75 cm2 culture flask containing 10 mL 
of prewarmed media and placed in the 37°C 5% CO2 incubator. After 24 hours, 
the cells were washed with PBS and fresh medium was added in order to remove 
DMSO.  
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2.2.3 Transient transfection of plasmid DNA 
Plasmid DNA was transiently transfected into HEK293 cells. Cells were passaged 
24 hours prior to transfection and seeded into the appropriate culture flask in 
order to ensure cells were at 50-70% confluency on the day of transfection. 
Transfections were performed using Lipofectamine LTX (Thermo Scientific, 
15338100) and OptiMEM reduced serum medium (Thermo Scientific, 11058021) as 
per manufacturer’s instructions. Plasmid DNA and transfection reagent 
concentrations were either scaled up or down for the culture plate in use. Cells 
were incubated with transfection medium for 24-48 hours to ensure plasmid 
expression. Mock transfections were performed as control without plasmid DNA. 
2.2.4 siRNA mediated knockout  
Small interfering RNA (siRNA) gene knockdown was used in order to assess the 
function of DHX9 in PC cells, as well as to test the novel phosphor-DHX9 
antibody. ON-TARGETplus SMART POOL siRNA against human DHX9, PDE4D7, 
SFPQ, GAPDH, and non-targeting were purchased from Dharmacon. Cells were 
plated until they reached 50-70% confluency in the culture plate. The following 
day, the cells were transfected with siRNA to a final concentration of 25 nM 
using either DharmaFECT 1 for DU145 and HEK293 cells or DharmaFECT 3 for 
LNCaP cells according to manufacturer’s instructions. Percentage knockdown 
was assessed by western blotting after 48 hours incubation at 37°C with 5% CO2. 
Table 2.3 siRNA and reagents used in the thesis 
siRNA Catalogue number 
siNon-Targeting D-001810-10-05 
Human GAPDH D-001830-10 
Human DHX9 L-009950-00-0005 
Human PDE4D7 Custom Made against following sequence: 
Sense strand: 5’ AUACCUGUGAUUUGCUUUC 3’ 
Antisense strand: 5’ GAAAGCAAAUCACAGGUAU 3’ 
Human SFPQ J-006455-09-0005 
Dharmafect 1 T-2001-03 
Dharmafect 3 T-2003-03 
5 x siRNA Buffer B-002000-UB-100 
RNA/DNA Free water B-003000-WB-100 
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2.2.5 Treatment of cells 
2.2.5.1 Forskolin, IBMX, and rolipram 
Cells were seeded in either 6 well plates or 10 cm cell culture dishes. 
Treatments were carried out when cells reached 80% confluent. Cells were 
treated with 25 µM forskolin (Sigma, F6886), 100 µM IBMX (Sigma, I5879) or 10 
µM rolipram (Sigma, R6520) for the indicated times at 37°C with 5% CO2. All 
drugs were reconstituted in DMSO, aliquoted into 10 µl aliquots and stored at -
20°C until required. 
2.2.5.2 Disruptor peptide treatment 
Disruptor peptides were reconstituted in DMSO, aliquoted into 10 µl aliquots and 
stored at -20°C until required. All peptides were synthesised by Genescript. 
Cells were plated in the appropriate culture flask until they reached 80 % 
confluency. They were then either treated with 10 µM of scrambled peptide, 10 
µM of UCR1-disruptor peptide, or DMSO for two hours at 37°C with 5% CO2. The 
cells were washed and analysed by immunoprecipitation (IP) with western 
blotting or immunocytochemistry (ICC) with confocal microscopy. 
2.3  Preparation of whole cell lysate 
2.3.1 Whole Cell Lysate 
Protein extracts from were produced from cells in culture. Culture media was 
removed, and cells were washed once in PBS. The cells were then harvested in 
3T3 lysis buffer (25mM HEPEs, 10% v/v glycerol, 50 mM NACl, 1% v/v Triton X-
100, 50 mM NaF, 30 mM NaPPi, 5 mM EDTA, pH 7.4) supplemented with 
cOmplete, EDTA-Free Protease inhibitor cocktail and PhosStop Phosphotase 
inhibitor cocktail (Roche, 5056489001, 5892970001). When 80% confluent, 
culture plates were scraped and lysates were transferred into 1.5 mL Eppendorf 
tubes where they were then incubated for an hour on an end-on-end rotation at 
4°C. Samples were centrifuged at 14 000 x G for 10 minutes at 4°C and the 
supernatants were transferred to a fresh tube and stored at -20°C for short term 
storage. Samples were stored at -80°C for long term.  
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2.3.2 Protein concentration assay 
A Bradford dye-binding method was used to determine the total protein 
concentration in cell lysates and purified recombinant protein. One-part 
Bradford dye (Bio-Rad, 5000006) was mixed with four parts of dH2O. Protein 
standards ranging from 0-5 µg/µL of Bovine Serum Albumin (BSA) was prepared, 
and experimental samples were diluted accordingly. All samples were loaded 
onto a 96 well plate in triplicate, followed by 200 µL of Bradford Dye. The 
absorption was measure at 595 nm using the Spectra Max Plus 
spectrophotometer. Protein concentrations corrected for the dilution factor was 
determined based on the standard curve. 
2.4 Subcellular fractionation 
All centrifugation steps were performed at 4°C. VCaP cells were plated into 10 
cm2 dishes and grown until 80% confluent. Cells were washed twice in phosphate 
buffered saline (PBS) then scraped in 500 µL of fractionation buffer (20 mM 
HEPES, 10 mM KCl, 2mM MgCl2, 1 mM EDTA, 1 mM EGTA) supplemented with 1 
mM DTT and cOmplete EDTA free protease inhibitor. Scraped cells were 
transferred to 1.5 mL Eppendorf tubes and incubated on ice for 15 minutes. Cells 
were then homogenised by passing the suspension through a 25-gauge needle 10 
times, then further incubated on ice for 20 minutes. 100 µL of the suspension 
was transferred into a fresh Eppendorf and used as the whole cell lysate (WCL). 
The remaining suspension was centrifuged at 720 x G for 5 minutes to pellet the 
nuclei from the sample. The supernatant was transferred into a fresh Eppendorf 
tube in order to obtain the cytoplasmic, mitochondrial, and membrane fractions. 
The nuclear sample was resuspended in 200 µL of nuclear preparation buffer 
(NPB) (10 mM NaCl, 10 mM Tris-HCl pH 7.5, 2 mM MgCl2, 0.5% NP-40). The 
nuclear pellet was lysed by passing the suspension through a 25-gauge needle 10 
times then incubated on ice for 15 minutes. The suspension was sonicated 3 
times for 15 seconds, then centrifuged for 5 minutes at 720 x G. The supernatant 
was transferred into a fresh tube and kept as the nuclear fraction (NF).  
The supernatant from the first spin was further centrifuged at 10 000 x G for 5 
minutes. The pellet from the spin was further processed as mentioned above. 
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The supernatant was then transferred into 1 mL UltraCentrifuge tubes (Beckman 
Coulter, 343778) and centrifuged for one hour at 100 000 x G in an Optima TLX 
Ultracentrifuge. The supernatant was transferred into a fresh Eppendorf tube 
and used as the cytoplasmic fraction (CF). The pellet was washed in 400 µL of 
fractionation buffer and resuspended by passing through a 25-gauge needle 10 
times. Samples were then centrifuged again at 100 000 x G for 45 minutes. The 
pellet was resuspended in 400 µL of fractionation buffer and used as the 
membrane fraction (MF). Samples were stored at -20˚C until required. 
Fractionation was checked by SDS-PAGE gel with western blotting. 
2.4.1 SDS-PAGE gel electrophoresis  
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was used 
in order to separate samples based on protein molecular weight. Following the 
Bradford assay, equal concentrations of protein samples were boiled in 5 x SDS 
loading buffer (10% SDS, 300 mM Tris-HCl pH 7.2, 0.05% bromothymol blue, 10% 
β-mercaptoethanol) to denature the proteins. Samples were loaded onto precast 
NuPage 4-12% SDS-PAGE gels (Invitrogen, NP0321BOX, NP0322BOX) in MOPs 
(Invitrogen, NP0001) according to manufacturer’s instructions. A protein ladder 
(Bio-Rad, 1610393) was loaded alongside protein samples and the gel was run at 
200 V for 50 minutes.  
2.4.2 Western Immunoblotting 
 SDS-PAGE gels were transferred onto nitrocellulose membrane using the 
Invitrogen Mini Blot module. Transfer sponges, filter paper, and nitrocellulose 
membranes (ThermoFisher Scientific, 88018) were soaked in transfer buffer (5% 
v/v Invitrogen transfer buffer Invitrogen NP00061, 20 % v/v methanol). The 
transfer sandwich was assembled in the Mini blot module and subjected to a 
constant 25 V for an hour and a half in transfer buffer. Nitrocellulose membranes 
were stained with Ponceau S (0.1% w/v Ponceau S, 5% v/v acetic acid) in order 
to confirm protein transfer, after which the membrane was washed in TBST until 
the stain was removed. Membranes were either blocked in 5% (w/v) non-fat milk 
(Marvel) or 5% (w/v) BSA) in TBST for one hour at room temperature after which 
they were incubated overnight with the appropriate primary antibody in 1% 
(w/v) milk or 1% BSA (w/v) in TBST (Table 2.4).  
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Table 2.4 Primary antibodies used for western blotting 
Primary 
Antibody 
Company and 
Catalogue 
Number 
Host Dilution Factor 
Β-Actin Sigma, A5441 Mouse 1:5000 
Cofilin pSer3 Cell Signalling, 
3313S 
Rabbit 1:1000 
DHX9  Abcam, ab26271 Rabbit 1:1000 
E-Cadherin Cell Signalling, 
3195 
Rabbit 1:1000 
FLAG Thermo, PA1-
984B 
Rabbit 1:1000 
GAPDH  Abcam, ab8245 Mouse 1:5000 
GST Santa Cruz, sc-
138 
Mouse 1:1000 
NDH II (DHX9) Santa Cruz, sc-
137232 
Mouse 1:1000 
P70 S6 Kinase 
pThr 389 
Cell Signalling, 
9205S 
Rabbit 1:1000 
PAN4D In House Goat 1:5000 
PDE4D7 In House Sheep 1:1000 
Phospho AKT 
Substrate 
Cell Signalling, 
9614S 
Rabbit 1:1000 
Phospho PKA 
substrate 
Cell Signalling, 
9624S 
Rabbit 1:1000 
Phospho-DHX9 In House Rabbit 1:200 
PKA Rii Ser96 Merck, ABT58 Rabbit 1:1000 
S6 Ribosomal 
Protein Ser 235 
236 
Cell Signalling, 
2211S 
Rabbit 1:1000 
S6 Ribosomal 
Protein Ser 240 
244 
Cell Signalling, 
5364S 
Rabbit 1:1000 
VSV Abcam, ab1874 Rabbit 1:1000 
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Membranes were washed three times in TBST the next day, after which it was 
incubated in the appropriate secondary antibody for one hour at room 
temperature (Table 2.5). Following a final three washes in TBST, membranes 
were imaged using either ECL substrate with X-ray film development or using the 
Odyssey Licor scanner. 
Table 2.5 Western Blot secondary antibody 
Antibody Company and 
Catalogue number 
Dilution 
IRDye® 800CW Donkey anti-
Rabbit IgG Secondary Antibody 
Licor, 926-32213 1:5000 
IRDye® 680RD Donkey anti-Mouse 
IgG (H + L) 
Licor, 925-68072 1:5000 
IRDye® 680RD Donkey anti-Goat 
IgG (H + L) 
Licor, 925-68074 1:5000 
Anti-Mouse Licor 1:5000 
Goat Anti Rabbit HRP  Jackson 
ImmunoResearch, 
111-035-144 
1:2000 
Rabbit Anti Mouse HRP Jackson 
ImmunoResearch, 
315-035-003 
1:2000 
Donkey Anti Sheep HRP Invitrogen, A16041 1:2000 
 
2.5 GST Protein Purification 
2.5.1 Determining IPTG concentration 
This protocol was developed by Amy J. Tibbo and adapted for DHX9 expression 
plasmids (Table 2.1). In order to determine the optimum concentration of 
isopropyl β-d-1-thiogalactopyranoside (IPTG), 5 mL of LB supplemented with 100 
µg/mL of ampicillin was inoculated with the DHX9-GST constructs overnight at 
37°C, 220 RPM. 10 mL of fresh LB supplemented with 100 µg/mL was inoculated 
with 200 µL of the overnight culture until the OD600 reached between 0.6-0.8. 
The OD600 of 1 mL of culture was recorded in order to calculate the volume in 
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which 1 mL of cell culture needed to be normalised to. 1 mL of culture was 
centrifuged for 10 minutes at 13 000 x G, and the pellet kept in the -20˚C and 
kept as the pre-induced sample. The remainder of the culture was induced for 
protein expression with either 1, 0.5, 0.2 or 0.1 mM of IPTG. Cultures were left 
to incubate overnight at 16°C 220 RPM. At the end of the induction period the 
next day, the OD600 was measured of 1 mL of culture. 1 mL of the culture was 
centrifuged for 10 minutes at 13 000 x G and the pellet was kept as the post-
induction sample. The remainder of the culture was appropriately discarded. 
The pre- and post-induction cell pellets were resuspended in 60 µL of GST 
binding buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1 mM EDTA) 
supplemented with 25 units of Benzonase (Sigma, E1014-5KU). Each sample was 
then made up to a final volume of 150 x OD600 with water. 5 µL of each sample 
was transferred into a fresh Eppendorf tube. 10 µL of water was added to each 
sample, and these were kept as either the total pre-induction or the total post-
induction sample. The remainder of the post-induction sample was further 
centrifuged for 5 minutes at 13 000 x G. The supernatant was transferred into a 
new Eppendorf tube and used as the post-induction soluble fraction. The pellet 
was resuspended in the original final volume, and 5 µL was transferred into a 
fresh Eppendorf tube. 10µL of water was added, and the sample was used as the 
post-induction pellet fraction. 3 µL of 5 x SDS sample buffer was added to each 
tube, then boiled for 5 minutes at 85˚C. Samples were loaded onto a SDS-PAGE 
gel and stained using Coomasie blue in order to determine optimum IPTG 
concentrations.  
2.5.2 Purification of GST tagged proteins 
BL21 E.Coli cells containing an N-terminal GST-tagged plasmid of the UCR1 
domain, GST tag only, or N-terminal GST-tagged DHX9 constructs were 
inoculated in 10 mL of LB supplemented with 100 µg/mL of ampicillin. Cells 
were incubated overnight at 37°C, 220 RPM. The overnight was then added to 
500 mL of fresh LB supplemented with 100 µg/mL of ampicillin. OD600 nm was 
measured every 30 minutes in order to assess cell growth. When OD600 reached 
between 0.6-0.8, the protein expression was induced with 0.2 µM of IPTG. The 
GST-UCR1 and GST tag constructs were incubated at 37°C, 220 RPM, for 3-5 
hours. DHX9 constructs were incubated overnight at 16°C, 220 RPM. Cultures 
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were then pelleted at 4°C by centrifugation at 6 000 x g for 10 minutes. Pellets 
can be stored at -80˚C until required.  
Pellets were resuspended in GST-binding buffer (25 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 0.1 mM EDTA) supplemented with 0.5 % Triton X-100 and protease inhibitor 
tablets. Suspensions were frozen at -80°C for 30 minutes then thawed on ice and 
subjected to sonication (40-60 kHz) for seven 30 second cycles with 30 second 
pause for cooling. Following sufficient lysis, cell debris was removed by 
centrifugation at 13 000 RPM for 15 minutes at 4°C. The supernatant was then 
collected and incubated with pre-equilibrated glutathione beads (GE Healthcare, 
GE17-0756-01) for 1 hour at 4°C with gentle rotation. The protein bound beads 
were then transferred to a gravity flow column (BioRad, 7321010) and washed 
three times with GST-binding buffer. Elution buffer (50 mM Tris-HCl pH 8.0, 10 
mM reduced glutathione) was then used to collect successive fractions of 
recombinant purified protein. Purity of the sample was assessed by SDS-PAGE, 
Coomassie staining, and immunoblotting as described in section 2.5. The purest 
fractions were subjected to ultrafiltration using Vivaspin with a 20 kDa or 50 kDa 
molecular weight cut off (Sartorius, VS15RXETO, VS0631) containing dialysis 
buffer (5% glycerol (v/v), 50 mM Tris-HCl pH 8.0, 100 mM NaCl) for buffer 
exchange and sample concentration. Protein concentration was determined by 
Bradford assay as described in 2.3.2, and samples were aliquoted and stored at -
80°C until required.  
2.6 Protein Chemistry 
2.6.1 Peptide array synthesis 
Peptide arrays were synthesised by automatic SPOT synthesis using the Auto Spot 
Robot (Intavis Instruments) and 9-fluorenylmethoxycarbonyl chloride (FMOC) 
chemistry (Figure 2.1). Solutions containing the amino acids and coupling 
reagents are spotted onto specific locations on a membrane. Spots are absorbed 
and form a circular spot to then acts as a reaction vessel. Full length DHX9 and 
PDE4D7 was spotted as overlapping 25-mer peptides, shifted by 5 amino acids. 
Specific protein domains were further spotted in order to determine crucial 
amino acids for protein-protein interactions (PPIs). Peptide array membranes 
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can be overlaid with purified protein, overexpressing cell lysate, or antibodies to 
verify PPIs and antigen epitopes.  
 
Figure 2.1 Principles of SPOT synthesis. Peptide array SPOT synthesis allows for the 
immobilization of peptide onto supports such as cellulose membranes (left panel). Peptides 
can be spotted as 5-mer shifts in order to spot the full-length protein, or specific regions can be 
spotted in order to investigate post-translational modifications or crucial amino acids for protein-
protein interaction. Figure taken from Volkmer, Tapia and Landgraf, 2012. 
2.6.2 In vitro PKA phosphorylation of DHX9 peptide arrays 
DHX9 peptide arrays were blocked in 5% BSA containing 0.5 mM DTT and 1 mM 
ATP in TBST for one hour at RT with gentle shaking. Peptide arrays were then 
incubated in phosphor-buffer (20 mM Tris-HCl; pH 7.5, 10 mM MgCl2, 0.5 mM 
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CaCl2, 1 mM DTT, 0.2 mg/ml BSA, 1 mM ATP) with or without 100 units of active 
bovine PKA catalytic subunit for 1 hours at 30°C with gentle shaking. Following 
the phosphorylation, the arrays were washed three times in TBST and incubated 
PKA phospho-substrate antibody that detects the conserved RXXpS/T consensus 
sequence. Following three TBST washes, the array was incubated in the 
appropriate HRP secondary antibody and subjected to ECL western blotting 
substrate with X-ray film development.  
2.6.3 Peptide array validation of novel phospho-DHX9 antibody 
The epitope for the novel phospho-DHX9 membranes were spotted onto 
membranes with truncations, alanine substitutions, and 5-mer shifts. Membranes 
were activated and blocked as described in 2.6.2, after which the array was 
incubated overnight in phospho-DHX9 antibody at 4°C with gentle agitation. The 
membrane was washed three times in TBST, then incubated with rabbit HRP 
secondary antibody for one hour at RT. After three final washes in TBST, the 
membrane was subjected to Immobilon Western blotting substrate (Merck, 
WBLUC0100) for X-ray film development.  
2.7  Protein-Protein Interaction studies 
2.7.1 Immunoprecipitation (IP) 
IPs were performed using 500 µg of cell lysate, adjusted to a final volume of 500 
µL with 3T3 lysis buffer, which were pre-cleared for one hour at 4˚C with pre-
washed protein G Sepharose beads. Beads were briefly centrifuge and the 
supernatant was transferred into a fresh 1.5 mL Eppendorf with 1 µg/µL of the 
appropriate antibody, or IgG control, and protein G Sepharose beads (Table 2.6). 
The IP left overnight at 4˚C on an end-end rotator with the appropriate antibody 
and the beads. 
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Table 2.6 Antibodies used for IPs 
Antibody Company and 
Catalogue Number 
Host 
DHX9 Abcam, ab26271 Rabbit 
PDE4D7 In House Sheep 
VSV Abcam, ab1874 Rabbit 
FLAG Sigma, F3165 Mouse 
phosphoPKA Substrate Cell Signalling, 9624S Rabbit 
Mouse IgG Millipore, NI03 Mouse 
Rabbit IgG Millipore, NI01 Rabbit 
Sheep IgG Thermo Fisher, 31243 Sheep 
 
The samples were centrifuged four times at 500 x G for 3 minutes the next day 
with a TBS wash between spin. IP samples were then eluted off the beads by 
boiling for 5 minutes at 95˚C in 2 x SDS loading buffer. Samples were analysed 
for interacting partners and post-translational modification by SDS-PAGE with 
western blotting using the antibodies in Table 2.4Table 2.5.  
 
2.7.2 Peptide array validation for PDE4D7-DHX9 binding 
Peptide array membranes were incubated in 100 % ethanol for 5 minutes in order 
to activate the spots, after which they were washed three times in 1 x TBST. 
The membranes were then blocked in 5% non-fat milk in TBST for 1 hour at RT 
with gentle shaking. Arrays were then incubated with either purified protein or 
overexpressing cell lysate in 1% milk overnight at 4°C with gentle shaking. The 
arrays were washed three times the following day in incubated with the 
appropriate antibody in 1% milk for three hours at RT, washed then incubated 
with the appropriate HRP secondary antibody for one hour at RT (Table 2.4Table 
2.5). The arrays were washed a final three times in TBST before subjected to 
enhance chemiluminescence (ECL) western blotting substrate for X-ray film 
development. Dark spots that were detected is indicative of a positive 
interaction with the array (Figure 2.2). 
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Figure 2.2 Peptide array workflow. Peptide array spotted for the protein of interest with 
overlaid with its interacting protein overnight at 4˚C. The array is then washed the following 
days and incubated with primary antibody that recognises the overlaid protein for three hours at 
RT, then washed. The membranes are then finally incubated in the appropriate secondary antibody 
and binding sequences are determined using HRP with ECL development. 
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2.8 Microscopy techniques 
2.8.1 Immunocytochemical (ICC) staining 
HEK293 cells were seeded onto sterile glass coverslips in either a 12 or 24 well 
plates and transfected as previously mentioned. PC cells were seeded in either 
12 or 24 well plate until it reached 80% confluency. Cells were fixed onto 
coverslips in 4% (v/v) paraformaldehyde in PBS for one hour at RT. The cells 
were washed three times in PBS. If only staining for one protein, the membrane 
was counter stained using Wheat Germ Agglutinin (WGA) (Thermo Scientific, 
W11261) in the dark for 20 minutes at RT. Cells were washed three times then 
blocked in blocking buffer (PBS, 0.5% BSA, 0.25% Triton-X100) for one hour. 
Primary antibodies were then incubated overnight at 4˚C diluted in blocking 
buffer in a humidity chamber at the appropriate concentration (Table 2.7). 
Coverslips were wash three times in PBS the following day, then incubated for 
two hours in a humidity chamber with Alexa-Fluor secondary antibody in the 
dark at RT. Cells were washed a further three times in PBS, before mounting 
face down onto glass slides with either DAPI or Sytox Orange nuclear stain 
(Thermo, P36935, P36987). Slides were left to dry overnight in the dark and 
imaged using a Zeiss Pascal laser scanning microscope (LSM) 510 Meta and an 
Axiovert 100 microscope with oil immersion objective. Images were acquired on 
the Zeiss LSM examiner and mean fluorescence intensity (MFI) was obtained on 
ImageJ. 
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Table 2.7 Antibodies and stains for ICC  
Primary Antibody Company and 
Catalogue Number 
Host Dilution Factor or 
Concentration 
DHX9  Abcam, ab26271 Rabbit 1:500 
NDH II (DHX9) Santa Cruz, sc-
137232 
Mouse 1:1000 
PDE4D7 In House Sheep 1:500 
Phospho PKA 
Substrate 
Cell Signalling, 
9624S 
Rabbit 1:1000 
Phospho-DHX9 In House Rabbit 1:100 
VSV Abcam, ab1874 Rabbit 1:500 
Nucleolin Cell Signalling, 
14574S 
Rabbit 1:1000 
Anti-DNA-RNA 
Hybrid Antibody, 
clone S9.6 
Merck, MABE1095 Mouse 1:100 
Alexa Fluor anti 
Rabbit 488 
Thermo, A32790 Donkey 1:500 
Alexa Fluor anti 
Mouse 546 
Thermo, A10036 Donkey 1:500 
Alexa Fluor anti 
Sheep 488 
Thermo, A-11055 Donkey 1:500 
Alexa Fluor anti 
Rabbit 546 
Thermo, A10040 Donkey 1:500 
Wheat Germ 
Agglutinin Alexa 
Fluor 488 
Thermo, W11261 N/A 1.0 mg / mL 
 
 
2.8.2 Proximity ligation assay (PLA) 
All PLA reagents were purchased from Sigma. PLA enzymes and buffers were 
provided as a kit (Sigma, DUO92105, DUO92101). HEK293 cells were seeded onto 
sterile glass coverslips in a 24 well plate and transfected as previously 
mentioned. AS PC cells were seeded in a 24 well plat until it reached 80% 
confluency. Cells were fixed and stained for the membrane and blocked as 
described in section 2.8.1. Primary antibodies were then incubated overnight at 
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4˚C as previously describe (Table 2.7). After washing the coverslips three times 
in PBS, cells were blocked for 30 minutes at RT in blocking buffer. Secondary 
PLA probes, that are combined with oligonucleotides, was pre-incubated for 20 
minutes on an end-to-end rotor at RT. Coverslips were then incubated with 
secondary probes in a humidity chamber for one hour at 37˚C. Coverslips were 
washed three times in Wash Buffer A (Sigma), then incubated for 30 minutes 
with ligase enzyme at 37˚C. Oligonucleotides on the secondary probes would 
only be able to hybridize if proteins or PTM were less than 40 nm of each other. 
Coverslips were then washed a further three times in wash buffer A, then 
incubated for 100 minutes with polymerase enzyme at 37˚C. After a final two 
washes in wash buffer B, coverslips were mounted face down onto glass slides 
with Sytox Orange nuclear stain. Images were taken the next day to allow the 
mounting media to dry. Interacting proteins or PTMs can only be visualised as 
small punctuate dots under the microscope (Figure 2.3).  
 
 
Figure 2.3 Principal of DuoLink proximity ligation assay. a. Binding of primary antibodies to 
target proteins. b. Binding of PLA secondary antibodies containing complementary DNA strands. c. 
Oligos will only bind if proteins are less than 40 nm from each other. d. Ligation of the oligos forms 
a circular template. e. Rolling circle amplification. f. Amplification results in the replication of the 
oligos, which is labelled with fluorophore indicating a positive reaction. Signal can be imaged using 
a confocal microscope. Figure taken from Bobrich et al., 2013. 
2.8.3 DHX9 Functional Assay – R-Loop assay 
This protocol was developed by Dr.Prasun Chakraborty from the University of 
Dundee and adapted for LNCaP cells. LNCaP were seeded onto a sterile cover 
glasses in a 24 well plate and left to grow until 80% confluent. Cells were then 
transfected with siRNA targeting Splicing Factor Proline and Glutamine Rich 
(SFPQ), GAPDH, or non-targeting control as mentioned in 2.2.4. The cells were 
washed with PBS, then fixed for 20 with 100 % methanol at -20˚C. The methanol 
was then removed and replaced with 100 % acetone for one minute. The 
coverslips were washed three times in PBS, then blocked with blocking buffer for 
a
. 
b
. 
c
. 
d
. 
e
. 
f
. 
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one hour. Coverslips were incubated with primary antibody against nucleolin and 
DNA-RNA hybrids overnight. After a further three washes PBS, coverslips were 
incubated in the appropriate secondary antibody for two hours at room 
temperature. Cells were washed a further three times in PBS, before mounting 
face down onto glass slides. Slides were left to dry overnight in the dark and 
imaged using a Zeiss Pascal laser scanning microscope (LSM) 510 Meta and an 
Axiovert 100 microscope with oil immersion objective. Images were acquired on 
the Zeiss LSM examiner and mean fluorescence intensity (MFI) was obtained on 
Image J. 
2.9 Real Time Cell Analysis (RTCA) measurement of cell 
proliferation (xCELLigence) 
The xCELLigence is a non-invasive electrical impedance instrument that is able 
to quantify cell proliferation. Cell growth can be monitored based on the change 
in the resistance of current flowing through the gold-electrode plate. Changes in 
electrical impedance is recorded by the RTCA instrument and interpreted by the 
software. Changes in impedance is represented as cell index (CI), where a CI of 0 
indicates there are no cells present. Increase in CI indicates that the cells are 
proliferating (Figure 2.4). 
 
Figure 2.4 Overview of xCELLigence technology. In the absence of cells, the electrical 
current is allowed to freely flow through the culture medium. It can complete the circuit 
between the electrode. In the presence of adhering and proliferating cells, the electrical current is 
impeded. This system provides a sensitive readout of cell number, cell morphology, and 
attachment quality. Figure taken from ACEA Biosciences. 
The xCELLigence system comprises a gold-plated 96 well plate, often referred to 
as E-Plate, a docking unit placed inside the incubator, and an impedance 
measurement unit kept at room temperature. The measurement unit is 
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connected to a computer with the software running in order to collect the data. 
The collected CI data is plotted as a growth curve and analysed using the RTCA 
software. 
2.9.1 RTCA plate set up 
96 cell E-plates (ACEA Biosciences, 300600910) were used to monitor cell 
growth. These plates are specifically designed as they contain interdigitated 
electrodes used to monitor cell growth. A cell number titration was initially 
carried out in order to obtain the optimum cell number to produce a growth 
curve. Prior to the addition of the cells, 10 sweeps every minute was performed 
with just media in order to obtain the background reading. A cell number 
titration for VCaP and LNCaP was then carried out into order to obtain the 
optimum cell number and cell line required to produce a growth curve. The 
appropriate cell number was seeded into each well. The plate was left in the 
hood for thirty minutes to allow the cells to settle to the bottom. The plate was 
then returned to the docking stations and the electrical impedance was 
measured every 15 minutes for 5 days. 5 000 cells per well of LNCaP cells was 
found to be the optimum cell density and cell line. The E-plate was set up as 
previously mentioned. However, after recording the impedance for 24 hours, 
cells were treated with either siRNA (Table 2.3), YK-4-279 (Tocris, 4067), or 
disruptor peptides (custom made by Genescript) at the required concentration. 
Impedance was measured every 15 minutes for a further four days. YK-4-279 was 
reconstituted to a stock concentration of 10 mM in DMSO and stored at 4˚C until 
required. The cell growth data was analysed using the RTCA software. Changes 
in maximum cell index or slope were extrapolated from the growth curves and 
analysed using GraphPad Prism 8. 
2.10  Reverse Phase Protein Assay (RPPA)  
All RPPA assay were performed at the HTPU MicroArray services at the MRC 
institute of Genetics and Molecular Medicine, University of Edinburgh. DU145 
cells were plated into a 10 cm dish and transfected with either non-targeting or 
DHX9 specific siRNA as previously described. Cells were washed twice in ice-cold 
PBS then lysed in1 x lysis buffer (1% Triton X-100, 50 mM HEPES (pH 7.4), 150 mM 
NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM Na4P2O7, 1 mM Na3VO4, 
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10% glycerol, freshly added protease and phosphatase inhibitors). The cells were 
then scraped and collected into a fresh 1.5 mL Eppeondorf tube and centrifuged 
at 14 000 x G for 10 minutes at 4˚C. The supernatant was collected, and the 
protein concentration was determined using a standard Bradford assay. The 
samples were normalised to 2 mg/mL in sample buffer and boiled at 95˚C for 5 
minutes. Samples were stored at -80˚C until required. Samples for RPPA analysis 
was then sent to the University of Edinburgh for analysis. 
The samples for RPPA analysis were transferred into a 96-well plate and serially 
diluted in order to serially dilute the samples to 1.5mg/ml, 0.75 mg/ml, 0.375 
mg/mL, and 0.1875 mg/mL. Dilutions were prepared in PBS containing 10% 
glycerol. RPPA samples were then printed in arrays of 12 x 12 spots at a 500µm 
spot-to-spot distance using the Aushon 1740 Arrayer platform with two rounds of 
sample deposition. Sample dilution series were spotted in triplicate on each 
array, with 16 arrays per slide, on a single pad SuperNova Nitrocellulose slides 
(GraceBioLabs). The slides were incubated with the sample for at least one hour 
in order to ensure sample capture on the nitrocellulose membrane.  
RPPA slides were washed four time for 15 minutes in deionised water with gentle 
agitation, the incubated with Antigen Retrieval Reagent for 15 minutes. The 
membrane was then washed another two times with deionized water then 
washed twice in PBS with tween for 15 minutes. RPPA slides were then 
incubated for 10 minutes in SuperBlock blocking buffer (ThermoScientific, 
37536), washed once in PBS-Tween, then incubated for one hour with primary 
antibody (Table 2.8) diluted 1:250 in SuperBlock. The slides were then washed 
twice in TBST for five minutes each time, then blocked for 10 minutes as 
previously mentioned. Slides were then incubated with secondary antibody 
diluted 1:2500 in Superblock for 30 minutes. After a final wash in TBST and 
deionised water, the slides were left to dry for 10 minutes at RT and imaged 
using an Innopsys 710 slide scanner. Array images were analysed using Mapix 
software, with the spot diameter set to 270 µm. The net signal for each spot was 
determined by subtracting the background signal from the sample spot.  
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Table 2.8 Primary antibodies used for RPPA analysis 
Antibody Type Pathway, Function 
CamKII P Thr286 rabbit Calcium Signaling 
HSP27 (HSPB1) P Ser78 rabbit Chaperones, MAPK Signaling, 
Stress pathway 
MEK1/2 P Ser217/221 rabbit MAPK Signaling 
MNK1 (MKNK) P Thr197,Thr202 rabbit MAPK Signaling, 
Translational Control 
MSK1 P Ser376 rabbit MAPK Signaling 
PKA RII P Ser96 rabbit cAMP Signaling 
Rap1 rabbit Integrin Signaling, cAMP 
Signaling 
IGF-1R beta P Tyr1162,Tyr1163 rabbit Metabolism, Receptors, 
Tyrosine Kinases 
Stat5 P Tyr694 rabbit Cytokine Signaling, Jak/Stat 
Signaling 
Akt P Thr308 rabbit Akt Signaling, Metabolism 
S6 Ribosomal protein P 
Ser235,Ser236 
rabbit Lipid Signaling, Metabolism, 
Translational Control 
p44/42 MAPK (ERK1/2) rabbit MAPK Signaling 
p44/42 MAPK (ERK1/2) P 
Thr202/Thr185,Tyr204/Tyr187 
rabbit MAPK Signaling 
Akt rabbit Akt Signaling, Metabolism 
Akt P Ser473 rabbit Akt Signaling, Metabolism 
beta-actin rabbit Housekeeping, Cytoskeleton 
NFkB p65 Ser536 rabbit inflammatory and immune 
responses 
Chk1 P Ser345 rabbit Cell Cycle Control 
Chk2 P Thr68 rabbit Cell Cycle Control 
E-Cadherin rabbit Adhesion 
 
4E-BP1 P Ser65 rabbit Metabolism, Translational 
Control, mTOR signalling 
4E-BP1 P Thr37,Thr46 rabbit Metabolism, Translational 
Control, mTOR signalling 
p70 S6 Kinase P Thr389 rabbit Lipid Signaling, Metabolism, 
Translational Control 
p70 S6 Kinase P Thr421,Ser424 rabbit Lipid Signaling, Metabloism, 
Translational Control 
GSK-3-alpha/beta P Ser21/Ser9 rabbit Akt Signaling, Metabolism, 
Wnt Signaling, Hedgehog 
Signaling 
Stat6 P Tyr641 rabbit Cytokine Signaling, Jak/Stat 
Signaling 
p38 MAPK PThr180,Tyr182 rabbit MAPK Signaling, Stress 
pathway 
mTOR P Ser2448 rabbit mTOR Signaling, 
Translational Control, 
Metabolism 
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mTOR rabbit mTOR Signaling, 
Translational Control, 
Metabolism 
PLC-gamma1 P Tyr783 rabbit Calcium, cAMP, Lipid 
Signaling  
p90 S6 kinase (Rsk1-3) P 
Thr359,Ser363 
rabbit MAPK Signaling 
p70 S6 Kinase rabbit Lipid Signaling, Metabolism, 
Translational Control 
c-Myc P Thr58,Ser62 rabbit MAPK Signaling, 
Transcription Factors 
S6 Ribosomal protein p 
Ser240,Ser244 
rabbit Lipid Signaling, Metabolism, 
Translational Control 
S6 Ribosomal Protein rabbit Lipid Signaling, Metabolism, 
Translational Control 
Rb P Ser807,Ser811 rabbit Apoptosis, Cell Cycle Control 
AMPK alpha rabbit Metabolism 
AMPK alpha P Thr172 rabbit Metabolism 
Caspase 3 rabbit Apoptosis 
Caspase 3 cleaved rabbit Apoptosis 
CREB rabbit Calcium, cAMP, Lipid 
Signaling, PKC Signaling 
GSK-3-beta P Ser9 rabbit Akt Signaling, Metabolism, 
Wnt Signaling, Hedgehog 
Signaling 
GSK-3-beta rabbit Akt Signaling, Metabolism, 
Wnt Signaling, Hedgehog 
Signaling 
Tau Phospho/non Phos ser 305 rabbit Neuroscience 
Profilin (C56B8) rabbit actin binding proteins, cell 
motility 
4E-BP1 rabbit Metabolism, Translational 
Control, mTOR signalling 
mTOR (7C10) rabbit mTOR Signaling, 
Translational Control, 
Metabolism 
Integrin Beta 1 [EP1041Y] rabbit scaffold protein 
Eph1A [EPR1786] rabbit metastasis and invasion 
EphB3 [EPR8280] rabbit brain development 
EphB2 [EPR10072(B)] rabbit regulating growth and 
development of multiple 
tissues and organs, interacts 
with FAK 
Cofilin P Ser3 (C77G2) rabbit cytokinesis, endocytosis, 
embryonic development, 
stress response, and tissue 
regeneration 
Cortactin (H222) rabbit coordinate actin 
reorganization during cell 
movement 
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Integrin alpha 4 rabbit scaffold protein 
Integrin beta3 rabbit scaffold protein 
Integrin beta4 rabbit scaffold protein 
Akt substrate P (RXXS/T) (110B7E) rabbit Akt Signaling, Lipid 
Signaling, Metabolism 
PKA substrate P (RRXS/T) (100G7E) rabbit cAMP Signaling 
mTOR P Ser2481 rabbit mTOR Signaling, 
Translational Control, 
Metabolism 
CamKII alpha (22B1) P Thr286 mouseI
gG1 
Neuroscience, Calcium, 
cAMP, Lipid Signaling, PKC 
Signaling 
 
2.11 Fluorescence Polarization (FP) Assays 
This protocol was developed by Dr Yuan Yan Sin and adapted for PDE4D7-DHX9 
binding assays. All FP measurements were performed on Mithras LB 940 plate 
reader (Berthold technologies) in a black 384 nonbinding well plate. Polarisation 
was measured at λexc = 485 nm and λem = 535 nm at room temperature. The 
sequence to which PDE4D7 binds to DHX9 was determined was determined by 
scanning peptide array. A 25-mer peptide was generated based on the DHX9 
peptide array data (E576DCIQMTHFVPPPKDKKKKDKDDDG600), with an N-terminal 5-
FAM tag. The peptide was synthesised by GenScript and dissolved in DMSO to a 
stock concentration of 10 mM. 
2.11.1 Determining minimum peptide concentration 
In order to determine the stable range of the DHX9 peptide, an assay was 
performed where the polarisation of a decreasing concentration of peptide was 
measure. A 1 µM peptide stock was prepared in FP buffer (PBS, 1 mM DTT and 
0.25% Tween-20), then serially diluted by 2 fourteen times. 10 µL of the diluted 
peptide was transferred in duplicate into the 384 dark walled plate then read on 
the Mithras LB 940 plate reader. All polarisation results were expressed in 
millipolarisation (mP). mP was then plotted on a Log scale and the minimum 
peptide concentration was determined. 
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2.11.2 Direct binding assay 
62.5 nM of the 5-Fam DHX9 peptide, in FP buffer, was added into the 384-assay 
plate. Purified protein was serially diluted in dialysis buffer in a 96 well plate, 
then transferred to the 384 well assay plate. The plate was incubated for a 
maximum five hours at room temperature, with a reading taken at 0.5, 1, 3 and 
5 hours of incubation. mP values were plotted in GraphPad Prism 8 and a 
sigmoidal curve was produced.  
2.12  Statistical analysis 
All data generated are representative of three independent experiments, unless 
stated otherwise. Values are presented as the mean ± the standard error of the 
mean (SEM). Statistical significance was determined using an ordinary one-way 
analysis of variance (ANOVA) with a Dunnet’s multiple comparison test or a T-
test if only comparing two variables. A p>0.05 value was considered not 
significant, a p of < 0.05 was considered significant (*), p<0.01 was considered 
highly significant (**), p<0.001 considered extremely significant (***), and 
p<0.0001 as considered most significant (****). All statistical analysis and data 
plotting were performed on GraphPad Prism 8. 
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Chapter 3 PDE4D7-DHX9 interaction in Prostate 
Cancer 
3.1 Introduction 
PDE4 enzymes degrade cAMP and are important in controlling the 
compartmentalized signalling of cAMP through their targeting to specific 
downstream protein complexes (Omar et al., 2019). In recent years, increasing 
evidence has shown the PDE4D7 expression is “protective” in PC, with high 
expression at early stages of PC predicting a better disease outcome (van Strijp 
et al., 2018). However, the molecular mechanisms behind these protective 
effects remains uncharacterised. One potential mechanism that could help 
explain how PDE4D7 is able to protect PC patients is the targeting of the enzyme 
to protein complexes that influence cell signalling during PC progression. 
Protein-protein interactions (PPIs) represent a highly promising, but challenging, 
class of targets for therapeutic intervention. In cancer, PPIs form signalling 
networks that can promote tumorigenesis, tumour progression, and metastasis 
(Ivanov, Khuri and Fu, 2013). Understanding these networks has gradually 
changed our view on cell biology by offering new ways of understanding the 
internal organization of a cell. With the rise of omics analysis, increasing 
information about PPIs in PC has emerged, providing important biological 
information for uncovering molecular mechanisms of PC progression (Chen et al., 
2016). If successful, drugs that either interrupt or enhance PPI could replace 
ADT or AR inhibitors in the treatment of PC.  
There is currently a need to develop new therapies to overcome resistance to 
ADT and AR inhibitors. In PC, recruitment of co-regulators to the AR could 
potentially offer an opportunity to develop new therapeutic agents that could be 
used during early and late stages of disease. Key structural surfaces involved in 
PPIs have been identified with co-regulators with the aim of developing novel 
binding inhibitors (Biron and Bédard, 2016). Cell-penetrating peptides (CPP) 
have quickly emerged as alternatives to classic drugs with the ability to directly 
disrupt target PPIs. CPPs are short peptides with the ability to cross biological 
membranes in an energy-dependent and -independent manner. Since initial 
discovery, natural and synthetic CPPs have been developed for applications 
ranging from imaging to gene editing and therapeutic delivery. CPP-based 
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therapies are considered highly efficacious due to their rapid delivery and low 
toxicity compared to most drugs (Habault and Poyet, 2019). Therapeutic CPPs 
are a promising new approach for the development of anti-cancer agents 
(Marqus, Pirogova and Piva, 2017).  
Previous work by the Baillie lab has revealed that DHX9 is a novel PDE4D7 
interactor (unpublished work). Increasing evidence has shown that DHX9 is 
important in the progression of multiple cancers, including breast and colon 
cancer (Fidaleo, De Paola and Paronetto, 2016; Lee and Pelletier, 2016). The 
potential PDE4D7-DHX9 interaction could indicate that these two proteins are 
part of a signalosome that could coordinate PC-related mechanisms. 
Development of small molecule inhibitors from CPPs has great potential in 
cancer biology, with specific peptides currently being developed against the Ras-
Raf-MEK-ERK pathway (Marqus, Pirogova and Piva, 2017). For example, work by 
Blair et al. (2019) has shown promising data supporting the use of CPPs in the 
treatment of cell models for melanoma by targeting the PDE8A-CRAF complex . 
PDE8A can bind c-Raf inhibiting PKA phosphorylation, leading to CRAF activation. 
Using a rational substitution approach, a peptide designed against the protein-
binding domains between PDE8A and CRAF was developed and shown to 
significantly increase levels of protective c-Raf phosphorylation both in vitro and 
in mouse melanoma models. This in turn resulted in significantly decreased cell 
growth and decreased ERK signalling (Blair et al., 2019). Due to the high success 
of targeting PDE8A-c-Raf interaction in melanoma, the hope would be that 
disruption of the interaction between PDE4D7-DHX9 could have similar results 
for PC.  
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3.2  Chapter Aims 
PDE4D7 is known to be protective in PC, with decreased expression of this 
protein known to drive disease progression leading to poor patient prognosis. 
However, the mechanism underlying how its decreased expression leads to 
increased cell growth is still unknown (Henderson et al., 2014). The interaction 
between PDE4D7-DHX9 could potentially be a novel PPI target that could have a 
role in the progression of disease. Hence, the aims of this chapters are as 
follows: 
 Aim 1: Show that interaction between PDE4D7 and DHX9 can be verified 
in my hands. By using a range of biochemical techniques, such as 
immunoprecipitation and proximity ligation assay, this will show the 
direct and robust interaction between these two proteins.  
 Aim 2: Map the PDE4D7-DHX9 PPI domains using peptide array technology. 
This information can then be used to develop CPPs that act specifically to 
disassemble the PDE4D7-DHX9 complex 
 Aim 3: Determine PDE4D7-DHX9 binding affinity using fluorescence-
polarization technology. This platform could then be configured into a 
small molecule screening assay to discover compounds with the ability to 
enhance or disrupt the PDE4D7-DHX9 interaction.  
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3.3 Results 
3.3.1 DHX9 and PDE4D7 expression in PC cell lines 
Although previous work by the Baillie lab has shown that PDE4D7 was highly 
expressed in AS (Henderson et al., 2014; Böttcher et al., 2015) , the expression 
levels of DHX9 in different stages of PC are still unknown. The expression levels 
of DHX9 and PDE4D7 was therefore determined in DU145, LNCaP and VCaP cell 
lines. DU145 was once considered one of the most highly used cell line PC 
research. This cell line was first isolated from a brain metastasis. It is hormone 
independent and no longer expresses AR at both the mRNA and protein level 
(Table 3.1) (Cunningham and You, 2015). Although both LNCaP and VCaP are 
both AS cell lines, they differ in AR expression. The LNCaP cell line was first 
derived from a needle aspiration biopsy of a lymph node metastatic lesion. 
Although it does express the AR, it contains the T877A mutations which alters its 
response to steroids (Table 3.1). VCaP were first derived from a vertebral 
metastatic lesion and expresses WT AR. Furthermore, this cell line expresses the 
TMPRSS2:ERG gene translocation, making it an ideal cell line to study the early 
stages of PC (Table 3.1) (Sobel and Sadar, 2005). DU145, LNCaP and VCaP cell 
lysates were therefore run on an SDS-PAGE gel and protein expression of DHX9 
was assessed by western blotting (Figure 3.1).  
 
Table 3.1 PC cell line characteristics  
DU145 LNCaP VCaP 
Androgen 
Sensitive 
No Yes Yes 
PSA expression No  RNA + protein RNA + Protein 
AR Expression  No RNA + protein 
T877A AR 
mutation 
RNA + Protein 
WT AR 
Derived from  Brain Lymph Vertebrate 
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Figure 3.1 PDE4D7 and DHX9 expression in PC cell lines. A. PDE4D7 and DHX9 expression 
was assessed by SDS-PAGE with western blotting. B. PDE4D7 expression in all cell lines were 
determined densitometrically. C. DHX9 expression in all cell lines were determined 
densitometrically. Data is presented as the mean ± SEM of three independent experiments and 
analysed using a one-way Anova. Data is not significant. 
Western blot analysis showed that DHX9 expression is highest in DU145 cell line 
(Figure 3.1 C). In recent years DU145, along with PC3, have become the most 
widely used cell models of late stage PC as they no longer express the AR 
(Cunningham and You, 2015). On the other hand, LNCaP and VCAP cells are 
currently used as models for early stage disease due to their expression of a 
functional AR. VCaP cells also express the TMPRSS2:ERG fusion protein, making it 
a very useful tool to study PC (Sampson et al., 2013). Previous work has shown 
that PDE4D7 expression is highest in AS cell lines, whereas AI cell lines no longer 
express high levels of this protein (R. Böttcher et al., 2015). My data confirms 
what has previously been reported (Figure 3.1 B), and in addition, I show that as 
the expression of PDE4D7 decreases, the expression of DHX9 increases. Due to 
the expression of both proteins of interest in the cell lysate, these three cell 
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lines were used throughout this thesis to study the interaction of PDE4D7 and 
DHX9 in prostate cancer. 
3.3.2 PDE4D7 mainly localizes to the cytoplasm, while DHX9 is 
expressed in the nucleus and cytoplasm 
So far, we have observed a negative correlation between the expression of 
PDE4D7 and DHX9 in cell lines. As the disease progresses into a more metastatic 
state, the expression of PDE4D7 decreases as the expression of DHX9 increases. 
Although previous work by Henderson et al (2015) demonstrated that PDE4D7 
expression was found at the plasma membrane (Henderson et al., 2014), I 
wanted to see if PDE4D7 could be expressed in other cellular compartments 
where DHX9 could also be present. Additionally, DHX9 is mainly expressed in the 
nucleus, however it has the ability to shuttle in and out of this compartment 
using the nuclear localisation (NLS) and nuclear export signal (NES) found within 
the C-terminal region of DHX9 (Lee and Pelletier, 2016; Ng et al., 2018). I 
therefore decided to perform a cellular fractionation in order to separate 
subcellular compartments for analysis. VCaP were chosen for these experiments 
as they had the highest expression of both PDE4D7 and DHX9 (Figure 3.1). Using 
a series of centrifugation steps at different speeds, VCaP cells were separated 
into the nuclear, mitochondrial, cytoplasmic, and membrane fractions by 
sequentially centrifuging the cell lysate at different speeds. Each fraction was 
then run on an SDS-PAGE gel and protein expression was assessed by western 
blotting. The percentage of protein expressed in each fraction was normalised to 
the whole cell lysate (Figure 3.2).  
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Figure 3.2 VCaP fractionation. A. VCaP cells from a confluent 10 cm dish were lysed, then 
separated into nuclear, mitochondrial, cytoplasmic, and membrane fractions by sequential 
centrifugation. Each fraction was run on an SDS-PAGE gel for protein expression analysis with 
western blotting. GAPDH was used as a control to ensure that each fraction was separated 
correctly. B and C. PDE4D7 and DHX9 expression from each . Data is presented at the mean ± 
SEM of two independent experiments.  
By running the different cellular fractions on an SDS-PAGE gel with western 
blotting, I was able to determine where each of these proteins were mainly 
expressed when probed with the appropriate antibody. By blotting for GAPDH, I 
was able to confirm that each fraction was separated from one another by 
sequential centrifugation (Figure 3.2 A bottom membrane) as the protein was 
only present in the cytoplasmic fraction. The cellular fractionation showed that 
PDE4D7 was almost completely expressed in the cytoplasm (Figure 3.2 A and B), 
whereas DHX9 expression was predominantly expressed in the nucleus (Figure 
3.2 A and C). Although PDE4D7 expression was previously reported to be at the 
plasma membrane by Henderson et al (2015), no detectable amounts of PDE4D7 
could be seen in the membrane fraction. Although I did not blot for a positive 
control for the nuclear fraction, DHX9 is known to be highly expressed in the 
nucleus in order to play an active role in gene transcription (Ng et al., 2018). 
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The fractionation presented here further supports the fact that DHX9 is almost 
exclusively expressed in the nucleus (Figure 3.2 A), while PDE4D7 is only 
expressed in the cytoplasmic region (Figure 3.2 B). 
However, this fractionation does raise the questions as to where the interaction 
between PDE4D7 and DHX9 could take place. The data shown here suggests that 
these two proteins exist in two separate compartments. Subcellular 
fractionations are known to enrich proteins in their cellular compartment. This 
technique is most commonly used in proteomic analysis to study a protein when 
expressed in its original organelle (Lee, Tan and Chung, 2010). Furthermore, 
data from the Human Protein Atlas (Figure 3.3) support the data presented here. 
The data presented in the database suggests that DHX9 is only expressed in the 
nucleus, while PDE4D7 is expressed in the cytoplasm (Berglund et al., 2008).  
 
 
Figure 3.3 PDE4D and DHX9 expression in vitro. PDE4D (A) and DHX9 (B) was investigated in 
HeLa and U2-OS cells. The protein of interest is stained in green in both images, while 
microtubules are stained in red (Berglund et al., 2008). Image were obtained from the Human 
Protein Atlas (https://www.proteinatlas.org/).  
Although DHX9 was not detected in the cytoplasmic fraction, DHX9 is known to 
shuttle in and out of the nucleus to the cytoplasm using its nuclear export signal 
(NES) and nuclear localization signal (NLS) both found within DHX9’s C-terminal 
domain (Lee and Pelletier, 2016). NLS signals direct the import of the proteins 
form the cytoplasm into the nucleus, whereas NES directs the export of protein 
from the nucleus to the cytoplasm (Xu et al., 2012). DHX9 therefore can shuttle 
in and out of the nucleus, and this is mediated by the NES/NLS signal. I therefore 
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decided to use immunocytochemistry with confocal microscopy to further 
investigate where the two proteins are expressed naturally in the cell. DU145, 
LNCaP and VCaP were all stained for PDE4D7 (green), DHX9 (red), and the 
nucleus (blue). Images were taken using a Zeiss LSM confocal microscope where I 
was able to visualise where each protein was expressed. I then used these 
images to quantify the levels of colocalization between the signal from PDE4D7 
and DHX9 using the Pearson’s coefficient (Figure 3.4). The Pearson’s coefficient 
between the staining for PDE4D7 and DHX9 was measured using the 
colocalization tool on Image J. Colocalization can often be considered subjective 
and only judged by the merging of colours. Pearson’s coefficient is a statistic 
tool to quantify the colocalization between two probes, with a value near 0 
indicating that the probes are unrelated to one another, whereas a value closer 
to 1 indicates that the two probes are overlapping (Dunn, Kamocka and 
McDonald, 2011). 
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Figure 3.4 PDE4D7 and DHX9 staining in PC cells. A. DU145, LNCaP, and VCaP cells were 
stained for PDE4D7 and DHX9 expression using immunocytochemistry with confocal microscopy. 
Images were taken under a x 40 water immersion lens on the Zeiss LSM microscope. B. The 
Pearson’s coefficient between PDE4D7 and DHX9 staining across the whole cells was determined 
using the Colocalization plug in on Image J. Data is presented as the mean ± SEM of 15 cells from 
each cell line. 
Immunocytochemical staining of DU145 (Figure 3.4 A top row) further confirmed 
that there is very little PDE4D7 expressed in this cell line. However, DHX9 could 
be seen in both the nuclear and cytoplasmic regions of the cell (Figure 3.4 A top 
row). DU145 served as a negative control for quantifying the levels of 
colocalization between PDE4D7 and DHX9. The lack of PDE4D7 signal in DU145 
resulted in a Pearson coefficient of 0 (Figure 3.4 B). On the other hand. LNCaP 
and VCaP both expressed PD4D7 within the cytoplasmic region, and small 
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amounts of PDE4D7 could be seen in the nucleus. The opposite observation could 
be made for DHX9, where the majority of the protein could be seen in the 
nucleus, and small amounts of it could be seen in the cytoplasm (Figure 3.4 A 
middle and bottom panel). The Pearson coefficient of the whole cell between 
PDE4D7 and DHX9 was 0.910 in VCaPs and 0.920 in LNCaPs, indicating that these 
two proteins are likely to be co-localizing in vitro (Figure 3.4 B). However, these 
images contradict the subcellular fractionation. The subcellular fractionation, as 
well as the data collected from the Human Protein Atlas, suggests that DHX9 is 
only expressed in the nucleus, while PDE4D7 is only expressed on the cytoplasm. 
However, subcellular fractionations are known to enrich proteins in their 
respective organelles (Lee, Tan and Chung, 2010), meaning DHX9 that may be 
expressed in the cytoplasm may not be detected using this method. Using 
confocal microscopy, we show here the DHX9 cam be expressed in the cytoplasm 
due to the presence of an NLS/NES sequence in its C-terminal (Lee and Pelletier, 
2016). Collectively, the data in this chapter so far has shown that DHX9 is mainly 
expressed in the nucleus, but small traces of this protein can be detected in the 
cytoplasm by confocal microscopy.  
As PDE4D7 and DHX9 were predominantly in different cellular locations I then set 
up an experiment to determine whether the colocalization between these two 
proteins could be increased when subjected to leptomycin B treatment. 
Leptomycin B (LMB) was originally identified as a metabolite of Streptomyces 
and has recently been used as a potent anti-tumour agent against murine 
tumours. LMB was shown to inhibit the function of chromosomal region 
maintenance/exportin 1 (CRM1) which is critical for the import/export of RNA 
and proteins that contains NES and NLS signals. Proteins that are expected to 
shuttle between the nucleus and the cytoplasm become trapped in the nucleus 
after LMB treatment, which in turn leads to their accumulation in this region 
(Kudo et al., 1998; Jang et al., 2003). DHX9 is known to be insensitive to LMB 
treatment and does not lead to any changes in DHX9’s cellular location following 
treatment (Lee and Pelletier, 2016), however PDE4D7 has never before been 
subjected to LMB treatment. Here, LNCaP cells were treated for either 0, 3 or 8 
hours with 20 nM of LMB, then stained for PDE4D7 and DHX9. The 8 hour time 
point was chosen as the longest treatment time as previous work has shown that 
this was the shortest time point used to inhibit nuclear export (Wolff, Sanglier 
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and Wang, 1997). The cells were visualised as previously mentioned, and the 
Pearson’s coefficient between the PDE4D7 and DHX9 staining was measured 
(Figure 3.5). 
 
Figure 3.5 Leptomycin B time course in LNCaP. A. LNCaP cells were treated for 0, 3 or 8 hours 
with 20 nM of leptomycin, then stained for PDE4D7 (green), DHX9 (red) and the nucleus (blue). 
Images were taken using a Zeiss confocal microscope under a x 40 water immersion lens. B. 
Pearson’s coefficient between the PDE4D7-DHX9 staining was determined using the 
Colocalization tool on ImageJ. Data is presented as the mean ± SEM of N > 15 individual cells from 
each condition. The data was analysed using a One-way Anova. Data was not significant. 
Treatment of LNCaP with LMB resulted in a visible increase of PDE4D7 within the 
nuclear region as the cells were subjected to longer exposure to LMB (Figure 3.5 
A). This also correlated to an increased in the Pearson’s coefficient between 
NS 
NS 
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PDE4D7 and DHX9 across the whole cell, although this was not shown to be a 
statistically significant increase when analysed using a One-way Anova (Figure 
3.5 B). To date, only the short PDE4D1 isoforms has been reported to be 
expressed in the nucleus, whereas other PDE4D isoforms are restricted to the 
cytoplasm. Sequence analysis revealed that the unique N-terminal region of 
PDE4D1 contains an NLS sequence allowing it shuttle in and out of the nucleus 
(Chandrasekaran et al., 2008). Using the NLS Mapper (http://nls-
mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi), the PDE4D7 amino acid 
sequence was analysed in order to identify potential NLS (Kosugi et al., 2009) 
(Figure 3.6). The NLS predictor identified a 33 amino acid sequence 
(D187RAPSKRSPMCNQPSINKATITEEAYQKLASET220) within the linker and UCR2 
region of PDE4D7 that is a potential NLS sequence (Beard et al., 2000). In 
addition to identifying NLS sequences, this predictor is also able to predict the 
protein’s cellular location. A score between 7 and 10 indicates that the protein 
is only expressed in the nucleus. A score between 3 and 6 indicates that the 
protein can be expressed in both the nucleus and the cytoplasm. A score below 3 
indicates the protein is expressed only in the cytoplasm (Kosugi et al., 2009). 
The NLS mapper revealed that PDE4D7 has a score of 5.3 indicating that the 
protein can be expressed in both the nucleus and the cytoplasm. 
 
Figure 3.6 NLS prediction in PDE4D7. A potential NLS sequence within the linker and UCR2 
region was identified using the software (Kosugi et al., 2009). 
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Using confocal microscopy and bioinformatic analysis, my data suggests that the 
interaction between PDE4D7 and DHX9 could potentially take place in both the 
nucleus or the cytoplasm of LNCaP and VCaP.  
3.3.3 Confirming PDE4D7-DHX9 interaction using pulldown and 
proximity ligation assays 
So far, I have shown that PDE4D7 and DHX9 proteins express well in PC cell lines 
and that there is a small amount of cross-over in their cellular location. In order 
to provide further evidence that these two proteins are novel interactors in PC, I 
transfected HEK293 cells with plasmids containing VSV-tagged PDE4D7 and FLAG-
tagged DHX9 and performed immunoprecipitation assays on the resulting cell 
lysates. This was used as a “proof of concept” step in order to verify that these 
two proteins could interact with one another. VSV-tagged PDE4D7 and Flag-
tagged DHX9 plasmids were transiently transfected into HEK293 for 24 hours, 
then lysed using 3T3 lysis buffer. The cell lysates were then incubated with 
Protein G beads with either anti-VSV or anti-FLAG antibody for three hours. The 
beads were thoroughly washed in order to remove any unbound protein, and the 
remaining protein was boiled off the beads in SDS-PAGE sample buffer. The 
eluate was separated on an SDS-PAGE gel and immunoblotted for VSV or FLAG 
(Figure 3.7).  
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Figure 3.7 PDE4D7-VSV and DHX9-FLAG IPs in overexpressing HEK293 Lysates. A. VSV-
tagged PDE4D7 was pulled down from HEK293 cells and probed for Flag-tagged DHX9 and VSV-
tagged PDE4D7 B. Flag-tagged DHX9 was pulled down from HEK293 cells and probed for Flag-
tagged DHX9 and VSV-tagged PDE4D7Data is representative of N=3 independent experiments.  
Both IPs were successful with respect to pulling down proteins using their 
respective tags (Figure 3.7) and a positive co-IP was clearly observed in the cells 
that were pulled down for PDE4D7-VSV (Figure 3.7 A) and blotted for the FLAG 
tag of DHX9. Conversely, a pull down for DHX9-FLAG did not result in the co-IP 
for PDE4D7-VSV (Figure 3.7 A). This effect could possibly be due to the native 
structure of DHX9, as the natural 3D structure of DHX9 could prevent the protein 
from binding both the antibody and PDE4D7 concomitantly. Despite this, I was 
able to show that PDE4D7 and DHX9 are interacting when overexpressed in 
HEK293 cells. I then repeated this IP in VCaP and DU145 in order to ensure that 
this interaction could take place endogenously. Endogenously-expressed PDE4D7 
and DHX9 were pulled down in VCaP or DU145 cells using target-specific 
antibodies (Figure 3.8). The cell lysate was incubated with either PDE4D7 
isoform-specific or DHX9 antibody overnight with protein G beads. The 
supernatant was then separated on an SDS-PAGE gel and the PPI was 
investigated using western blotting (Figure 3.8).  
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Figure 3.8 IP assay in PC cells to confirm PDE4D7-DHX9 binding. A+B. PDE4D7 was pulled 
down using an isoform specific antibody in VCaP (A) and DU145 (B). Membranes were probed for 
PDE4D7 and DHX9. C. DHX9 was pulled down in VCaP lysate using a target specific antibody. 
The membrane was probed for PDE4D7 and DHX9. Data is representative of N=3 independent 
experiments. 
As in the HEK293 experiment with transfected proteins (Figure 3.7), pulldown of 
endogenous PDE4D7 lead to a successful co-IP of endogenous DHX9 in VCaP cells 
(Figure 3.8 A). However, as expected, this co-IP was not observed in DU145 cells 
where no PDE4D7 expression could be seen (Figure 3.8 B). Furthermore, like in 
the HEK293 cells, pulldown for DHX9 in VCaP cells did not lead to a positive 
pulldown for PDE4D7 (Figure 3.8 C). Again, it is possible that the DHX9 antibody 
epitope and the PDE4D7 docking domain are close on the 3D structure preventing 
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IP. Nevertheless, I show here that DHX9 and PDE4D7 interact with each other 
endogenously in PC cell lines. 
Next, to further verify existence of the interaction, I performed proximity 
ligation assay (PLA) in the same cell lines. PLA uses oligonucleotide-modified 
antibodies, also called PLA probes, to visualise target proteins. Upon binding of 
the PLA probes, the conjugated oligonucleotides pair to generate circular DNA, 
and replication of this DNA signals that the target proteins are interacting at this 
site. DNA signals can be visualised using a fluorescent microscope as these PLA 
probes are often hybridized with a fluorophore. A positive reaction will only be 
seen if the two target proteins are less than 40 nm from each other (Klaesson et 
al., 2018). Overexpressing HEK293 cells, as well as LNCaP and VCaP, were 
stained for PDE4D7 and DHX9 then subjected to PLA staining (red). The cells 
were also stained for the membrane (green) and the nucleus (blue) in order to 
visualise where putative DHX9 and PDE4D7 PPI may happen (Figure 3.9 and 
Figure 3.10). 
 
Figure 3.9 PLA between PDE4D7-VSV and DHX9-FLAG in overexpressing HEK293 cells. 
Wheat Germ Agglutinin (green) was used to stain the membrane of these cells, while SYTOX 
orange was used to stain the nucleus (blue). PLA signal are shown in red. Images are 
representative of eight different cell images. A. Negative control for PLA, where no primary 
antibody was present. B. Positive control for PLA, where the cells were probed for anti-mouse and 
anti-rabbit DHX9. C. PLA between VSV-tagged PDE4D7 and Flag-tagged DHX9.  
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As expected, no PLA signal was visible in the negative control as no primary 
antibody was present (Figure 3.9 A). PLA signal could be seen in the positive 
control, which was probed for DHX9 using a rabbit and mouse primary antibodies 
(Figure 3.9 B) indicating that the PLA probes can successfully bind to each other 
and generate a fluorescent signal. Interestingly, PLA signals was also visible in 
the sample probed for VSV tagged PDE4D7 and Flag tagged DHX9 (Figure 3.9 C), 
indicating that PDE4D7-DHX9 are within 40 nm of each other and are potentially 
interacting with one another. The PLA spots were observed across the whole 
cell, which is often the case in HEK293 cells transfected with plasmid constructs. 
In order to pinpoint where this interaction occurred, the PLA was performed in 
LNCaP and VCaP to probe for endogenous PDE4D7-DHX9 complexes (Figure 3.10 
C and F). 
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Figure 3.10 PLA between PDE4D7 and DHX9 in LNCaP and VCaP cells. Wheat Germ 
Agglutinin (green) was used to stain the membrane of these cells, while SYTOX orange was used 
to stain the nucleus (blue). PLA signal are shown in red. Images are representative of eight 
different cell images. Cells were stained with different antibodies. A+D. Negative control for PLA 
where the cells were not probed for primary antibody. B+E. Positive control for PLA where the cells 
were probed for anti-rabbit and anti-mouse DHX9 primary antibody. C+F. PLA between PDE4D7 
and DHX9.  
As in the HEK293 cells, a PLA signal was observed in the positive control (Figure 
3.10 A and D), indicating that the probes are able to bind to each other and 
generate a fluorescent signal. This signal was absent in the negative control 
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where no primary antibody was present (Figure 3.10 B and E). Visible spots could 
be observed in the cells probed for PDE4D7 and DHX9 (Figure 3.10 C and F) 
indicating that these two protein are able to interact with each other in an 
intact cell. Upon closer inspection, PDE4D7 and DHX9 complexes could be 
observed in the cytoplasm and the nucleus (Figure 3.10 C and F). Hence I have 
been able to provide further evidence that these two proteins are interacting 
and that this interaction takes place within the cytoplasmic and nuclear regions. 
3.3.4 Mapping PDE4D7-DHX9 binding domains 
Although I have been able to show that PDE4D7-DHX9 exist in a complex, it is 
unknown whether the binding between these two proteins is direct and if so, the 
binding domains remain undetermined. I therefore used peptide array 
technology to demonstrate direct interactions and map the binding domains 
between the two interactors. A large proportion of PPIs are mediated by 
compact interaction motifs within different regions of the protein. These regions 
are recognised and/or post-translationally modified by a structured domain of an 
interacting partner (Tompa et al., 2014). These regions, most commonly known 
as peptide motifs, can be categorised into two groups: binding motifs which 
mediate the interaction between two proteins, and posttranslational 
modification sites recognised by modifying enzymes (Tompa et al., 2014). These 
protein binding motifs are short segments found within either the terminal end 
or within a loop of an interacting protein. Interestingly, numerous oncogenic 
proteins either contain a motif, or recognise these binding motifs, for which 
inhibiting these is a potential drug target (Corbi-Verge and Kim, 2016). These 
binding motifs not only help PPIs, but they also coordinate protein function, 
localization, and degradation (Tompa et al., 2014). Modulating PPIs with small 
drug-like molecules targeting these motifs holds great promise in drug discovery 
(Shen et al., 2019). Traditionally, mapping of binding motifs were discovered 
using tandem affinity purifications or yeast-two hybrids experiments, However, 
in recent years, high throughput screening assays and computational studies, 
such as direct peptide library and protein chip-based assays, have been used to 
identify novel binding motifs that mediate PPIs Tompa et al., 2014) 
In recent years, peptide array technology has been used to map novel PPI 
binding motifs. Peptide array technology was first developed by Ronald Frank in 
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the early 1990s and since then, it has become a powerful tool to investigate PPI 
as well as post translational modifications (PTMs) (Volkmer, Tapia and Landgraf, 
2012). Using an array approach, specific domains or sequential sequences of full-
length proteins can be immobilised on cellulose for further investigation. Here, 
full length DHX9 or PDE4D7 amino acid sequences were spotted onto CelluSpot™ 
glass slides as 25-mer spots, with each spot shifting by 5 amino acids (Figure 
3.11).  
 
Figure 3.11 Peptide Array design layout. Full length protein in 25-amino acid peptides is spotted 
onto a glass slide with a cellulose membrane where each spot is shifted by 5 amino acids.  
PDE4D7 full length slides were incubated with HEK293 lysate overexpressing 
DHX9-FLAG, then probed for the FLAG tag in order to identify which 25-mer 
peptides from PDE4D7 could be bound by DHX9-FLAG. The slides were then 
probed with the appropriate secondary antibodies, then imaged using 
chemiluminescence detection (Figure 3.12). 
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Figure 3.12 PDE4D7 peptide array overlaid with HEK293 overexpressing DHX9-FLAG lysate. 
A. Whole peptide array images. Regions of interest are highlighted in the red box. B. Full length 
PDE4D7 peptide array was incubated with DHX9-FLAG cell lysate, then probed for the binding 
sites using a FLAG tag antibody. Image adapted from Tibbo, Tejeda and Baillie, 2019. 
Peptide array technology revealed that DHX9 binds to a PDE4D7 25mer within 
the UCR1 region (Figure 3.12). Within this binding site is the FLY motif, 
highlighted in green in Figure 3.12, has recently been shown to be an important 
multi-docking site for protein interactors of PDE4 isoforms (Houslay et al., 
2017). Although the UCR1 is highly conserved between all long PDE4 isoforms 
there are some small areas of divergence and the binding site sequence 
identified above (Figure 3.12) is unique to PDE4D isoforms due to the presence 
of a single serine at residue 205 (Figure 3.13).  
 
Figure 3.13 PDE4 Sequence alignment. PDE4 isoforms were BLASTed against each other in 
order align the newly identified DHX9 binding site. This site is unique to long PDE4 isoforms due to 
the presence of a single serine at position 205 (highlighted by a red arrow). (Altschul et al., 1997). 
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In order to identify any crucial amino acids for DHX9 binding, a walking alanine 
substitution scan on the sequence was performed. Furthermore, single and triple 
substitution of the FLY docking site (to alanine) was also performed in order to 
determine whether the loss of one or all these amino acids is detrimental to 
DHX9 binding (Figure 3.14). 
 
Figure 3.14 Walking alanine and triple substitution of DHX9 binding site. A. Walking alanine 
scan of the DHX9 binding site. B. Single and triple substitution of the FLY docking site. 
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Alanine substitution of Ser190 at spot 5 (Figure 3.13 A) appears to decrease the 
binding between PDE4D7 and DHX9 when compared to the control spot (spot 1). 
However, single amino substitutions between spots 12 and 21 increases the 
interaction probably due to change in the overall charge of the peptide 
sequence (Figure 3.14 A). Interestingly, single substitutions of the amino acids 
between spots 14 and 23 increases the binding of DHX9-FLAG to the peptide 
array (Figure 3.14 A). As with other binders of the FLY motif (Houslay et al., 
2017) , triple substitution of the FLY with alanine decreases the interaction 
between PDE4D7 and DHX9, however this interaction is not completely ablated 
(Figure 3.14 B). We can then assume that this region may be needed for the 
interaction between the two proteins as reported for the interaction between 
PDE4A5 and mitogen-activated protein kinase-activated protein kinase 2 (MK2) 
(Houslay et al., 2017).  
I was then interested in repeating this peptide array experiment with purified 
recombinant DHX9. A group led by Professor Richard Wozniak at the University of 
Alberta had recently been able to purify a full length functional, as well as 
truncated, DHX9 GST recombinant protein (Capitanio, Montpetit and Wozniak, 
2017). The truncated proteins consisted of a 67.8 kDa N-terminal region protein, 
a 75 kDa helicase core domain protein, and a 75.8 kDa C-terminal protein (Figure 
3.14 A). The full-length protein has an expected molecular weight of 166 kDa. I 
transformed each GST-tagged DHX9 plasmids into E.coli BL21-Codon Plus (DE3) 
cells (Figure 3.15 A). Protein expression was induced with the addition of 0.2 mM 
of IPTG and the cells were left overnight at 16˚C with shaking. The cells were 
pelleted and lysed the next day and the proteins purified as detailed in the 
methods. Protein expression was determined by running the samples on an SDS-
PAGE gel with western blotting, where the membrane was probed for GST 
(Figure 3.15 B,C and D).  
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Figure 3.15 Purification of recombinant DHX9 purified protein. A. Schematic diagram showing 
the full-length and truncated DHX9 recombinant proteins used in these experiments. DHX9 
plasmids were a kind gift from Prof Richard Wozniack at the University of Alberta. B-D. E.coli cells 
transformed with these plasmids were induced overnight with 0.2 mM of IPTG at 16˚C. Quality 
control samples were taken at each step of the purification and run on an SDS-PAGE gel. Protein 
expression was assessed by western blotting. All membranes were probed for GST. This work was 
carried out by Dr Yuan Yan Sin. 
Although we were able to express the N-terminal and Helicase domain of DHX9 
(Figure 3.15 D, lane 4 and 5), we were unable to elute the protein from the GST 
tagged beads (Figure 3.15 D, lane 8). Bizarrely, the bands representing the N-
terminal and helicase domain of DHX9 was not detected in the other gels, 
potentially indicating that the expression is at very low levels and can only be 
detected when bound to GST beads (Figure 3.15 B and C). We were therefore 
unable to verify our peptide arrays using the purified DHX9 protein. Alternative 
methods were used to elute the protein, such as the addition of NaCl to increase 
the ionic strength, however this remained unsuccessful (data not shown here). I 
was therefore unable to verify that the purified DHX9 protein could bind the 
same peptide sequence as the DHX9-FLAG lysate. However, using HEK293 DHX9-
FLAG lysate I was able to show that DHX9 binds to the UCR1 region of PDE4D7 
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(Figure 3.12); I therefore purified this region of PDE4D to investigate where 
PDE4D7 binds to DHX9 using full length DHX9 peptide arrays. Unfortunately, I did 
not have access to an appropriate construct to purify the full length PDE4D7 
protein for these experiments. I chose to purify this region as it is highly 
conserved within PDE4D isoform (Houslay, 2010). PDE4D-UCR1 was cloned by a 
previous member of the Baillie lab into the pGEX-5X-1 expression vector then 
transformed into BL21 E.Coli competent cells. The GST tag alone was also 
purified in order to ensure that any possible positively interacting spots were 
due to protein binding, and not due to the tag itself. Each construct was induced 
with 0.2 mM of IPTG for 5 hours at 37˚C, then pelleted and lysed in order to 
obtain the protein (Figure 3.16 A and B). Proteins eluted from GST beads was 
then dialysed in order to remove any remaining salts and detergents, and 
proteins were stored at -80˚C until required (Figure 3.16 C and D). Quality 
control samples, eluted, and dialysed proteins were then all run on an SDS-PAGE 
in order to check for protein expression by western blotting (Figure 3.16).  
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Figure 3.16 PDE4D UCR1-GST purification from BL21 E.Coli. The following samples were all 
run on an SDS-PAGE gel and UCR1-GST expression was assessed by western blotting using a 
GST antibody. A. Pre, post-inductions, soluble and insoluble fractions. B. Flow through, washes 
and beads from the purification column. C. Elutions 1-9 in D. UCR1-GST and GST purified protein 
after dialysis.  
By running all the elution samples on an SDS-PAGE gel and probing for GST by 
western blotting, I was able to show that I successfully purified recombinant 
PDE4D-UCR1 GST, as shown by a band at 39 kDa (Figure 3.16 C and D). Purified 
PDE4D proteins are highly prone to protein degradation, even in the presence of 
protease inhibitor, as shown by the presence of multiple smaller bands (Figure 
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3.16 C). In order to obtain the purest recombinant protein, I decided to only 
dialyse elutions 9-13 as these samples contained the least amount of degradation 
(Figure 3.16 C). The dialysed protein (Figure 3.16 D) was then used in order to 
map PDE4D7 binding on immobilised DHX9 peptides via peptide array. The 
recombinant purified proteins were overlaid onto full length DHX9 peptide array 
slides, then probed using a GST antibody. Purified recombinant GST alone was 
used as a control in order to ensure that the spot detected were due to protein 
binding, and not the tag binding to the peptide sequence (Figure 3.17 B).  
 
Figure 3.17 Mapping PDE4D7 binding on DHX9. A. Whole peptide array. Regions of interest are 
highlighted in the red boxes. B. Full length DHX9 peptide array, spotted as duplicates on the slide, 
was overlaid with either GST or PDE4D UCR1-GST, then probed using a GST antibody. PDE4D 
UCR1 was shown to bind to DHX9 within its helicase core domain. 
The data from the peptide array suggests that PDE4D7 binds within the helicase 
core domain of DHX9. This could mean that the binding of PDE4D7 could have a 
role in regulating the helicase activity of DHX9 by potentially regulating its 
phosphorylation. This helicase core domain is highly conserved between species, 
and its structure has been partially solved using X-Ray crystallography (Schütz et 
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al., 2010). However, the sequence used for this structure unfortunately does not 
include the PDE4D7 binding sequence therefore we were unable to model the 
potential binding site. Interestingly, this binding region also contains multiple 
prolines, lysines and aspartic acids (Figure 3.17 B). In order to identify which 
amino acids were crucial for PDE4D7 binding, peptide array membranes were 
synthesised with a walking alanine scan, as well as substitutions of specific 
amino acids (Figure 3.18).  
 
Figure 3.18 Amino Acid Substitutions of the PDE4D7 binding site on DHX9. The peptide array 
membranes were incubated with either GST or PDE4D-UCR1 GST. They were then probed with 
GST primary antibody. Binding sites were detected after probing the membrane with an anti-mouse 
HRP secondary. A. Walking alanine scan of the PDE4D7 binding sequence. B. Single and multiple 
substitution of the proline to an alanine. C. Single and multiple substitution of the lysine to a 
glutamic acid. D. Single and multiple substitution of aspartic acid to an arginine.  
The walking alanine scan suggests that the I579 (spot 5) and H583 (Spot 9) are 
important for PDE4D7 binding (Figure 3.18 A). Interestingly, substitution of the 
lysines between spots 18-20 (Figure 3.18 A) lead to a decrease in PDE4D-UCR1 
binding. Furthermore, when these lysines were substituted with a negatively 
charged glutamic acid led to inhibition of PDE4D7 binding onto the membrane 
indicating that these residues are important for protein binding at spot 8 (Figure 
3.18 C). Substitution of the prolines and the aspartic acids had no deleterious 
effects on binding (Figure 3.18 B and D). Studies have shown that lysine residues 
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of proteins play an important role in protein-protein and protein-DNA binding. 
The amino group of the residue itself often binds to the hydrogen bonds and 
catalyses the interaction with a ligand that may be important for protein 
function and substrate specificity (Sun et al., 2013). Lysine-rich regions are also 
known to be important in multiple post translational modifications, such as 
SUMOylation (Lamoliatte et al., 2014). I was then interested to see if the 
deletion, rather than substitution, of any of these lysines led to a decrease in 
PDE4D7 binding. Peptide array membranes with either N-, C-, or simultaneous N- 
and C-terminal truncations of the DHX9 binding sequence were constructed 
(Figure 3.19) and overlaid with either GST, as a control, or recombinant PDE4D-
UCR1 GST. 
 
Figure 3.19 PDE4D7 binding site truncations A. N-terminal truncations. B. C-terminal truncations 
C. Simultaneous N and C terminal truncations  
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Loss of F584 to P587 by N-terminal sequence truncation appeared to reduce the 
interaction between PDE4D7 and DHX (Figure 3.19 A spot 9-12). Single alanine 
substitution of F584 in Figure 3.17A (spot 10) also led to a loss in interaction. It 
has been shown that in soluble proteins, hydrophobic amino acids such as 
phenylalanine play a significant role in rapid protein folding as well as stabilizing 
protein scaffolds (Makwana and Mahalakshmi, 2015). Loss or substitution of this 
F584 in DHX9 could potentially cause the interaction to destabilise, leading to a 
decrease in protein-protein interaction. Truncations that resulted in the loss of 
the lysine at position 593 lead to a complete loss of PDE4D7 binding, indicating 
that this is a crucial residue for binding (Figure 3.19 A spot 19 and B Spot 10). 
This was also observed in the simultaneous N- and C-terminal truncations (Figure 
3.19 C spot 11). In order to further investigate if this lysine is crucial binding, 
site-directed mutagenesis of this lysine (K592) could be undertaken in our DHX9-
FLAG plasmids. The PDE4D7 IPs could be repeated, and if there is a decrease in 
co-IP this could further confirm that this lysine is important for the interaction 
between PDE4D7 and DHX9. Unfortunately, due to time constraints, I was unable 
to design and create these mutants.  
3.3.5 Development of cell penetrating peptides to disrupt PDE4D7-
DHX9 interaction 
In recent years, peptide therapeutics have played an important role in medical 
practices. Currently, there are over 60 peptide drugs approved in the United 
Stated and other major countries, and an increasing amount of clinical trials 
include the use of therapeutic peptides (Lau and Dunn, 2018). These therapeutic 
peptides have a maximum of 40 residues and are not limited to the 20 
genetically encoded amino acid (Davenport et al., 2020). These peptides have a 
high affinity and specificity to their target tissue or cell. They are typically 
identified using phage display experiments. In recent years, therapeutic 
peptides have grown in interest due to the fact that they can easily be 
synthesised, are smaller in size, and have a lower toxicity. These peptides can 
often be conjugated with carriers or therapeutic agents, improving its 
pharmacokinetics (Mousavizadeh et al., 2017; Davenport et al., 2020). 
Classically, these peptides are delivered as injectable. However, alternative 
methods of administration forms are gaining interests, such as oral, intranasal, 
and transdermal delivery routes (Fosgerau and Hoffmann, 2015).The main 
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diseases currently driving the use of peptide drugs are metabolic diseases, such 
as type 2 diabetes, and oncology. However, with the development of alternative 
delivery methods, such as topical administration, the hope is to enable the 
greater use of peptide therapeutics in other disease areas (Fosgerau and 
Hoffmann, 2015). 
Although we have been able to map putative binding sites between the two 
proteins using peptide arrays, these needed to be further verified in vitro using 
the overexpressing HEK293 and VCaP cell lines. One way of doing this would be 
to use peptide disruptors that could disassociate the PDE4D7-DHX9 complex. 
Hence, I used information gathered from the peptide arrays (Figure 3.12 and 
Figure 3.17), to devise cell-permeable peptide encompassing residues R187-S212 of 
PDE4D7. This peptide was synthesised and named “UCR1 disruptor peptide” 
(Figure 3.20 A). At the same time, a complementary approach using a peptide 
containing residues E576-G606 from DHX9 was also used. This peptide was named 
“DHX9 disruptor peptide” (Figure 3.20 B). Both peptides were made by 
GenScript, to a purity of 98% and dissolved in sterile DMSO to a stock 
concentration of 10 mM for future use. Although these peptides were synthesised 
using the information gained in the peptide arrays, they may not be specific to 
this interaction alone. The UCR1 domain is shared between all long PDE4D 
isoforms (Houslay and Adams, 2003), while the helicase domain is shared 
between all DExD/H helicases (Lee and Pelletier, 2016). This could potentially 
mean that these peptides have the potential to disrupt other protein-protein 
interactions that could take place in these domains.  
 
PDE4D7-DHX9 interaction in Prostate Cancer 125 
 
Figure 3.20 Designing peptide to disrupt the PDE4D7-DHX9 interaction. A. The UCR1 
disruptor sequence in based on the DHX9 binding domain on PDE4D7. B. The DHX9 disruptor 
peptide is based on the PDE4D7 binding domain of DHX9. 
A control peptide which consisted of a 25-mer peptide that was different from 
both disruptor peptides (PEVPLSYRRKLPGEFKKVRIKELM) was also synthesised and 
named “scrambled peptide”. This scrambled peptide was made by a previous 
member of the Baillie lab and was shown to not have any effects on their 
protein-protein interaction of interest (data not shown here). This scrambled 
peptide sequence was checked against the UCR1 and DHX9 disruptor peptide 
sequence in order to ensure that there were no similarities between peptides. 
Furthermore, this scrambled peptide was used by a previous member of the lab 
and was not shown to disrupt any PPIs or interest. All peptides contained an N-
terminal stearic acid allowing it to cross the cell membrane. The ability of these 
peptides to displace the PDE4D7-DHX9 interaction was first assessed by IP. By 
repeating the IPs shown in Figure 3.7 and Figure 3.8 in the presence of our newly 
synthesised disruptor peptides, I would be able to further confirm that I had 
successfully mapped the binding sites in PDE4D7 and DHX9. PDE4D7 was pulled 
down from lysates extracted from overexpressing VSV-tagged PDE4D7 in HEK293 
and VCaP cells using a VSV and PDE4D7 isoform-specific antibody respectively. 
The IPs were then thoroughly washed, and the amount of DHX9 that was co-IPed 
with PDE4D7 was assessed by SDS-PAGE gel electrophoresis with western blotting 
(Figure 3.21 and Figure 3.22).  
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Figure 3.21 Disruption of PDE4D7-DHX9 interaction in HEK293 and VCaP using the UCR1 
disruptor peptide. A. HEK293 were transfected with a plasmid encoding PDE4D7-VSV and 
treated with 10 µM of either disruptor peptide, scrambled peptide or DMSO vehicle control for 2 
hours. Lysates were immunoprecipitated for PDE4D7-VSV and probed for VSV and DHX9. The 
amount of DHX9 pulled down was normalised to PDE4D7-VSV IP, then normalised to DMSO 
vehicle control. B. VCaP cells were treated with 10 µM of either disruptor peptide, scrambled 
peptide or DMSO vehicle control for 2 hours. Lysates were immunoprecipitated for PDE4D7 and 
probed for Pan4D and DHX9. The amount of DHX9 pulled down was normalised to PDE4D7 IP, 
then normalised to DMSO vehicle control. The data is presented as mean ± SEM of three 
independent experiments. Statistical significance was determined using a One-Way Anova. 
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Figure 3.22 Disruption of PDE4D7-DHX9 interaction in HEK293 and VCaP following DHX9 
disruptor peptide treatment. A. HEK293 were transfected with PDE4D7-VSV and treated with 10 
µM of DHX9 disruptor peptide, scrambled peptide or DMSO vehicle control for 2 hours. Lysates 
were immunoprecipitated for PDE4D7-VSV and probed for VSV and DHX9. The amount of DHX9 
pulled down was normalised to PDE4D7-VSV IP, then normalised to DMSO vehicle control. B. 
VCaP cells were treated with 10 µM of either disruptor, scrambled peptide or DMSO vehicle control 
for 2 hours. Lysates were immunoprecipitated for PDE4D7 and probed for Pan4D and DHX9. The 
amount of DHX9 pulled down was normalised to PDE4D7 IP, then normalised to DMSO vehicle 
control. The data is presented as mean ± SEM of three independent experiments. Statistical 
significance was determined using a One-Way Anova, where p*=0.0355. 
Although not significant in statistical terms, treatment of PDE4D7-VSV-
overexpressing HEK293 and VCaP with the UCR1 disruptor peptide decreased the 
interaction between both ectopic PDE4D7-VSV (HEK293, Figure 3.21 A lane 6 
compared to lane 2) and endogenous PDE4D7 (VCaP, Figure 3.21 B lane 6 
compared to lane 2) and DXH9 when compared to the DMSO vehicle control. 
Treatment with the DHX9 disruptor peptide had little effect in overexpressing 
HEK293 (Figure 3.22 A), but significantly reduced the interaction of endogenous 
PDE4D7-DHX9 in VCaP cells (Figure 3.22 B lane 6 compared to lane 2). As often is 
the case, exogenously expressed proteins do not reflect what is occurring 
endogenously. Overexpressing a protein in cell line is often used in order to 
understand a function of a protein, as well as identify any interacting proteins. 
However, this does potentially force an interaction to take place (Prelich, 2012), 
thus not truly reflecting what is happening when endogenous levels of proteins 
are expressed. Overexpression of PDE4D7 and DHX9 in HEK293 cells allowed for 
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the protein to remain bound to one another, despite being treated with the 
disrupted peptide.  
 
The newly synthesised UCR1 disruptor peptide was able to disrupt the 
interaction between PDE4D7 and DHX9 by out-competing DHX9 for binding site 
within the UCR1 domain. I then decided to repeat the PLA experiments 
investigating the interaction between PDE4D7 and DHX9 in the presence of the 
UCR1 disruptor peptide or the scrambled peptide. VCaP cells were treated for 
two hours with DMSO, 10 µM UCR1 disruptor peptide, or 10 µM scrambled 
peptide. The PLA was then performed and imaged, and the red fluorescent spots 
representing each PLA signal was quantified using Image J (Figure 3.23). Since 
the FLY region has been shown to be a multi-docking site for PDE4 isoforms, I 
decided to first further validate this binding domain. Unfortunately, due to time 
constraints, I was unable to further test the DHX9 disruptor peptide by PLA assay 
with confocal microscopy.  
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Figure 3.23 Disruption of the PDE4D7-DHX9 interaction by the UCR1 disruptor peptide. A. 
VCaP cells were treated with 10 µM of disruptor peptide, scrambled peptide or DMSO vehicle 
control for 2 hours, then probed by PLA for PDE4D7 and DHX9. Cell membrane was stained using 
wheat germ agglutinin (green), and PLA was detected using a x 40 oil immersion lens. B. Mean 
fluorescence intensity of at least 20 cells from each condition was measured. Statistical 
significance was determined using a One-Way Anova where p>0.0001. Data is presented as the 
mean ± SEM of n>20 cells.  
Treatment of VCaP cells with the UCR1 disruptor peptide significantly decreased 
the interaction between PDE4D7 and DHX9 (Figure 3.23 A, last row). I then 
quantified the PLA signal from the cells treated with DMSO, scrambled peptide 
or UCR1 disruptor peptide (Figure 3.23, middle column). These values were 
plotted against each other, and a One-Way Anova was performed (Figure 3.23 
B). This analysis revealed that the interaction between PDE4D7 and DHX9 was 
significantly decreased when compared to the DMSO and scrambled peptide 
controls (Figure 3.23 B). The data presented so far confirms that DHX9 binds 
within the UCR1 domain of PDE4D7, and this interaction can be ablated with the 
use of our newly synthesised disruptor peptide.  
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3.3.6 Determining PDE4D7-DHX9 binding affinity using 
fluorescence polarization 
The data presented thus far in this chapter has confirmed that PDE4D7 and DHX9 
are novel interactors in PC cell lines. By using peptide array technology, I was 
able to map where these interactions took place. PDE4D7 binding to DHX9 within 
its helicase domain, while DHX9 binds within the UCR1 region of PDE4D7. By 
using the peptide array information, novel cell penetrating peptides were 
developed in order to confirm these binding sites. Treatment of VCaP and 
HEK293 cells with these peptides lead to a decrease in PDE4D7 and DHX9 
interaction when compared to the vehicle control (Figure 3.21Figure 3.22Figure 
3.23). Knowing that the interaction of PDE4D7 and DHX9 took place within the 
UCR1 domain, I was then interested in determining the binding affinity between 
these two proteins. Currently, fluorescence polarization (FP) is the most 
commonly used technique to study molecular interactions including PPIs (Lea 
and Simeonov, 2011). FP provides a nondisruptive way of measuring the 
association of a fluorescent ligand with a larger molecule, such as a purified 
recombinant protein (Rossi and Taylor, 2011). When a fluorophore is covalently 
bonded to small ligand, such as a peptide in solution, it is excited by the 
polarized light causing the emitted light to be largely depolarized. This is due to 
the rapid reorientations, or tumbling, of the fluorophore giving a low 
polarization value (Figure 3.24 A). However, if the labelled ligand is bound to a 
high molecular weight protein (> 10 kDa), the fluorophore reorients itself and 
this results in a slower molecular rotation. The binding of the larger molecule 
leads to a decrease in ligand rotation, which in turn leads to an increase in FP 
signal (Moerke, 2009) (Figure 3.24 B). By plotting these FP values, we are then 
able to then produce a sigmoidal curve from which we can obtain the 
dissociation constant of a PPI. By interpolating this information from the 
sigmoidal curve, we are able to quantify the strength of the interaction between 
two partners (Rossi and Taylor, 2011). 
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Figure 3.24 Ligand binding analysis by fluorescence polarization. A. In the absence of a high 
molecular weight protein, the rapidly rotations ligand gives low FP signal. B. The association of the 
ligand with a large molecule slows does the motion of the fluorophore, leading to an increase in the 
FP signal. Image adapted from Arkin et al., 2004. 
In this series of experiments, the interaction between UCR1-GST, or GST control, 
and a fluorescently tagged DHX9 peptide (5-FAM DHX9) was studied using FP. 
The DHX9 peptide sequence was the same sequence as the disruptor peptide as 
this contains the binding domain for PDE4D7. The UCR1-GST and the GST protein 
that was previously purified was used for this assay (Figure 3.16 D). 
Furthermore, full length PDE4D5-GST was also used in this assay in order to 
investigate if the full-length protein conformation is needed for the interaction. 
Like PDE4D7, PDE4D5 is a long isoform and shares the same UCR1 region (Tibbo, 
Tejeda and Baillie, 2019). These two proteins are identical in their sequences, 
apart from their unique N-terminal regions, and both contain the unique Ser196 
previously identified as only being expressed in PDE4D isoforms (Figure 3.13). 
PDE4D5-GST, expressed in the pGEX-6P-1 expression vector, was previously 
purified by Connor Blair (Baillie Lab) from BL21 E.Coli bacterial cells. Protein 
expression was induced 0.1 mM IPTG at 16˚C overnight. Cells were collected the 
next day and subjected to lysis. Cells lysates were then sonicated, and the 
supernatant incubated in Glutathione Sepharose beads. Recombinant purified 
protein was then eluted from the beads (Figure 3.25 A). 
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Figure 3.25 PDE4D5-GST and GST protein purification. PDE4D5-GST and GST were purified 
from E.Coli. A. Expression and purity of the recombinant protein was assessed via SDS-PAGE gel 
stained with Coomassie Blue. Presence of a 140 kDa protein confirmed that PDE4D5-GST was 
successfully purified. This protein purification was performed by Connor Blair. B. Expression and 
purity of recombinant GST protein was assessed via SDS-PAGE with Coomasie Blue staining. 
Presence of a 25 kDa protein confirmed that GST was successfully purified.  
By running the eluted proteins on an SDS-PAGE gel, then staining with coomasie 
blue, I was able to show that both PDE4D5-GST (Figure 3.25 A)and GST alone 
(Figure 3.25 B) were both purified to the highest quality. Although the UCR1-GST 
sample previously purified showed slight protein degradation (Figure 3.16 D), 
this sample was still taken forward for FP binding assays. Using the information 
from the peptide array (Figure 3.17 Spot 116), a 25-mer peptide was generated 
from the PDE4D7 binding site in DHX9. Residues E576-G606 based on the PDE4D7 
binding sequence on DHX9 was synthesised with an N-terminal 5-FAM fluorescent 
tag. This peptide was generated by Genscript and dissolved in DMSO to a stock 
concentration of 10 mM. Although we have been able to purify the proteins of 
interest, a pilot assay with just the newly synthesised peptide needs to be 
performed. This allows us to determine the minimum amount of peptide needed 
for future FP binding assays (Figure 3.26). 
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Figure 3.26 Determining minimum DHX9 peptide concentration for FP assay. Fluorescently 
tagged DHX9 peptide was serially diluted, and the FP value was plotted against the concentration 
of peptide present.  
By using the linear portion of the graph (indicated by dotted lines in Figure 
3.26), we were able to determine the lowest amount of peptide needed for 
future FP assays. The lowest peptide concentration was chosen in order to 
minimise the amount of DMSO present in the FP assay. DMSO concentration 
above 4% of the final volume can potentially destabilize PPI (Chan et al., 2017). 
The minimum peptide needed for future binding assays was found to be 62.5 nM. 
Using this information, the direct binding assay was performed using the 
previously obtained purified recombinant protein. All proteins were serially 
diluted 1:2, from a starting concentration of 10 µM. 62.5 nM of the 5’FAM-DHX9 
peptide was then added and the reaction was left to incubate at room 
temperature. The FP value was recorded after 0.5, 1, 3 and 5 hours, and the 
values obtained were plotted against the log10 of the protein concentration 
present (Figure 3.27).  
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Figure 3.27 PDE4D UCR1-GST and PDE4D5-GST binding assay to DHX9 peptide. Serial 
dilutions of purified PDE4D UCR1-GST protein, full-length PDE4D5 protein or GST alone (10 µM to 
0.02 µM) were incubated with 62.5 nM of 5-FAM DHX9 peptide. FP values were measured at the 
indicated times and plotted against the log10 values of protein concentration. This is representative 
of two independent protein purifications.  
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Upon ligand-protein binding, the FP value would normally result in a reading 
above 100 mP (indicated as a dotted line in Figure 3.27) (Speranzini, Fish and 
Mattevi, 2014, and personal conversation with Dr Yuan Sin). Highest mP values 
could be seen after 30 minutes of incubation (Figure 3.27 A), however no 
difference could be seen between any of the protein samples. Furthermore, the 
presence of the UCR1 domain, either in the truncated or full-length protein, did 
not result in the increase in mP values indicating the our DHX9 peptide was not 
binding to the protein. Increased incubation at room temperature led to a 
decrease in the mP values, suggesting that the protein was slowly degrading at 
room temperature (Figure 3.27 B,C and D). Due to continuous decrease in the FP 
values after the first 30 minutes reading, it can be suggested that if the 
interaction were to take place, it may have taken place prior to the first 
reading. This could mean that the interaction between PDE4D7 and DHX9 is rapid 
and transient. Ideally, the UCR1 peptide sequence should have been synthesised 
and binding assays be performed using purified recombinant DHX9. However, as 
we were unable to purify recombinant DHX9 protein, this approach was not 
possible. UCR1 and PDE4D5 GST tagged protein was used for these binding assays 
as they were highly abundant in the lab at the time. Unfortunately, I was unable 
to repeat these experiments and optimise conditions in order to obtain any 
binding affinity information due to time constraints.  
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3.4 Discussion 
3.4.1 DHX9 is a novel interactor of PDE4D7 in PC cell lines 
In recent years, PC has become one of the most common type of cancers 
diagnosed in men over the age of 50 across Europe and the USA. Although risk 
factors have been identified, these are not fully understood. There is currently a 
need to identify and understand PC-associated cell signalling processes and how 
these link to pathogenesis. In order to fully understand the signalling machinery 
that leads to disease progression, identification of new protein-protein 
interactions is needed in order to understand molecular regulatory networks 
(Chen et al., 2016). Importance of these interactions can be assessed using 
network analysis which can predict how mutations within the genome can affect 
each interaction, as well as any other downstream pathways (Ruffalo and Bar-
Joseph, 2019). Detection of key regulators and regulatory pathways is important 
in order to discover new genes in cancer (Mangangcha et al., 2019).  
Here, I was able to confirm that PDE4D7 and DHX9 are novel interactors in vitro. 
This interaction was first identified by Dr Ashleigh Byrne in a PDE4D7 IP coupled 
with mass spectrometry (MS) (Byrne, 2014), which is a tool that can be used to 
identify novel interacting proteins (Smits and Vermeulen, 2016). By using 
biochemical techniques, we were able to provide further evidence that these 
two proteins are interacting in vitro (Figure 3.7 and Figure 3.8), and this 
interaction could be disrupted in the presence of the newly synthesized CPP 
(Figure 3.21, Figure 3.22, and Figure 3.23). Interestingly, DHX9 was found to 
bind a sequence containing the newly discovered FLY multi docking site (Houslay 
et al., 2017) for PDE4 interacting proteins, whereas PDE4D7 binds within the 
helicase domain of DHX9 (Figure 3.12 and Figure 3.17). As previously mentioned, 
DHX9 belongs to the DExD/H box superfamily of proteins that are highly 
conserved across all species. RNA helicases are enzymes that are able to unwind 
dsRNA and DNA in an energy-dependent fashion through the hydrolysis of ATP 
(Tanner and Linder, 2001b). Members of this family are defined by the presence 
of seven or eight evolutionarily conserved motifs that are involved in the binding 
of ATP within the helicase domain (de la Cruz, Kressler and Linder, 1999). While 
individual DExD/H helicase family members have been extensively studied, 
identifying novel cofactors and protein interactors for them is crucial in order to 
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fully understand the function and regulation of these helicases (Silverman, 
Edwalds-Gilbert and Lin, 2003).  
Recent work has identified DHX9 and Nup98 to be novel interactors. Nup98 is a 
member of the highly conserved nuclear pore complex (NPC) family of proteins. 
Nup98 lies near or at the nuclear membrane and forms scaffolds that act as 
binding surfaces for other members of the NPC family. This in turn helps to 
facilitate the movement of nuclear transport factors, and their cargo, across the 
nuclear membrane. Nup98, is also involved in the export of mRNA as well as the 
shuttling of proteins from the nucleus via its numerous interacting partners 
(Franks and Hetzer, 2013). DHX9 was recently identified as a novel interactor of 
Nup98. Using a bead halo assay, they were able to show that Nup98 was able to 
bind to the N-terminal region of DHX9, containing the RNA binding motif, and 
the C-terminal region, containing the RGG box. The interaction of Nup98 and 
DHX9 within this region appeared to be facilitated by the presence of RNA as this 
interaction was sensitive to the endoribonuclease RNAse A. Interestingly, the 
binding of NUP98 within these regions of DHX9 stimulated the ATPase activity of 
DHX9. In the presence of RNA, the addition of recombinant NUP98 induced a 
dose-dependent increase in the ATPase activity of DHX9 (Capitanio, Montpetit 
and Wozniak, 2017). This data indicates that Nup98 acts as a positive regulator 
of DHX9 helicase activity. PDE4D7, and other members of the PDE4 family, are 
able to control the total cellular content of cyclic nucleotides and are able to 
create nanodomains of cyclic nucleotide signalling. (Baillie, Tejeda and Kelly, 
2019a; Houslay et al., 2019). As previously discussed, the PDE8A-cRAF 
interaction was shown to activate downstream signalling pathways, which could 
in turn lead to the progression of melanoma (Blair et al., 2019). I suggest here 
that the interaction between PDE4D7 and DHX9 could potentially influence DHX9 
helicase activity that could have a knock-on effect on disease progression. This 
interaction could potentially regulate the expression of downstream proteins, 
which in turn could alter the rate at which the disease could progress. The 
effects of PDE4D7 and DHX9 interaction on cell growth and helicase activity will 
be further investigated in chapter 5. 
Interestingly, DHX9 is also able to form a complex formation with cAMP Response 
Element-Binding Protein (CREB) binding protein (CBP) and RNA polymerase II 
(Nakajima, Uchida, Stephen F. Anderson, et al., 1997). CREB is one of the best 
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characterised phosphorylation-dependent transcription factors, and several 
kinases have been shown to promote its phosphorylation at its transactivation 
site. Once phosphorylated, CREB interacts with its coactivator protein, CBP or 
p300, at CREB responsive-genes (Wen, Sakamoto and Miller, 2010). CBP/p300 is 
thought to serve as a bridge between diverse gene-specific transcription factors 
and components of the basal transcriptional machinery (Karamouzis, 
Konstantinopoulos and Papavassiliou, 2007). Using transient transfections, DHX9 
was found to cooperate with CBP in mediating target gene activation via CREB, 
and mutation of its helicase domain was found to reduce the expression of 
proteins containing CREB-dependent transcription factors (Nakajima, Uchida, 
Stephen F. Anderson, et al., 1997). Examination of the promoter regions of 
PDE4D7 identified multiple CREB binding sites upstream of the starting 
methionine, suggesting that the cAMP/ PKA pathway may regulate the 
transcriptional expression of PDE4D7 (Wang et al., 2003). I tentatively suggest 
here that DHX9 could potentially play a role in the transcriptional expression of 
PDE4D7. DHX9 could form a complex with RNA polymerase II and CBP (Aratani et 
al., 2001) at one of the CREB binding sites in the PDE4D7 gene, potentially 
altering its expression at different stages of disease. It has been suggested DHX9 
can reduce expression of certain proteins. Binding of DHX9 to the transcriptional 
activator of tonicity-responsive enhancer (TonE) binding protein (TonEBP) results 
in the decreased activity of TonEBP, leading to a decrease in its transcriptional 
activity (Colla et al., 2006). Furthermore, the C.elegans DHX9 homologue RHA-1 
is required for silencing transcription. Transcriptional silencing due to RHA-1 
activity lead to a decrease in lysine methylation of histone H3, which in turn 
lead to defects in meiosis and a sterile phenotype. RHA-1 has since been 
suggested to be an important protein in maintaining appropriate transcriptional 
activity in order to control germline proliferation and development in C.elegans 
(Walstrom et al., 2005). My data has shown that the expression of DHX9 
increases from early to late stage models of disease, whereas PDE4D7 expression 
decreases (Figure 3.1). It can be suggested that the increased expression of 
DHX9 in the late stages of disease acts as a repressor of PDE4D7 expression by 
recruiting other transcription factors, which in turn could contribute to disease 
progression. Further work is needed to verify this hypothesis. 
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3.4.2 DHX9 binds within the UCR1 domain of PDE4D7 
PDEs represent a large family of enzymes that hydrolyse cAMP and cGMP and at 
least 25 PDE genes have been identified and cloned. By using multiple promoters 
and alternative mRNA splicing, a single PDE gene can generate variant products 
in a tissue-specific manner (Ong et al., 2009). PDE4 enzymes exclusively 
hydrolyse cAMP and it is the predominant cAMP degrading enzyme in a number of 
specific cell types. PDE4 plays a crucial role in cell signalling and it has been a 
target for clinical drug development for various diseases, with actions ranging 
from anti-inflammation to memory enhancement (Zhang et al., 2005). 
Functional PDE4 isoforms can be divided into four major categories: long, short, 
super short, and dead short (Figure 1.8). The expression of various UCR1/2 
combinations allows each specific PDE4 isoform to regulate distinct pools of 
cAMP by their cellular location and ability to be phosphorylated by a variety of 
kinases, including PKA (Omar et al., 2019). The PDE4D family is characterised by 
the expression of seven long isoforms (D3, D4, D5, D7, D8, D9, D11), one short 
isoform (D1), and three super short isoforms (D2, D6, D10) (Tibbo, Tejeda and 
Baillie, 2019). Of the long PDE4D isoforms, PDE4D3, D5, D7, D9 are expressed in 
PC, and the mRNA expression of PDE4D3 and PDE4D7 is differentially affected 
between AS and AI models (Henderson et al., 2014).  
Long PDE4D isoforms all contain a UCR1 domain and, along with UCR2, provide 
the molecular machinery that confers key regulatory functions on the PDE4D 
catalytic unit (Houslay and Adams, 2003). The presence or absence of these UCR 
domains determines critical functional differences between long and short 
isoforms. The UCR1 region of all PDE4 isoforms harbours a PKA consensus site 
which in turn activates the cellular activity of PDE4 when modified (Xie et al., 
2014). The data presented in this chapter has shown that the UCR1 region of 
PDE4D7 can also act as a binding site for interaction partners. DHX9 was seen to 
bind within the UCR1 domain by peptide array (Figure 3.12), and this interaction 
was significantly reduced in IPs and PLA when cells were treated with disruptor 
peptide that was designed based on the binding sequence (Figure 3.21 and 
Figure 3.23). This binding sequence is unique to PDE4D isoforms by the presence 
of a single serine at residue 196 (Figure 3.13) and shared between other long 
PDE4D isoforms. This could indicate that DHX9 has the potential to bind to other 
long PDE4D isoforms that are present in the prostate. However, as PDE4D7 is the 
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most highly expressed isoform in PC (Henderson et al., 2014), we can assume 
that the majority of the DHX9 would be bound to PDE4D7. It is unknown if the 
single serine change at residue 196 is enough to make this binding site PDE4D-
specific, though this could easily be resolved by further peptide array 
experiments. 
Interestingly, the UCR1 binding sequence for DHX9 contained the newly 
identified FLY multi-docking sequence. PDE4 enzymes having binding domains 
that allow interactions with various kinases, and domains that allow binding to 
other scaffolding proteins. These allow for the spatial degradation of cAMP in 
order to provide compartmentalised signalling, which in turn can then regulate 
the cross talk with other signalling processes (Houslay, 2010). The FLY docking 
site was first identified as a binding site for MK2 on PDE4A5 (Houslay et al., 
2017). The stress-activated p38 mitogen activated protein kinase (p38MAPK) 
pathway regulates a range of cellular processes, including apoptosis and cell 
invasion. The downstream substrate of this pathway, mitogen-activated protein 
kinase-activated protein kinase 2 (MK2), is involved in the post-translational 
regulation of cytokines (Soni, Anand and Padwad, 2019). Interestingly, PDE4A5 
can be phosphorylated by MK2 on Ser 147 within the UCR1 domain. 
Phosphorylation of this serine was shown to attenuate the activation of PDE4A5 
by PKA phosphorylation at Serine 140 (MacKenzie et al., 2002b, 2011). Mutation 
of the FLY sequence within the UCR1 domain was shown to completely inhibit 
the interaction with MK2. Furthermore, loss of MK2-PDE4A5 interaction led to a 
reduction in the phosphorylation of Serine 147 in PDE4A5. The interaction 
between PDE4A5-MK2 via the docking site is needed to facilitate the efficient 
activation of PDE4A5 at Ser 147 (Houslay et al., 2017). Although the 
phosphorylation of PDE4D isoforms by MK2 has not been extensively studied, we 
can assume that DHX9 and MK2 could potentially be competing for this binding 
domain. Binding with MK2 could act as a negative regulator of PDE4D7 activity by 
attenuating PKA phosphorylation of the UCR1 domain, whereas DHX9 could 
potentially act as a positive regulator by outcompeting for this binding site. The 
loss of regulation of PDE4D activity can have a profound effect on 
compartmentalised cAMP signalling, and could contribute to disease progression 
(Böttcher et al., 2016).  
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3.4.3 Using cell permeable peptides as therapeutic agents in PC 
In recent years, ADT has been the mainstay treatment for PC, and a marked 
increase in its use can be observed (Liu et al., 2019). In most men, ADT leads to 
the relief of PC-related symptoms, regression of metastases, and a fall in serum 
PSA levels. If managed correctly, the median survival for men with metastasis is 
30-49 months with the potential to extend it to 10 years if managed correctly. 
However, with time, the disease no longer responds to hormone treatment and 
the patient eventually develops the CRPC lethal phenotype (Varenhorst et al., 
2016). Furthermore, long-term use of ADT has been reported to reduce quality 
of life and increase the risk of adverse events, such as cardiovascular events, 
fractures, metabolic syndrome, and memory loss (Casey, Corcoran and 
Goldenberg, 2012; Kim et al., 2018). There is currently a need to find new 
therapeutic targets for the treatment of PC in order to potentially alleviate the 
negative outcomes of long-term ADT use. Therapeutic peptides are potentially a 
novel approach to treat many diseases, including cancer (Marqus, Pirogova and 
Piva, 2017). Furthermore, protein-protein interactions in cancer has slowly 
become a new target in multiple cancers as they allow clinicians to target 
cancer cells expressing protein complexes that are known to progress the 
disease (Ruffalo and Bar-Joseph, 2019). 
Using the information obtained from our peptide arrays, we were able to 
synthesise two cell penetrating peptides. The UCR1 disruptor peptide was based 
on the DHX9 binding sequence in PDE4D7, while the DHX9 peptide was based on 
the PDE4D7 binding sequence in DHX9 (Figure 3.12 and Figure 3.17). These 
peptides were synthesised with an N-terminal stearic acid making them cell 
permeable. Using biochemical techniques, the interaction between PDE4D7 and 
DHX9 was significantly reduced when the cells were treated with the UCR1 
disruptor peptide (Figure 3.21 and Figure 3.23). In recent years, peptides have 
become promising therapeutic agents in the treatment of cancer. When 
compared to other biological treatment options, such as monoclonal antibodies, 
peptide therapeutics possess many advantages such as their small size, ease of 
synthesis and their tumour penetrating ability (Thundimadathil, 2012). The 
TMPRSS2:ERG gene fusion product remains an attractive therapeutic target as it 
is known to be an oncogenic driver in both early and late stage of PC (Brenner et 
al., 2011). By screening a phage display peptide library, Wang et al. (2017) were 
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able identify peptides that were able to interact specifically with wild-type ERG. 
Specifically, they discovered 12 unique ERG inhibitory peptides (EIPs) that were 
able to bind to the protein itself. These EIPs were able to block the interaction 
of ERG with both DNA and interaction partners, which attenuated ERG-mediated 
transcription, PPIs, cell invasion and proliferation in vitro (Wang et al., 2017). In 
my view, the newly designed UCR1 disruptor peptide has the potential to impact 
the progression of PC in a similar manner to EIPs. The disruption of the PDE4D7-
DHX9 interaction could potentially decrease the transcriptional activity of DHX9, 
as the EIPs did on ERG-mediated transcription. This would then lead to 
decreased mRNA translation, potentially resulting in PC cell death. Methods such 
as individual-nucleotide resolution UV crosslinking and immunoprecipitation 
(iCLIP) can be used to map mRNA DHX9 binding sites in different cell lines to 
determine how DHX9 mRNA binding can be affected by the disruption of PDE4D7-
DHX9 complex (Huppertz et al., 2014; Murat et al., 2018).  
Alternatively, cell penetrating peptides could potentially be used to transport 
therapeutic cargos into cells (Hoffmann et al., 2018). Discovery of novel 
peptides has traditionally been performed by screening large libraries of 
peptides, produced either synthetically or biologically. These large libraries 
include phage, ribosomal, and mRNA displays and have become the standard for 
peptide discovery (Henninot, Collins and Nuss, 2018). Peptides can be used 
directly as cytotoxic agents by targeting protein complexes or receptors, or they 
can be modified to act as a carrier of cytotoxic agents and radioisotopes to 
specifically target cancer cells. These types of therapies have been extensively 
studied in PC (Boohaker et al., 2012). As well as the UCR1 peptide, we also 
synthesised a disruptor peptide that was able to compete with PDE4D7 for the 
DHX9 binding site (Figure 3.17 and Figure 3.22). Although this peptide did not 
lead to a significant decrease in PDE4D7-DHX9 interaction in both cell models, 
this peptide could potentially be reutilised as a homing peptide to specifically 
target cancer cells that are expressing both PDE4D7 and DHX9. Homing peptides 
are capable of selectively delivering many kinds of molecules and hold great 
promise for the development of less toxic therapies in several diseases (Wada et 
al., 2019). Normal and diseased organs can be treated with a specific 
macromolecular tag, or homing peptide, that can be used to specifically target 
only the diseased cells (Laakkonen and Vuorinen, 2010).  
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Such an approach has already been shown to be successful in mouse models of 
PC. D(KLAKLAK)2 is an amphipathic D-amino acid peptide that binds selectively 
to bacterial cell membrane. This peptide is known to initiate apoptosis in 
eukaryotic cells by disrupting mitochondrial membranes (Ma et al., 2012). In 
recent years, D(KLAKLAK)2 has been conjugated with multiple homing peptides to 
target specific cancer, in turn causing cell death (Agemy et al., 2011). By 
conjugating the prostate homing peptide with D(KLAKLAK)2 and delivering it 
systemically through an IV, they were able to cause tissue destruction in the 
prostate, but not in other organs in PC mouse models (Ma et al., 2012) This 
chimeric peptide also delayed the development of cancers in PC-prone 
transgenic mice (Arap et al., 2002). Our newly synthesised DHX9 peptide could 
potentially be reutilised as homing peptide that could transport anti-cancer 
agents to the prostate directly. If delivered systemically, this would be an 
alternative to ADT and could reduce PC recurrence. However, due to the 
expression of DHX9 in multiple organ systems, further phage display studies 
would need to be carried out in order to ensure that this peptide will only target 
the prostate itself. Additionally, we would also need to ensure that this peptide 
would not interfere with other members of the DExD/H helicase proteins.  
3.4.4 Fluorescence polarization as a new screening tool to 
identify binding enhancers or disruptors 
Since its discovery in the 1920s, FP has become one of the most widely used 
methods in clinical and biomedical sciences for assessing protein-protein 
interactions (Croney, 2003). FP is a powerful tool for characterizing the 
interaction between two proteins, or between a protein and DNA fragments, in 
order to provide details on the strength of these interactions (Lundblad, 
Laurance and Goodman, 1996). FP assay allows the user to closely monitor the 
association and dissociation of a fluorescent ligand with its interacting protein 
without the need to separate the bound ligand from the unbound ligand (Rinken, 
Lavogina and Kopanchuk, 2018). This allows ligand binding to be quantified 
without perturbing the binding equilibrium, making it a suitable way to measure 
low affinity interactions. Once the assay is optimized, the FP assay can be used 
to provide high throughput screening in order to find small molecule drugs that 
can either enhance or disrupt an interaction. FP assays are non-destructive, 
allowing repetitive measurements of the same sample under different conditions 
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(Rossi and Taylor, 2011). In this chapter, I tried to establish a simple binding 
assay between the purified recombinant UCR1 protein and a fluorescently tagged 
DHX9 peptide. I was able to show that the minimum peptide required for the 
assay was 62.5 nM (Figure 3.26). However, once the peptide was incubated with 
the purified recombinant protein, no binding information could be obtained as 
all FP measurements were similar to the GST tag negative control (Figure 3.27). 
Furthermore, as we increased the incubation time between the protein and the 
fluorescent peptide, the FP value continually decreased (Figure 3.27 B, C and D). 
Highest FP values could be observed after 30 minutes of incubation (Figure 3.27 
A), suggesting that the interaction between the UCR1 region and DHX9 is rapid 
and transient. However, lack of FP change in the samples of interest can also be 
due to the purity of the sample. Although we were able to purify the UCR1 
domain, the dialysed protein still contained multiple smaller bands indicating 
that the protein itself was highly degraded (Figure 3.16). Although we were able 
to use these protein samples in our peptide array experiments, this sample may 
not have been suitable for FP. The presence of precipitated matter in the assay 
solution can cause light scattering interference with FP measurements (Moerke, 
2009). It could be possible that the high presence of degraded UCR1 protein was 
interfering with the accurate detection of FP.  
Once a successful binding assay can be established, the assay can be adapted in 
order to identify small molecular drugs that are able to modulate the 
interaction. Although therapeutic peptides have emerged as a novel tool in the 
treatment of PC, it would be of interest to find small molecule drugs that can 
complement or replace the existing peptide therapy. Small molecules that 
inhibit the interaction between the protein and the fluorescent peptide, and are 
able to displace the peptide from the its binding site, can be observed as a 
decrease in FP value (Lea and Simeonov, 2011). Alternatively, if maintenance of 
the interaction between two proteins is needed to inhibit progression of a 
disease, small molecules that are able to stabilize and enhance the interaction 
can be identified (Simonetta et al., 2019). Such an approach has been used in 
order to increase the interaction between the oncogenic transcription factor β-
catenin and its E3 ligase β-TRCP (Simonetta et al., 2019). β-catenin is a 
multifunctional protein that is central to many physiological processes but high 
expression of this protein contributes to various diseases such as cancer. It acts 
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both as a transcriptional regulator and an adaptor protein for intercellular 
adhesion. Continuous activation of its signalling pathway gives rise to the 
accumulation of β-catenin in the nucleus, which in turn promotes the 
transcription of many oncogenes such as c-Myc and Cyclin-D1. β-catenin 
contributes to the carcinogenesis and progression of several cancers, such as 
colorectal cancer (Shang, Hua and Hu, 2017). Oncogenic activation of β-catenin 
occurs by escaping ubiquitin-mediated proteasomal degradation. Proteasomal 
degradation of β-catenin is mediated by the β-TrCP subfamily of F-box proteins, 
which regulate the turnover of many proteins by acting as a E3 ubiquitin-protein 
ligase that target its substrates for protein degradation. However, mutations 
within β-catenin can impair the ability of β-TrCP to effectively bind, leading to 
β-catenin stabilization and oncogenic activity (Ougolkov et al., 2004). Simonetta 
et al. (2019) therefore used FP to find prospective small molecule drugs that 
work by restoring the binding between β-TrCP and mutant β-catenin. They were 
able to identify a compound that was able to potently increase the interaction 
between β-TrCP and mutant β-catenin, and induced β-catenin degradation in 
vitro. This small molecule was able to insert into the PPI binding site, and 
increase the interaction between substrate and ligand (Simonetta et al., 2019). 
Although I was unable to determine if the interaction between PDE4D7 and DHX9 
increases the speed at which PC progresses, FP assays such as the one described 
above could help find novel small molecule drugs that could be used to enhance 
or disrupt the interaction. When established, the optimized FP conditions can be 
used in high throughput screening assays (HTSs) to evaluate more than 20 000 
compounds from a library (Alquicer et al., 2012) in order to identify novel small 
molecules for the treatment of PC. This in turn could potentially modulate 
down-stream signalling pathways that could alter the progression of disease. 
3.4.5 Chapter summary 
The data presented in this chapter has confirmed the interaction between 
PDE4D7 and DHX9. These two proteins can interact with each other in 
overexpressing VSV-tagged PDE4D7 and Flag-tagged DHX9 HEK293 and 
endogenously in VCaP cells. Although these two proteins are expressed in two 
different cellular compartments, PDE4D7 has the potential to shuttle into the 
nucleus through an NLS sequence that has been identified within the linker and 
UCR2 domain of PDE4D7. Treatment with LMB increased the presence of PDE4D7 
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within the nuclear region, which in in turn increased the interaction between 
PDE4D7 and DHX9 in LNCaP cells. The interaction between PDE4D7 and DHX9 was 
confirmed by IPs and PLA imaging and using peptide array we were able to map 
where this interaction takes place in each protein. DHX9 was found to bind 
within the UCR1 region of PDE4D7 and this binding sequence was found to 
contain the FLY docking site of PDE4 isoforms. Although this domain is shared 
between all long PDE isoforms, this binding sequence was found to be unique to 
PDE4D due to the presence of a serine at residue 196. PDE4D7 was found to bind 
within the helicase domain of DHX9, indicating that this interaction could 
potentially have a role in regulating the helicase activity of DHX9. By using cell 
permeable peptides, I was able to confirm that DHX9 binds within the UCR1 
domain, but the binding site of PDE4D7 within DHX9 still needs further 
confirmation. Using purified recombinant UCR1 and PDE4D5, FP binding assays 
were performed in order to determine the dissociation constant. Unfortunately, 
due to the purity of UCR1 I was unable to determine this constant. However, if 
this binding assay was established, this assay would permit us to find new small 
molecules that could enhance or disrupt the interaction between PDE4D7 and 
DHX9.  
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Chapter 4 DHX9 Phosphorylation by Protein 
Kinase A 
4.1  Introduction 
The cAMP-PKA signalling pathway is known to have an important role in a range 
of physiological processes, including cell growth, secondary metabolism, and cell 
differentiation (Zhu et al., 2017). cAMP controls a wide range of cellular 
processes that are triggered by a variety of extracellular signals, such as 
hormones or neurotransmitters. Many signalling pathways are initiated by the 
binding of a ligand to a GS-coupled GPCR at the plasma membrane, which in turn 
leads to the activation of AC converting ATP into cAMP (Figure 1.7) (Koschinski 
and Zaccolo, 2017). GPCRs are the largest family of plasma membrane 
receptors, mediating the effects of multiple ligands. Due to their involvement in 
fundamental biological processes and their accessibility, GPCRs are targets for 
major drug classes, including beta-blockers (Calebiro, Nikolaev and Lohse, 
2010). The major effector for cAMP in cells is PKA, which has the ability to 
phosphorylate multiple targets in each individual cell (Koschinski and Zaccolo, 
2017). PKA is a serine/threonine kinase which is composed of a dimer of two 
regulatory subunits (R) that each bind to a catalytic subunit (C) when inactive. 
Four types of R subunits (RIα, RIβ, RIIα, and RIIβ) and three types of C subunits 
(Cα, Cβ, Cγ) have been identified in humans. All PKA holoenzymes are named 
based on their R subunit isoform, referred to as PKA-I and PKA-II. PKA-I contain 
homodimers of RIα and Riβ, whereas PKA-II contain homodimers of RIIα or RIIβ 
subunits (Yang and Yang, 2016; Smith and Scott, 2018). Each R subunit contains 
two cAMP binding sites, and binding of cAMP leads to a conformational change 
that results in release of the active C subunit (Figure 4.1) (Yang and Yang, 2016). 
Furthermore, each R subunit contains an N-terminal docking and dimerization 
domain (D/D domain) that not only facilitates formation of the heterotetramer, 
but also tether is to an A-kinase anchoring protein (AKAP) (Nygren and Scott, 
2015). Once activated by cAMP, the C subunit can phosphorylate nearby 
substrates, before being sequestered by an AKAP bound to an R subunit, forming 
small signalling complexes in the cell (Autenrieth et al., 2016). AKAPs tether PKA 
and other signalling proteins, such as PDEs, to defined cellular sites, providing 
compartmentalized cAMP signalling. AKAPs can coordinate multiprotein 
complexes, allowing for compartmentalized signalling (Christian et al., 2011).  
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Figure 4.1 Structure of inactive and active PKA. A. Inactive PKA is as a dimer of two regulatory 
subunits (R) that each bind to a catalytic subunit (C). B. When bound to cAMP, the C-subunit is 
released from the R-subunit, allowing it to phosphorylate near-by proteins. Figure taken from 
Zhang et al., 2012. 
Although ADT is seen as a highly successful therapy, PC tumours often become 
hormone refractory (androgen insensitive) and can grow despite low levels of 
androgens. One possible way that these tumours can grow in such conditions is 
through cross talk with other signalling pathways, such as the cAMP-PKA pathway 
(G. Wang et al., 2006). The activity of many transcription factors, including AR, 
is regulated by their phosphorylation status. In the case of steroid receptors, 
increased phosphorylation of the receptor itself leads to an increase in its 
transcriptional activity. The AR is phosphorylated by PKA, which in turn can 
modulate AR activity and downstream gene expression (Nazareth and Weigel, 
1996). The AR is a phosphoprotein with at least 16 residues that can be 
phosphorylated by multiple kinases (Figure 4.2). These residues are sequentially 
phosphorylated upon the treatment of PC cells with androgens, antiandrogens, 
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or reagents that activate downstream signalling pathways. This results in 
alteration in the transcriptional activity of AR, its cellular localization, and its 
stability (van der Steen, Tindall and Huang, 2013). Interestingly, phosphorylation 
of different serines or threonines in AR can predict disease outcome. For 
example, phosphorylation of Ser515 by Cdk1 may predict biochemical relapse in 
PC patients. Work by Willder et al (2013) suggested that phosphorylation at AR 
at Ser515 may be the driving force in PC disease progression. However, their work 
also showed that high expression of Ser515 lead to a shorter time to biochemical 
relapse and a reduction in disease specific survival in hormone naïve PC patients 
(Willder et al., 2013). Furthermore, phosphorylation of AR at Ser81 by PKC was 
also shown to be associate with poor disease outcome. Increase expression of 
pAR Ser81 has been shown to be associated with decrease disease-specific 
survival (Patek et al., 2017). 
 
Figure 4.2 AR can be phosphorylated at multiple sites and by multiple kinases. A. Schematic 
representation of AR phosphorylation within different regions of the protein. B. Overview of AR 
phosphorylation, their kinases, and functional effects. (Figure taken from Koryakina, Ta and Gioeli, 
2014). 
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Elevated levels of cAMP/PKA in LNCaP cells following treatment with the PDE4 
inhibitor rolipram induces an increase in expression of AR and PSA proteins in the 
absence of androgens. Lower expression of PDE4 isoforms and increased levels of 
cAMP/PKA at later stages of disease favours the constitutive activation of the AR 
pathway, which in turn could contribute to disease progression (Sarwar et al., 
2014; van Strijp et al., 2018).  
Changes in protein phosphorylation represent a major way transcription factors 
can regulate their activity. Exposure of cells to different extracellular stimuli 
leads to the phosphorylation of downstream transcription factors by different 
kinases, such as PKA, which can change the cell’s behaviour due to altered gene 
expression (Whitmarsh and Davis, 2000). Although DHX9 is not considered as a 
transcription factor itself, most of DHX9’s functions have been found because of  
its interaction with multiple transcription factors, such as CREB and RNA 
polymerase II (Fuller-Pace, 2006). Through its ability to unwind secondary RNA 
structures, DHX9 is able to mediate the initiation of transcription (Murat et al., 
2018). To date, DHX9 is only known to be phosphorylated by DNA-dependent 
protein kinase (DNA-PK) in the presence of RNA, as well as by 
phosphatidylinositol 3-kinase-related kinases (PI3KKs) (Zhang et al., 2004; Lin et 
al., 2020). The phosphorylation of DHX9 was increased when mediated by RNA 
binding (Zhang et al., 2004). Inhibition of PI3KK-mediated phosphorylation of 
DHX9 was shown to decrease the ability of colorectal cancer cells to develop 
chemoresistance. This was the first study where phosphorylation of DHX9 was 
linked with the development of chemoresistance (Lin et al., 2020). 
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4.2 Chapter aims 
Increasing evidence has shown that the cAMP-PKA pathway is involved in PC by 
modulating the activity of AR. However, nothing is known about whether DHX9 
can be phosphorylated by PKA and if this phosphorylation could be modulated by 
PDE4D7 activity in the vicinity of DHX9. The aims of this chapter are as follows: 
AIM 1: Determine if DHX9 can be phosphorylated by PKA. By using a range 
of biochemical techniques, the ability of DHX9 to be PKA phosphorylated 
will be investigated in vitro. 
AIM 2: Map putative DHX9 PKA phosphorylation site using peptide array 
technology and develop a phospho-DHX9 antibody. This antibody can be 
used to confirm DHX9 phosphorylation. 
AIM 3: Investigate if interaction between PDE4D7 and DHX9 has a role in 
regulating the phosphorylation of DHX9. Using the UCR1 disruptor peptide 
described in other chapters of this thesis, I have investigated if the 
disruption of this interaction can alter the levels of DHX9 phosphorylation.  
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4.3 Results 
4.3.1 DHX9 can be phosphorylated by PKA at multiple serines. 
To date, DHX9 is only known to be phosphorylated by DNA-PK and PI3KKs. 
However, due to the role the cAMP/PKA has in PC and disease progression, I was 
interested to know if DHX9 can also be phosphorylated by PKA. Using the 
NetPhos 3.1 server, I was able to predict whether DHX9 could potentially be 
phosphorylated by PKA. This server was first developed by Blom et al. (1999) in 
order to identify serine, threonine or tyrosine residues that can be 
phosphorylated by multiple protein kinases (Blom, Gammeltoft and Brunak, 
1999). Here, the full-length sequence for DHX9 (accession number Q08211) was 
submitted. The server can identify putative PKA phosphorylation sites that 
contain the consensus sequence RX1-2S/T, where X1-2 means one or two amino 
acid residues follows the first arginine. The server identified 5 serines that can 
potentially be phosphorylated by PKA. A prediction score above 0.500 indicates 
that these are most likely to be phosphorylated in vitro (Table 4.1).  
 
Table 4.1 DHX9 can be phosphorylated at multiple serines by PKA 
Residue Number Sequence Score 
449 PRRISAVSV 0.870 
477 VRFESILPR 0.552 
485 RPHASIMFC 0.600 
506 IRGISHVIV 0.723 
1142 ISRPSAAGI 0.505 
 
Of the 5 serine residues identified, residues 449, 477, 485, and 506 are all found 
within the helicase core domain of DHX9. Interestingly, PDE4D7 binds DHX9 from 
residues 576-600 (Figure 3.16), indicating that PKA-mediated phosphorylation of 
DHX9 may be partly regulated by the interaction with PDE4D7. The last serine 
residue potentially phosphorylated by PKA (1142) is situated between the OB-
fold and NLS/NES sequence of DHX9 (Figure 1.13).  
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4.3.2 Serine 449 is readily phosphorylated in DHX9 
One of the advantages of peptide array technology is the ability to identify novel 
post-translational modifications (PTMs) using PTM-specific antibodies. Knowing 
that DHX9 could potentially be phosphorylated at 5 different serine residues, the 
DHX9 peptide arrays that, were prepared at the same time as the arrays used in 
chapter 3, were used to identify which of these residues could readily be 
phosphorylated in vitro using a PKA phosphorylation assay. To do so, the peptide 
arrays were incubated with the PKA catalytic subunit and ATP for 30 minutes at 
37˚C. The peptide arrays were then incubated with Phospho-(Ser/Thr) PKA 
Substrate Antibody (CST, 9621L) overnight at 4˚C. Phospho-(Ser/Thr) PKA 
Substrate Antibody is able to detect peptides or proteins with a phosphorylated 
PKA consensus site (RXXpS/pT). The DHX9 was incubated with the appropriate 
secondary antibody, and the spots detected using chemiluminescence (Figure 
4.3). 
 
 
Figure 4.3 Serine 449 is phosphorylated by PKA in vitro. Full length DHX9 peptide array was 
incubated with purified recombinant PKA catalytic subunit and ATP. Phosphorylated serine or 
threonine were detected using a Phospho-(Ser/Thr) PKA Substrate Antibody. This experiment was 
performed by Jane Findlay. 
Of the 5 residues that was predicted to be phosphorylated by PKA (Table 4.1), 
only the serine at residue 449 was detected by peptide array analysis at spot 89 
(Figure 4.33). Although the PKA consensus sequence was available on spots 88 
and 90, these did not result in a positive detection by the PKA antibody (Figure 
4.33). As previously mentioned, and illustrated in Figure 4.1, the serine that is 
readily phosphorylated by PKA was found within the helicase core domain of 
DHX9. Interestingly, this site was recently identified as an important 
phosphoprotein by mass spectrometry (MS)-based phosphoproteomics (Zhou et 
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al., 2013). In order to provide further evidence that this serine is readily 
phosphorylated by PKA, the sequence at spot 89 was truncated at either the N- 
or C-terminus. Furthermore, the PKA consensus site was substituted with either 
an alanine, aspartic acid or a phospho-serine in order to ensure that changes to 
this sequence also leads to a change in detection. These peptide array 
membranes were incubated with PKA catalytic subunit and PKA antibody as 
previously described. (Figure 4.4 and Figure 4.5) 
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Figure 4.4 Substitution and truncation of the newly identified PKA site of DHX9. Peptide 
array membranes were spotted for the newly identified DHX9 PKA site. One set of 
membranes were incubated with bovine catalytic PKA subunit in order to phosphorylate the Serine 
449. A. Substitution of serine 449 with an alanine and arginine 446 and 447 with aspartatic acid 
leads to a loss of DHX9 phosphorylation. B. Simultaneous N- and C- terminal truncation 
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Figure 4.5 N- and C-Terminal truncation in order to identify minimum sequence for DHX9 
phosphorylation. Peptide array membranes were spotted for the newly identified DHX9 PKA site. 
One set of membranes were incubated with bovine catalytic PKA subunit in order to phosphorylate 
the Serine 449. A. N-Terminal truncation. B. C-terminal truncation 
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Loss of the RRIS PKA sequence, either by substituting the serine with an alanine 
(Figure 4.4 A spot 2 and 3) or the arginine with aspartic acid (Figure 4.4 A spot 
5), inhibited the ability of this sequence to be phosphorylated by the PKA 
catalytic subunit. Recent advances in peptide array technology permits the 
direct spotting of phosphorylated amino acids (Parikh et al., 2009). By doing so, 
I was able to design a spot that already contains a phosphorylated serine in the 
PKA consensus sequence (Figure 4.4 A spot 4). Although this phospho-serine was 
detected, it was detected at a much lower level than spot 1, where the serine 
was only phosphorylated after incubation with bovine PKA C-subunit (Figure 4.4 
A spot 1 and 4). Although this serine was predicted to have the highest score in 
the NetPhospho analysis, the sequence specifically spotted with this phospho-
serine could barely detect it. This could potentially be due to the fact that this 
particular spot was not correctly deposited on the membrane. By creating N- and 
C-terminal truncations of this, I was able to determine the minimum amino acids 
required to phosphorylate DHX9. These peptides arrays provided further 
evidence that DHX9 can be phosphorylated by PKA at serine 449. Interestingly, 
loss of arginine 446 and the alanine at residue 450 by sequence truncation also 
leads to a loss of DHX9, highlighting the importance of these amino acids in the 
phosphorylation of serine 449 (Figure 4.5 A and B). Using the information 
gathered in Figure 4.4 and Figure 4.5, the minimum sequence for DHX9 
phosphorylation was found to be T443QPRRISAVS452. This information was then 
used later in the chapter in order to generate a custom DHX9 phospho-specific 
antibody.  
4.3.3 DHX9 can be phosphorylated by PKA in vitro 
My data so far has shown that the serine at residue 449 of DHX9 is readily 
phosphorylated by PKA on peptide arrays. Although detection of PTMs on peptide 
arrays is a useful tool, this may not always mimic what is happening in vitro. The 
DHX9 peptide arrays were incubated with purified PKA catalytic domain, 
therefore we may have forced this phosphorylation to occur by creating the 
optimum conditions. In order to ensure that DHX9 can be phosphorylated in a 
cellular context, HEK293 cells were transfected with Flag-tagged DHX9 plasmid 
for 24 hours. They were then treated for 5 minutes with 25µM of forskolin and 
100 µM of 3-isobutyl-1-methylxanthine (IBMX) in order to increase the levels of 
intracellular cAMP. IBMX is a nonspecific PDE inhibitor that is known to elevate 
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the levels of intracellular cAMP (Schroeder et al., 2012). Forskolin is a rapid and 
reversible activator of AC, which in turn contributes to an increase of 
intracellular levels of cAMP (Alasbahi and Melzig, 2012). After forskolin and IBMX 
treatment, the cells were lysed and the protein concentration was determined 
using a standard Bradford assay. Before subjecting these lysates to IP, 30 µg of 
the non-treated and treated lysates from all experiments were run on an SDS-
PAGE gel and blotted for phosphorylated PKA substrate and GAPDH. This was 
done in order to ensure that all cells treated with forskolin and IBMX did lead to 
an increase in the detection of total PKA phosphorylated proteins (Figure 4.6).  
 
Figure 4.6 Treatment of HEK293 cells transfected with Flag-tagged DHX9 with forskolin and 
IBMX. A. Lysates from 6 independent experiments were run on an SDS-PAGE gel and blotted for 
phospho-PKA substrate and GAPDH. B. Total PKA phosphorylation from each sample was 
measured densitometrically and normalised to the GAPDH loading control. The data is presented 
as the mean ± SEM of 6 independent experiments. Statistical significance was determined using a 
Student’s T-Test, where p*= 0.0277. 
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Treatment with forskolin and IBMX led to a visible increase in PKA 
phosphorylation when compared to the non-treated controls (Figure 4.6 A). 
When the signal from each lysate was quantified, forskolin-IBMX treatment led 
to a significant increase in the total amount of proteins that could be 
phosphorylated by PKA (Figure 4.6 B). Knowing that the treatment with 
forskolin-IBMX led to an increase in PKA phosphorylation, these lysates were 
then further used for an IP. The lysates were incubated for 3 hours at 4˚C with 
protein G beads that were conjugated with FLAG antibody to pull down ectopic 
DHX9. The beads were thoroughly washed, and the protein was eluted off the 
beads by boiling. IP samples were run on an SDS-PAGE gel and blotted for FLAG 
and phospho PKA substrate (Figure 4.7).  
 
Figure 4.7 Flag-tagged DHX9 IP following forskolin-IBMX treatment in HEK293. A. Flag-
tagged DHX9 was pulled down in HEK293 transfected cells following treatment with 25 µM 
forskolin and 100 µM IBMX. Western blot membranes were probed for Flag (top) and phospho 
PKA substrate (bottom). B. The ratio between Flag-tagged DHX9 in the PKA substrate and FLAG 
blot was measured. Data is presented as the mean ± SEM of six independent experiments. 
Statistical significance was determined using a T-Test where p*=0.049. 
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Flag-tagged DHX9 was successfully pulled down from the HEK293 transfected 
cells (Figure 4.7 A top membrane). Furthermore, a band representing DHX9 was 
recognised by the PKA substrate from this pulldown (Figure 4.7 A bottom 
membrane). The ratio between phosphorylated and total DHX9 was then 
measured from the six independent experiments. Treatment with forskolin-IBMX 
lead to a 50% increase in the detection and pulldown of phosphorylate DHX9, and 
this was shown to be significant when statistically analysed (Figure 4.7 B). The 
data presented above demonstrate that DHX9 is readily phosphorylated by PKA 
when over-expressed in HEK293 cells. This same experiment was then repeated 
in VCaP cells in order to see if endogenously expressed DHX9 can be 
phosphorylated by PKA. VCaP cells from a 10 cm dish were treated with 25 µM of 
forskolin and 100 µM IBMX for five minutes. The cells were then lysed and 
protein concentration of was determined using a standard Bradford assay. These 
lysates were then incubated with protein G beads and DHX9 specific antibody 
overnight at 4˚C. IP samples were then washed and analysed by SDS-PAGE gel 
and western blotting. Membranes were probed for DHX9 and PKA substrate 
(Figure 4.8) 
 
Figure 4.8 DHX9 IP following forskolin-IBMX treatment in VCaP. VCaP cells were treated with 
25 µM forskolin and 100 µM IBMX, after which endogenously expressed DHX9 was IPed. Western 
blot membranes were probed for DHX9 (top) and phospho-PKA substrate (bottom). Representative 
of N=3. 
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Although endogenously expressed DHX9 was pulled down in the VCaP lysates 
(Figure 4.8 top membrane), I could not clearly identify if it was readily 
phosphorylated in these cells due to smear that appeared in the IP (Figure 4.8 
bottom membrane). I therefore decided to use PLA to identify if DHX9 can be 
phosphorylated in vitro. LNCaP cells were chosen for this experiment as their 
morphology was better suited for confocal microscopy. LNCaP cells were plated 
in a 24 well plate with glass coverslips for 24 hours. They were then treated with 
25 µM of forskolin for five minutes then fixed and stained for phospho-PKA 
substrate and DHX9. The cells were then subjected to PLA secondary antibody 
treatment and visualised using the Zeiss LSM confocal microscope (Figure 4.9).  
 
Figure 4.9 PLA between DHX9 and phospho-PKA substrate in LNCaP cells. LNCaP were 
plated onto coverslips and probed for either DHX9 alone for the positive control (B), or DHX9 and 
PKA phospho-substrate with or without 250 µM forskolin (C+D). No primary antibody was included 
for the negative control (A). All cells were stained for the membrane (green) and the nucleus (blue) 
in order to appropriately identify each cell. PLA signal is visible in the red channel. 
As expected, the positive control resulted in the detection of spots when 
visualised under the microscope (Figure 4.9 B), whereas no spots were detected 
in the negative control (Figure 4.9 A). This indicated that any spots detected can 
only be attributed to the interaction between secondary antibodies bound to our 
primary antibody. Furthermore, PLA spots could be detected in samples stained 
with DHX9 and phospho-PKA substrate antibody (Figure 4.9 C and D) indicating 
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that DHX9 can readily be phosphorylated by PKA in LNCaP cells. The PLA signal 
from the cells from each conditions were then quantified using Image J in order 
to determine if treatment with forskolin led to any changes in detection (Figure 
4.10). 
 
Figure 4.10 Quantification of PLA in LNCaP. PLA signal from the non-treated control and 
forskolin treated cells were quantified. Data is presented as the mean ± SEM of at least 20 cells 
from each condition. Statistical significance was determined using a T-Test, where p****<0.0001. 
Interestingly, treatment with forskolin led to a significant increase in PLA signal 
when compared to the other condition (Figure 4.9 D and Figure 4.10) The data so 
far has shown that DHX9 is readily phosphorylated by PKA in exogenous and 
endogenous settings. Further experiments, such as site-directed mutagenesis of 
S449, would have added more support to this chapter. By creating a phospho-null 
mutant, I could have investigated if the loss of S449 ablates the phosphorylation 
of DHX9 by PKA.  
4.3.4 Testing of novel phospho-DHX9 antibody  
My data so far has shown that DHX9 is readily phosphorylated by PKA in 
exogenous and endogenous settings. DHX9 has been shown to be phosphorylated 
at S449, and the phosphorylation of this serine can be increased by forskolin-IBMX 
treatment. Using the information gathered in Figure 4.4, a custom phospho-
antibody (Ab) against DHX9 was commissioned. The amino acid sequence 
T443QPRRIpSAVS452 was used to create a peptide antigen that was injected into a 
rabbit to raise the antibody. The rabbit was immunized six times at two weeks 
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intervals and a blood samples were taken after each immunization. After the 
final round of immunisation, the rabbit serum was collected from which the 
phospho-antibody was purified using an affinity column. The purified antibody 
was first tested on peptide arrays in order to ensure that the antibody was able 
to recognise the epitope against which it was raised. Encouragingly, the DHX9 
phospho-Ab recognised phosphorylated epitopes, and these were attenuated 
following treatment with a blocking peptide (T443QPRRISAVS452) (Figure 4.111). 
 
Figure 4.11 Testing of novel pDHX9 antibody using peptide array technology. Peptide array 
technology was used to verify that the novel pDHX9 antibody was able to bind to its epitope. A. 
Non-phosphorylated sequence. B. Phosphorylated sequence. 
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The strongest signal could be seen between spots 4-6 where the full antigen was 
present (Figure 4.11 B array 2). Interestingly, the presence of the blocking 
peptide in the third peptide array ablated the detecting of the antigen (Figure 
4.11 B array 3). Spot 8, where only the last two amino acid of the antibody 
epitope was observed to show a positive signal, in all three arrays including the 
two negative controls. This may be due to unspecific binding from the secondary 
antibody (Figure 4.11 all three arrays). Although the antibody was able to detect 
the non-phosphorylated epitope (Figure 4.11 A), the signal was visibly weaker 
when compared to the arrays with the phosphorylated serine. In order to provide 
further evidence that the newly purified antibody was able to detect phospho-
S449, the in vitro PKA assay previously performed should have been repeated. 
This would have confirmed that the antibody does in fact recognise its epitope 
and would have also further validated the results from the initial PKA assay. 
Furthermore, this antibody should have been tested against other members of 
the DExD/H helicase family by peptide array in order to ensure that the antibody 
is able to only detect DHX9, and no other isoforms. This is due to the high 
homology within the helicase core domain amongst the DExD/H helicase family. 
Spotting of other DExD/H helicase proteins on peptide arrays, such as DHX15 
which has recently been shown to be involved in CRPC (Xu et al., 2019), would 
have allowed us to test the specificity of this antibody. Unfortunately, due to 
time constraints and technical issues with the peptide array spotter, I was 
unable to perform this experiment.  
Although I was unable to test the specificity of the antibody by peptide array, 
the newly synthesised antibody was tested for western blotting detection of 
phospho-DHX9. HEK293 cells were transfected with Flag-tagged DHX9, and the 
next day the cells were treated for 0, 3, 10, 15 or 30 minutes with 25 µM 
forskolin and 100 µM IBMX. 30 µg of cell lysate were then run on an SDS-PAGE gel 
and both total and phosphorylated DHX9 was detected by western blotting 
(Figure 4.12 A). The ratio between phosphorylated and total protein was 
determined in order to see if the treatment with forskolin and IBMX lead to an 
increase in the detection of phospho-DHX9. (Figure 4.12 B).  
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Figure 4.12 Forskolin and IBMX in Flag-tagged DHX9 transfected HEK293 cells. A. HEK293 
cells transfected with Flag-tagged DHX9 were treated with 25 µM forskolin and 100 µM IBMX for 
the indicated times. Lysates were run on an SDS-PAGE gel and proteins were detected using 
western blotting. Membranes were probed for total DHX9, phospho-DHX9, and GAPDH. B. The 
ratio between phospho-DHX9 and total DHX9 was measured and normalised to the non-treated (0) 
control. C. B. The ratio between phospho-DHX9 and total DHX9 was measured and normalised to 
the non-treated (0) control after being incubated with the phospho-Ab and the blocking peptide. 
Data is presented as the mean ± SEM of three independent experiments. No statistical significance 
was found when analysed using a One-Way Anova. 
Our newly synthesised antibody was able to detect phosphorylated DHX9 by 
western blotting (Figure 4.12 A membrane 2 and 3). Interestingly, treatment 
with forskolin-IBMX for 3- and 10-minutes led to the highest levels of 
phosphorylated DHX9 detected. Although this data is not significant due to the 
high variability between experiments, this western blot shows that the purified 
phospho-DHX9 antibody is able to recognise the protein (Figure 4.12 A, blot 2). 
When incubated with the phospho-Ab and a blocking peptide, I am still able to 
detect phosphorylated DHX9 after 3- and 10-minutes of treatment (Figure 4.12 
A, blot 3). However, when analysed, these bands were detected at a much lower 
level (Figure 4.12 C), indicating that like in the peptide array in Figure 4.11, 
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incubating the membrane with the blocking peptides reduces the detection of 
phosphorylated DHX9. Interestingly, treatment for longer than 15 minutes lead 
to a rapid decrease in DHX9 phosphorylation, like that of the non-treated control 
(Figure 4.122 B). Knowing that the antibody can successfully detect 
phosphorylated DHX9 by western blotting, I then decided to test its ability to 
detect phospho-DHX9 by confocal microscopy. HEK293 were transfected with a 
Flag-tagged DHX9 plasmid, the treated with 25 µM forskolin and 100 µM IBMX for 
0, 3 or 10 minutes. These times were chosen as the western blots showed that 
these times points lead to the highest detection of phospho-DHX9 (Figure 4.12 
B). The cells were then fixed and stained for phospho-DHX9 using our newly 
commissioned antibody (Figure 4.13).  
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Figure 4.13 Testing of Novel phospho-DHX9 antibody by confocal microscopy. A. HEK293 
overexpressing Flag-tagged DHX9 were treated for either 0, 3, or 10 minutes with 25 µM forskolin 
and 100 µM IBMX, then stained for the membrane using wheat germ agglutinin (green) and 
phospho-DHX9 (red). B. The mean fluorescence intensity of each condition was measured in at 
least n>30 cells. The data is presented as the mean ± SEM. Statistical significance was measures 
using a One-Way Anova, where p**=0.0041.  
The newly synthesised phospho-DHX9 antibody was able to detect the protein by 
ICC with confocal microscopy. Under basal conditions, some phospho-DHX9 
staining can be visible. However. treatment with forskolin-IBMX for 3- or 10-
minutes led to a visible increase in phospho-DHX9 staining (Figure 4.13 A). When 
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the mean fluorescence intensity (MFI) was measured, treatment for 3-minutes 
with forskolin-IBMX led to a significant increase in the detection of phospho-
DHX9. Treatment for 10-minutes also led to an increase in the detection of 
phospho-DHX9, however this was shown not to be a statistically significant 
increase (Figure 4.13 B). Interestingly, phosphorylated DHX9 could only be 
detected in the cytoplasmic region, which is also where the highest 
concentration of cAMP and PKA can be found (Koschinski and Zaccolo, 2017). In 
order to confirm that this is truly the case, a subcellular fractionation following 
forskolin-IBMX treatment could be performed. We would expect to only detect a 
band in the cytoplasmic fraction, compared to the nuclear fraction, following 
treatment with forskolin-IBMX. 
My data so far has shown that the newly synthesised antibody is able to detect 
phospho-DHX9 in HEK293 overexpressing Flag-tagged DHX9. However, I was 
interested to know if this antibody can detect endogenously expressed phospho-
DHX9. Therefore, the ICC experiment was repeated in DU145 cells. Previous 
work has shown that out of the three PC cell lines used in this thesis, DU145 has 
the highest expression of DHX9 (Figure 3.1 C). Furthermore, DU145 expresses the 
lowest amount of PDE4D7 (Figure 3.1 B), leading to a potential accumulation of 
cAMP and PKA in the cell. This could mean that DHX9 exists in a 
hyperphosphorylated state in DU145 cells. DU145 cells were seeded onto glass 
coverslips in a 24 well plate, then treated with 25 µM forskolin and 100 µM IBMX 
for 0, 3, or 10 minutes. The cells were then stained for the membrane using 
wheat germ agglutinin, and for phospho-DHX9 using the custom antibody. The 
cells were then fixed onto a glass slide then visualised using the Zeiss LSM 
confocal microscope (Figure 4.14). 
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Figure 4.14 Testing of the new phospho-DHX9 antibody in DU145 cells. A. DU145 cells were 
treated with 25 µM forskolin and 100 µM IBMX for 0, 3, or 10 minutes. Cells were stained for the 
membrane (green), phospho-DHX9 (red), and nucleus (blue), then visualised using the Zeiss LSM 
confocal microscope. B. The mean fluorescence intensity for phospho-DHX9 from each condition 
was measured. Data is presented as the mean ± SEM of n>6 cells. Statistical significance was 
determined using a One-Way Anova where p*=0.0255. 
Phosphorylated DHX9 could be detected in DU15 by confocal microscopy. 
Treatment with forskolin-IBMX led to a visible increase in the detection of 
phospho-DHX9 after 3-minutes of treatment (Figure 4.14 A middle row). 
However, very little phospho-DHX9 could be detected in DU145 cells treated for 
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10-minutes (Figure 4.14 A bottom row). As in the HEK293 cells, phosphorylated 
DHX9 was mainly found in the cytoplasm where highest levels of cAMP and PKA 
can be found (Figure 4.14 A second column). Unlike in the HEK293 ICC staining 
(Figure 4.13), some phosphorylated DHX9 could be detected within the nuclear 
region of DHX9. This data is further supported by the fact that PLA signal 
between endogenously expressed DHX9 and phospho-PKA substrate could be 
found across the whole cell in LNCaP cells (Figure 4.9) When the MFI for 
phospho-DHX9 was measured from each condition, treatment with forskolin-IBMX 
did lead to an increase in phospho-DHX9 detection after three minutes. Although 
this was not shown to be significant when compared to the non-treated control, 
there was a significant increase in the detection of phospho-DHX9 when the 3-
minute condition was compared to the 10-minute condition (Figure 4.14 B).  
4.3.5 Disruption of the DHX9-PDE4D7 leads to an increase in 
DHX9 phosphorylation. 
So far, my data has suggested that DHX9 can be readily phosphorylated by PKA 
at Ser449 and our newly synthesised antibody is able to detect it by western 
blotting and ICC with confocal microscopy. However, I was interested to know if 
PDE4D7 can influence the levels of DHX9 that can be phosphorylated in vitro. 
Previous work in chapter 3 has shown that PDE4D7 binds downstream of the 
newly identified PKA phosphorylation site. The interaction between PDE4D7 and 
DHX9 could potentially regulate the levels of DHX9 being phosphorylated by 
modulating the local levels of cAMP (Fertig and Baillie, 2018). The UCR1 
disruptor peptide (described previously in chapter 3 and in Figure 3.20 A) was 
used in order to investigate how PDE4D7 can influence the phosphorylation of 
DHX9. To do so, HEK293 cells were transfected with VSV-tagged PDE4D7 for 24 
hours. The cells were then treated for two hours with either DMSO, 10 µM 
scrambled peptide, or 10 µM UCR1 disruptor peptide, after which they were 
lysed, and total protein concentration was determined used a standard Bradford 
assay. The lysates were then subjected to IP, where they were incubated with 
DHX9 antibody and protein G sepharose beads overnight at 4˚C. The IPs were 
thoroughly washed the next day and boiled in sample buffer. IPs were run on an 
SDS-PAGE gel and protein expression was assessed by western blotting. The 
membranes were probed for total DHX9, phospho-PKA substrate, and VSV (Figure 
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4.15). The commercially available phospho-PKA substrate antibody was used 
here as the custom phospho-DHX9 antibody was not available at the time.  
 
Figure 4.15 Disruption of the PDE4D7-DHX9 interaction leads to an increase in DHX9 
phosphorylation A. IPs were run on an SDS-PAGE gel and protein expression was assessed by 
western blotting. Membranes were probed for DHX9 (top blot), phospho-PKA substrate (middle 
blot), and VSV (bottom blot). B. The ratio between DHX9 in the PKA substrate and DHX9 blot was 
measured. Data is presented as the mean ± SEM of three independent experiments. Statistical 
significance was determined using a One Way Anova.  
I was able to successfully pull down DHX9 from transfected HEK293 cell lysate, 
and this was also detected in the phospho-PKA blot (Figure 4.15 A top and 
middle blot). PDE4D7-VSV was also successfully transfected into the cells (Figure 
4.15 A bottom blot). Under basal conditions, disruption of the interaction 
between PDE4D7 and DHX9 led to an increase in the levels of phospho-DHX9 
detected. However, this was not found to be significant when compared to the 
DMSO-treated condition (Figure 4.15 B). This data indicates that PDE4D7 acts as 
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a negative regulator of DHX9 phosphorylation. PDE4D7 can hydrolyse the cAMP 
located within close proximity to DHX9, and by doing so, it can inhibit the 
phosphorylation of DHX9, potentially regulating the helicase activity of DHX9. 
Loss of this interaction using our UCR1 disruptor peptide leads to a ~37.5% 
(Figure 4.15 B) increase in the levels of DHX9 being phosphorylated by PKA under 
basal conditions.  
In order to provide further evidence that the decreased interaction between 
PDE4D7 and DHX9 leads to an increase in DHX9 phosphorylation, HEK293 cells 
were transfected with FLAG-tagged DHX9 and PDE4D7-VSV overnight on 
coverslips in a 12 well plate. The cells were then treated with the UCR1 
disruptor peptide, or appropriate controls, as previously described. A subset of 
the UCR1 disruptor peptide, scrambled peptide and DMSO treated cells were 
further treated with 25 µM forskolin and 100 µM IBMX for 3-minutes in order to 
investigate if this could lead to any further increase in DHX9 phosphorylation. 
This timepoint was chosen as it was shown to lead to the highest detection of 
phospho-DHX9 by our custom-made antibody (Figure 4.13 and Figure 4.14). The 
cells were then stained for the membrane using wheat germ agglutinin, for 
phospho-DHX9 using our custom antibody, and for total DHX9. The cells were 
then fixed and visualised using a Zeiss LSM confocal microscope (Figure 4.16). 
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Figure 4.16 Detection of phosopho-DHX9 following UCR1 disruptor peptide treatment. A. 
HEK293 overexpressing Flag-tagged DHX9 and PDE4D7-VSV were stained with phospho-DHX9 
and DHX9 following peptide treatment. B. HEK293 overexpressing Flag-tagged DHX9 and 
PDE4D7-VSV were stained with phospho-DHX9 and DHX9 following peptide and forskolin and 
IBMX treatment. 
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By staining for both phospho- and total-DHX9, it can be noted that the 
distribution of these two stains are completely different. Total DHX9 is found 
exclusively in nucleus, while phospho-DHX9 is only found within the cytoplasm 
(Figure 4.16). In order to investigate if peptide treatment led to any changes in 
the detection of phosopho-DHX9, the MFI from each condition was measured 
from each. The statistical significance of the mean was determined using a Two-
Way Anova (Figure 4.17).  
 
Figure 4.17 MFI of phosho-DHX9 from cells treated with UCR1 disruptor peptide and 
forskolin-IBMX. The MFI from cells stained with phospho-DHX9 in Figure 4.16 was determined. 
The data presented is representative of the mean ± SEM of N>14 cells from each condition. 
Statistical significance was determined using a Two-Way Anova, where p*=0.0138, p***=0.0007, 
and p****<0.0001. 
Treatment with the UCR1 disruptor and scrambled peptide led to a slight non-
significant decrease in the amount of phospho-DHX9 detected in the cells under 
basal conditions (Figure 4.16 A, last row, and Figure 4.17). However, a 
significant increase in levels of phospho-DHX9 could be detected in cells where 
the interaction between PDE4D7 and DHX9 was inhibited in conjunction with 
increased levels of intracellular cAMP due to the forskolin-IBMX treatment 
(Figure 4.16 B, last row, and Figure 4.17). Treatment of the cells with the UCR1 
disruptor peptide and forskolin-IBMX led to a highly significant increase in levels 
of phospho-DHX9 detected when compared to all other conditions (Figure 4.17). 
Interestingly, this effect was not observed when the cells were pre-treated with 
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the scrambled peptide control. Although treatment of these cells with forskolin-
IBMX did lead to a slight increase in the detection of phospho-DHX9, this was not 
to the same extent as the UCR1 disruptor peptide (Figure 4.16 A and B, middle 
row, and Figure 4.17). The increase in the levels of DHX9 phosphorylated can be 
attributed to the fact that DHX9 and PDE4D7 are no longer interacting with each 
other. This data provides further evidence that the binding of PDE4D7 to DHX9 
gates DHX9 phosphorylation. PDE4D7 acts as a negative regulator of DHX9 
phosphorylation, and dissociation of this complex leads to an increase in DHX9 
phosphorylation by PKA.  
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4.4 Discussion 
4.4.1 DHX9 PKA phosphorylation is regulated by PDE4D7 
PTMs are known to be essential mechanisms in eukaryotic cells to diversify the 
function any single protein can have within the cells. Dynamic coordination of 
different signalling networks allows a single protein to respond to multiple 
extracellular signals. Reversible, or irreversible, biochemical reactions allow 
cells to regulate downstream signalling pathways and alter their physiological 
state (Wang, Peterson and Loring, 2014). Understanding the roles and 
mechanisms of PTMs is essential in biomedical sciences as certain PTMs are 
known to interfere with drug action. This in turn can influence different 
biochemical networks than can alter drug response (Brunk et al., 2018).  
Protein phosphorylation is one of the most important PTMs, with the ability to 
orchestrate a variety of cellular functions and processes (Gao et al., 2008). This 
reversible reaction occurs through protein kinases that can mediate the addition 
of a phosphate group to the polar R group of various amino acids. This addition 
allows the protein to change its conformation when interacting with other 
molecules (Ardito et al., 2017). The phosphate group has been shown to be used 
to regulate critical biological functions, as well as coordinate an appropriate 
drug response (Schwartz and Murray, 2011). Protein phosphatases are slowly 
being recognised as crucial regulators of signalling pathways (Reiterer et al., 
2020). The phosphorylation state of a single protein is a dynamic process that 
depends on the activities of both protein kinases and phosphatases acting on 
their appropriate substrate (Barford, Das and Egloff, 1998). PP1 is the major 
Ser/Thr phosphatase and it is expressed in all eukaryotic cells. This protein is 
involved in multiple cellular processes, including cell cycle regulation, 
highlighting its importance in maintaining normal cellular functions (Shi, 2009). 
Modification of proteins via their phosphorylation and subsequent 
dephosphorylation, is a critical function in multiple signalling pathways (Vitrac, 
Mallampalli and Dowhan, 2019).  
In this chapter, I have shown that DHX9 is phosphorylated by PKA in biochemical 
assays and in vitro in cultured cells. Although DHX9 has previously been shown to 
be phosphorylated by DNA-PK and PI3KKs (Zhang et al., 2004; Lin et al., 2020), 
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this is the first study to show that DHX9 may be phosphorylated by PKA. Using 
PKA consensus site prediction software and peptide array technology, I was able 
to show that DHX9 can be phosphorylated at S449 in the helicase domain (Table 
4.1 and Figure 4.3). Interestingly, loss of the PDE4D7-DHX9 interaction due to 
the UCR1 disruptor peptide treatment also led to an increase in DHX9 
phosphorylation under basal conditions when investigated by IP (Figure 4.15). 
Further treatment by forskolin-IBMX lead to a highly significant increase in the 
detection of phospho-DHX9 (Figure 4.16). It is now widely accepted that 
compartmentalization of cAMP signalling and PKA action is regulated by localised 
pools of PDEs. The direct interaction between AKAP, PDEs, and PKA is complex 
and governs the dynamic signalling changes which in turn can direct down-
stream signalling pathways and protein activity (Willoughby et al., 2006). 
Interestingly, inhibition of PDEs using a combination of different inhibitors 
results in the global increase in levels of cellular cAMP (Beltejar et al., 2017). 
Using a mass spectrometry-based phosphoproteomic analysis after treatment 
with various selective PDE inhibitors, Beltejar et al. (2017) attempted to 
characterise how PDEs can regulate the phosphoproteome in the Jurkat T-cell 
line. Using this approach, they were able to identify 3241 proteins that were 
phosphorylated when different PDEs were directly inhibited. Upon further 
inspection, phosphorylation of a subset of these proteins was directly mediated 
by PKA when PDE3 and PDE4 isoforms were directly inhibited. The proteins 
identified as being phosphorylated in this analysis were found to be associated 
with a wide range of biological functions, highlighting the ability of the cAMP to 
regulate multiple processes in T-cells (Beltejar et al., 2017). Although this study 
was conducted in T-cells, it demonstrates the importance of PDEs in regulating 
the global phosphoproteome. However, interactions with specific PDE isoforms 
are known to regulate phosphorylation. The targeting of single PDE-protein 
interactions allows for the precise regulation of individual cAMP nanodomains 
(Blair and Baillie, 2019). Such is the case with the interaction between PDE4D 
and heat shock protein 20 (HSP20) in cardiac myocytes (Sin et al., 2011). HSPs 
are a large family of molecular chaperones which have important roles in cell 
survival and development. While some HSPs are constitutively expressed, 
expression of certain Hsps are upregulated under stress conditions (Miller and 
Fort, 2018). The protective action of HSP20 is triggered following 
phosphorylation by PKA at S16. Activation of β-adrenergic stimulation and 
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increases in levels of intracellular cAMP leads to the phosphorylation of HSP20 by 
PKA, which is vital for cardioprotective actions of this protein (Edwards, Scott 
and Baillie, 2012). Using peptide array technology, Sin et al. (2011) were able to 
show that HSP20 binds to the catalytic region of PDE4D. Disruption of this 
interaction using cell permeable peptides was shown to increase the levels of 
PKA-mediated phosphorylation of HSP20 in neonatal rat cardiomyocytes. This in 
turn protected these cardiac cells against β-adrenergic-induced hypertrophy (Sin 
et al., 2011; Martin et al., 2014).  
Due to the importance of the cAMP/PKA pathway in multiple key processes, such 
as cell survival, proliferation, and differentiation (Palorini et al., 2016), it is 
important that we identify novel proteins that can be phosphorylated by PKA. In 
this chapter, I suggest that disruption of the interaction between PDE4D7 and 
DHX9 leads to an increase in DHX9 phosphorylation detected by western blotting 
and ICC using an antibody directed towards a novel PKA phosphorylation site in 
DHX9 (S449) (Figure 4.15 and Figure 4.16). Future work into the functional 
implication of DHX9 phosphorylation is needed in order to understand how this 
change can alter its helicase activity. Previous work by Lin et al (2020) 
demonstrated that the inhibition of DHX9 phosphorylation by PI3KKs decreased 
the expression of oxaliplatin-induced circRNA expression, which in turn blocked 
the development of chemo-resistant cells (Lin et al., 2020). It would be 
interesting to find out if DHX9 phosphorylation promotes the expression of 
circRNA that could lead to chemo-resistance. Inhibition of DHX9 PKA 
phosphorylation could potentially desensitize chemo-resistant cells, and 
potentially ameliorate treatment outcome of patients with hormone refractory 
or CRPC tumours. 
Interestingly, other members of the helicase superfamily have been reported to 
be phosphorylated, which in turn affected their activity. The DDX1 helicase has 
recently been shown to be phosphorylated (Gustafson and Wessel, 2010). DDX1 is 
a member of the DEAD family of RNA helicases and its activity is associated with 
multiple aspects of cellular metabolism (Li, Monckton and Godbout, 2008). 
Research by Li et al. (2008) demonstrated that DDX1 colocalizes with ataxia 
telangiectasia mutated (ATM) kinase at DSBs within the nucleus following 
ionising radiation treatment . Interestingly, this co-localisation was associated 
with an increase in DDX1 phosphorylation in vitro and in vivo, suggesting that 
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DDX1 phosphorylation promotes DDX1 role in the repair (Li, Monckton and 
Godbout, 2008; Gustafson and Wessel, 2010). By identifying DHX9 as a novel PKA 
phospho-substrate is a step towards identifying a mechanism by which this 
protein is regulated.  
4.4.2 DHX9 and other PTMs 
Although I have shown that DHX9 is readily phosphorylated by PKA, DHX9 is 
known to be SUMOlyated at its N-terminus and methylated at its C-terminus 
(Fidaleo, De Paola and Paronetto, 2016). Many enzymes that are responsible for 
PTMs are able to recognise and modify multiples sites within the same target 
protein (Barber and Rinehart, 2018). Over 59% of proteins within the human 
genome are modified by more than one PTM (Woodsmith, Kamburov and Stelzl, 
2013). Modified proteins are key regulators of signalling pathways and cellular 
homeostasis (Perchey et al., 2019). PTMs represent a key mechanism by which a 
cell can regulate protein function (Beltrao et al., 2013). Owing to the reversible 
nature of most PTMs, normal cells can use this switch in order to determine the 
resting and proliferative state of cells, enabling rapid and tight regulation of cell 
proliferation. However, in cancer cells, activation of oncogenes and loss of 
tumour suppressor genes provides continuous proliferative signals in part due to 
the changes in PTMs of effector proteins that are involved in proliferation 
(Hitosugi and Chen, 2014). Sustained proliferative signalling due to changes in 
PTMs and their downstream signalling pathways is recognised as one of the 
hallmarks of cancer, and understanding these changes is vital in order to find 
new therapeutic targets (Hanahan and Weinberg, 2011). In this chapter, DHX9 
was shown to be by phosphorylated by PKA but I did not investigate whether this 
PTMs had any downstream effects on DHX9´s ability to mediate CREB 
transcription. Recent work in the Baillie lab used a PDE4D7 luciferase construct 
in order to investigate if AR signalling influenced PDE4D7 expression (Henderson 
et al., 2014). This assay could be adapted in order to investigate whether DHX9 
phosphorylation by PKA alters PDE4D7 mRNA expression via its CREB sites. Not 
only would this experiment show that DHX9 has a role in PDE4D7 expression, it 
would also allow us to determine if PKA phosphorylation of DHX9 alters its 
transcriptional activity. 
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As previously mentioned, DHX9 has recently been shown to be SUMOylated by 
the SUMO-conjugating ubiquitin-conjugating enzyme 9 (UBC9) (Fidaleo, De Paola 
and Paronetto, 2016). SUMOylation is an evolutionarily conserved PTM, 
characterised by the covalent attachment of the small ubiquitin-like modifier 
(SUMO) to its target proteins (Li et al., 2020). The SUMO conjugation pathway 
involves the use of three enzymes (E1-3), each having individual roles during the 
reaction (Hannoun et al., 2010). The first step in this pathway is the activation 
of the mature SUMO protein at its C-terminus by a SUMO-specific E1 enzyme. 
The active SUMO protein is then transferred to an E2 conjugating enzyme UBC9, 
which can then transfer SUMO to its target protein. The transfer of the SUMO 
protein is mediated by a SUMO E3 ligase (Geiss-Friedlander and Melchior, 2007). 
Although several proteins have been reported to be SUMOylated, including 
PDE4D5 (X. Li et al., 2010), SUMO modification is less commonly detected in 
cells when compared to other PTMs as it is more difficult to identify (Chen and 
Lu, 2015). Attachment of a SUMO peptide to its target protein has been 
implicated in numerous cellular processes, including DNA repair and cell cycle 
regulation (Andreou and Tavernarakis, 2009).  
Recent studies have shown that transcription factors can be modified by 
SUMOylation, affecting target gene expression (Rosonina, 2019). Therefore, it 
comes as no surprise that DHX9 has been shown to be a substrate for SUMO 
modification. Work by Argasinska et al. (2004) recently showed that the N-
terminal region of DHX9 (amino acids 1-37) can interact with UBC9. This in turn 
led to the attachment of a Sumo-1 complex to DHX9, both in vitro and in vivo. 
Interestingly, the interaction between UBC9 and DHX9 was shown to mediate 
CREB transcription by DHX9. However, DHX9 does not need to be SUMOylated to 
mediate CREB transcription. They suggested that although DHX9 has been shown 
to be SUMOylated in the presence of UBC9, this modification is not necessary in 
regulating DHX9 helicase activity (Argasinska et al., 2004). However, DHX9 
SUMOylation may have an impact on disease progression. Using mass 
spectroscopy analysis from Kaposi’s sarcoma-associated herpesvirus (KSHV) cell 
lysate, DHX9 was recently found to contain a SUMO interacting motif (SIM). This 
SIM was shown to potentially regulate virus-mediated gene expression through 
SUMOylation of DHX9, therefore having an important role in KHSV persistence 
and pathogenesis (Gan et al., 2015). The GPS-SUMO website can predict the 
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potential SUMOylation sites and SIMS within a protein of interest (Zhao et al., 
2014). The SUMOylation sites were classified into two groups (consensus and 
non-consensus) based on the canonical ψ–K–X–E, where ψ is a hydrophobic amino 
acid (I, V, L, A, P, or M), K is lysine and x is an arbitrary amino acid (Zhao et al., 
2014; Chang et al., 2018). SUMOylation at a non-consensus site refers to the fact 
that a Lysine residue can be phosphorylated despite not being flanked by a 
hydrophobic amino acid (Impens et al., 2014). By using the GPS-SUMO predictor 
site (http://sumosp.biocuckoo.org/online.php) I was able to identify 5 potential 
SIMs and SUMOylation consensus sites within DHX9 (Table 4.2).  
Table 4.2 Identification of multiple SIMs and SUMOylation sites within DHX9. 
Position Peptide Type 
54 GMGNSTNKKDAQSNA Sumoylation 
Nonconcensus 
69 - 73 ARDFVNYLVRINEIKSEEV SUMO Interaction 
76 LVRINEIKSEEVPAF Sumoylation Concensus 
120 LPPHLALKAENNSEV Sumoylation Concensus 
152 LKDYYSRKEEQEVQA Sumoylation 
Nonconcensus 
365 EQISMDLKNELMYQL Sumoylation Concensus 
406 - 410 EAISQNSVVIIRGATGCGK SUMO Interaction 
560 - 564 EYFFNCPIIEVYGRTYPVQ SUMO Interaction 
596 KDKKKKDKDDDGGED Sumoylation 
Nonconcensus 
725 - 729 TSITINDVVYVIDSCKQKV SUMO Interaction 
1081 - 1085 KVQSDGQIVLVDDWIKLQI SUMO Interaction 
1111 - 1115 RAAMEALVVEVTKQPAIIS SUMO Interaction 
 
Interestingly, the GPS-SUMO analysis identified a SUMOylation non-consensus site 
within the PDE4D7 binding domain (Table 4.2 Position 596). This could suggest 
that binding between PDE4D7 and DHX9 could be further regulated by the 
SUMOylation status of DHX9. Interestingly, a study by Li et al. (2010) revealed 
that inhibiting the interaction between two interacting protein by blocking 
SUMOylation of a target protein, using a synthetic SIM peptide, inhibits DNA 
repair and increases cancer cell sensitivity to radiation (Y.-J. Li et al., 2010). By 
treating cells with a SIM peptide designed to compete with SIM sites within a 
protein, they were able to inhibit SUMO-dependent protein-protein interactions. 
They were then able to test the effects of the disruption of these interactions on 
the cellular DNA damage response. Following SIM or control peptide treatment, 
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the cells were treated with the chemotherapeutic drug doxorubicin. 
Interestingly, treatment with the SIM peptide increased the sensitivity to 
doxorubicin treatment when compared to the control peptide (Y.-J. Li et al., 
2010). Inhibiting SUMO-mediated PPI are of pharmaceutical interest as an 
increasing number of studies have revealed that disruption of these interactions 
could potentially alter chemo- and drug sensitivity (Voet et al., 2014). 
Interestingly, protein phosphorylation and SUMOylation are known to be linked 
to one another. Rather than modification at a single site, a protein is 
dynamically altered at multiple sites by an array of modifications, including 
phosphorylation and SUMOylation (Yang and Grégoire, 2006) Studies have 
revealed that certain lysine residues are flagged for SUMOylation following the 
phosphorylation of a serine/threonine immediately downstream of the SUMO 
consensus sequence (Anckar and Sistonen, 2007). In addition to the ψ–K–X–E 
SUMO consensus site, a second phosphorylation-dependent SUMOylation motif 
(PDSM), composed of a SUMO and a proline-directed phosphorylation site (Ψ-K-x-
E-x-x-S-P) has been identified. This motif has been involved in the 
phosphorylation-dependent SUMOylation of transcription factors nuclear factor 
erythroid-derived 2 (NF-E2) and shown to alter their activity (Hietakangas et al., 
2006). Work by Su et al. (2012) demonstrated that the transcriptional activity of 
NF-E2 was increased following SUMOylation and PKA-mediated phosphorylation. 
By purifying recombinant NF-E2 protein, they showed that PKA phosphorylation 
increased protein SUMOylation, which in turn promoted the dimerization of NF-
E2 which in turn regulated its activity (Su et al., 2012). Although not studied 
here, it would be interesting to investigate if the SUMOylation of DHX9 is 
dependent on DHX9 phosphorylation.  
In addition to being PKA phosphorylated and SUMOylated, DHX9 is also 
methylated at its C-terminal end (Fidaleo, De Paola and Paronetto, 2016). 
Proteins can be methylated on the sidechain nitrogen of arginine and lysine 
residues on their C-terminal ends. This PTM subtly changes their primary protein 
structure in order to encode more information (Bedford, 2006). Interestingly, 
arginine methylation is associated with gene regulation, including regulating the 
binding between DNA and transcriptional activators (Lee et al., 2005). DHX9 has 
recently been shown to be methylated within its RGG-box at its C-terminal 
domain (Smith et al., 2004). Methylation of DHX9 was found to be crucial in its 
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ability to localise to the nucleus. Inhibition of DHX9 methylation using protein 
arginine methyltransferase (PRMT) inhibitors led to the accumulation of DHX9 in 
the cytoplasm when visualised by confocal microscopy. However, when a 
methylated DHX9 was expressed in Hela cells, this led to the immediate 
expression of DHX9 within the nuclear region, indicating that DHX9 methylation 
is crucial for its nuclear import (Smith et al., 2004). Interestingly, the data 
presented in this chapter shows that PKA phosphorylation of DHX9 appears to 
lead to the accumulation of DHX9 within the cytoplasm when investigated by ICC 
with confocal microscopy (Figure 4.13, Figure 4.14 and Figure 4.16). Unlike 
protein methylation, phosphorylation of DHX9 by PKA could potentially act as an 
inhibitor of DHX9 import in order to sequester the protein within the cytoplasm 
to promote DHX9’s translational activity. Multiple mRNA structures relies on 
DHX9 for efficient folding and unfolding (Murat et al., 2018). Therefore, PKA 
phosphorylation of DHX9, and its sequestering in the cytoplasm, could promote 
the unwinding of aberrant mRNA structures in order to initiate protein 
translation. Translation initiation is known to play an important role in PC 
tumorigenesis and hyperactivation of the mTOR pathway in PC is often 
associated with increased translational output (Hernández et al., 2019). In order 
to confirm that this is the case, further investigation such as subcellular 
fractionation need to be performed. If DHX9 phosphorylation does lead to its 
accumulation in the cytoplasm, we would expect to see a band representing 
phospho-DHX9 in the cytoplasmic fraction and unphosphorylated DHX9 within the 
nuclear fraction. DHX9 has recently been shown to be recruited by the mTOR 
pathway to promote the translation of specific mRNA (Nandagopal and Roux, 
2015). Therefore, the accumulation of DHX9 in the cytoplasm as a result of PKA 
phosphorylation could lead to an increase in mRNA translation via the mTOR 
pathway.  
4.4.3 Can DHX9 phosphorylation promote PC progression? 
Protein phosphorylation is one of the most important mechanisms by which 
different cellular processes are regulated. Many enzymes and receptors are 
activated and deactivated by the reversible action of phosphorylation (Ardito et 
al., 2017). Although protein phosphorylation is essential for normal cellular 
processes, abnormal phosphorylation is one of the main PTMs that causes 
structural and functional changes that lead to disease (Singh et al., 2017). 
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Although the AR is activated by ligand binding, it is known to be phosphorylated 
at least 15 different sites, most of which are found within the N-terminal region. 
Phosphorylation of AR leads to an increase in its transcriptional activity, 
increased expression of AR, and changes in cell growth. Activation of AR has 
been identified as one of the mechanisms by which a PC tumour can progress 
into the lethal CRPC phenotype. Despite ADT lowering the levels of androgens, 
AR phosphorylation by PKA has been identified as a key mechanism by which PC 
can progress via the cross talk with the cAMP-PKA pathway (Daniels et al., 2013). 
It is widely accepted that the PKA signalling pathway is highly involved in PC 
progression. Elevated levels of intracellular cAMP are known to increase the 
expression of PSA, highlighting the importance in PC (Sarwar et al., 2014). This 
may potentially be due to the decrease in the global expression of PDE4 isoforms 
that has recently been reported by our group and others (R. Böttcher et al., 
2015; Böttcher et al., 2016; van Strijp et al., 2018). 
The data presented in this chapter has shown that decreased interaction 
between PDE4D7 and DHX9 leads to an increase in DHX9 phosphorylation by PKA 
(Figure 4.15 and Figure 4.16). Although these experiments were performed in 
HEK293 cells overexpressing these proteins, we can suggest that the effect could 
be observed in PC cell lines. But this also poses the question: does DHX9 
phosphorylation change depending on the stage of disease? Decreased expression 
of PDE4D7, and other PDE4D isoforms, could potentially contribute to an overall 
increase in intracellular levels of cAMP and PKA activation. This in turn could 
increase the amount of phosphorylation of DHX9 and other proteins such as AR in 
vivo. This could contribute to progression of the disease to the more lethal CRPC 
phenotype. In order to investigate if there is a difference in level of phospho-
DHX9 between early and late stage disease, PC cells could be probed for 
phospho-DHX9 under basal conditions. We could also investigate if the 
interaction between DHX9 and other binding partners are also altered by PKA 
phosphorylation. Furthermore, by using our newly synthesised phospho-DHX9 
antibody, we would be able to directly detect changes in levels of 
phosphorylated DHX9 from matched patient-derived tumours. These experiments 
could help us understand if DHX9 phosphorylation in crucial for PC progression.  
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4.4.4 Chapter summary 
Data in this chapter has provided evidence that DHX9 is a novel substrate for 
PKA phosphorylation. Using PKA consensus site prediction software and peptide 
array technology, I was able to show that DHX9 is phosphorylated at Ser449 in the 
helicase domain of DHX9. Interestingly, this site is found upstream of PDE4D7’s 
binding site. Loss of this serine by sequence substitutions and truncations shows 
that DHX9 phosphorylation is completely lost in biochemical assays, further 
providing evidence that DHX9 can be phosphorylated by PKA. Using the 
information obtained from the peptide array, a custom phospho-DHX9 antibody 
was synthesised. This antibody was able to successfully detect phospho-DHX9 by 
western blotting and confocal microscopy. Such a phosphorylation could 
potentially alter the activity of DHX9 and could contribute to a change in mRNA 
levels. The interaction between PDE4D7 and DHX9 was shown to be important in 
regulating the levels of DHX9 phosphorylation. Loss of this interaction was shown 
to increase the levels of PKA-mediated DHX9 phosphorylated. Unfortunately, the 
effects of DHX9 phosphorylation on its activity was not studied in this chapter. 
By performing a helicase assay using purified recombinant DHX9, we would be 
able to determine if DHX9 phosphorylation can increase its helicase activity. This 
assay directly looks at helicase activity by detecting levels of single stranded 
DNA or RNA by agarose gel electrophoresis following incubation with a helicase 
(Wang et al., 2014). By phosphorylating DHX9 in the assay, we would be able to 
directly observe how this modification can affect DHX9 activity. This information 
could potentially provide us with information on whether DHX9 phosphorylation 
and activity contributes to PC disease progression.  
  
Characterising the role of DHX9 in Prostate Cancer 186 
Chapter 5 Characterising the role of DHX9 in 
Prostate Cancer 
5.1  Introduction 
5.1.1 DHX9 in prostate cancer 
As PC is a mainly driven by testosterone and DHT, it is understandable that 
current research focuses on trying to find innovative ways to inhibit hormone 
production and initiation of hormone-activated signalling pathways (Crawford et 
al., 2019). Although ADT is known to be a highly successful course of treatment, 
the mean progression time to CRPC was found to be 13.1 – 19.3 months under 
this regime. The majority of patients eventually progress into the more 
phenotypically lethal PC, with a significant proportion of their life span spent in 
this castration-resistant state (Damodaran, Kyriakopoulos and Jarrard, 2017). 
There is currently a need to find alternative targets that have the potential to 
supplement and strengthen therapies in use today. In recent years, the DNA 
damage response and repair mechanism has become a potential new therapeutic 
target. DNA helicases are found to be involved in every aspect of nucleic acid 
metabolism and are known to unwind alternate DNA structures and displace 
proteins bound to ssDNA/dsDNA. Mutations in these helicases are known to be 
associated with various cancers (Datta and Brosh, 2018).  
In recent years, DHX9 has emerged as a potential new target in multiple cancers. 
Dysregulation of the mechanisms guiding cell death plays an important part in 
cancer. One of the hallmarks of cancer is the evasion of apoptosis leading to 
drug resistance and tumorigenesis. Genetic mutations and changes in DHX9 
expression have been observed in different cancers, indicating that this protein 
may be involved in the development of disease. Work by Mills et al. (2013) has 
shown that suppression of DHX9 was able to reverse the resistance of Eµ-
Myc/Bcl-2 lymphoma to the chemotherapeutic agent ABT-737. Loss of DHX9 
expression in these cells was shown to lead to activation of the p53 apoptosis 
pathway via an increase in cellular stress (Mills et al., 2013). Not only has it 
been observed that DHX9 increases cell sensitivity to chemotherapeutic agents 
but decreasing DHX9 levels also has profound cellular effects and can be lethal 
in vitro. Knockdown of DHX9 in a panel of cancer cells has a detrimental effect 
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on cell growth, and when suppressed in mice, it had not negative impact on 
their health (Lee et al., 2016). YK-4279 has the unique ability to be lethal only 
to cancer cells, but not have any deleterious effects in animal models, thus 
demonstrating that DHX9 is new target in cancer treatment. 
In prostate cancer, DHX9 has been shown to be a target gene of SOX4. The sex 
determining region Y (SOX), is a family of transcription factors that plays an 
important role in development. SOX4 is a 47 kDa protein that is overexpressed in 
multiple cancers, such as PC: increased expression at an mRNA and protein level 
is correlated with high Gleason scores and tumour grades (Liu et al., 2006). 
Activation of the transcriptional activity of SOX4 via the Wnt pathway leads to 
an increase in the binding of SOX4 to the DHX9 promoter (Lai et al., 2011). 
Stimulation with recombinant WNT3A and leptomycin B (LMB) resulted in a 
decrease in the promoter binding (Lai et al., 2011; Cai et al., 2017). These 
studies suggest that DHX9 may play a role in the development of PC, however 
the direct mechanisms through which it contributes to the disease are still 
unknown (Lee and Pelletier, 2016). Current research suggests that DHX9 may be 
a contributor to tumorigenesis. 
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5.2 Chapter Aims  
DHX9 is known to play a major role in cancer development and response to 
therapy. Although DHX9 maps to a PC susceptibility locus, its function in PC and 
cellular proliferation is currently undefined. Considering this, the aims of this 
chapter are as follows: 
AIM 1: Determine if changes in DHX9 expression or its interaction with EWS-
FL1 affects the proliferation of PC cells. Using the RTCA XCELLigence plate 
reader, the importance of DHX9 expression and its interactions with EWS-
FL1 will be assessed. DHX9 expression will be suppressed using siRNA 
technology, while the interaction between DHX9 and EWS-FL1 will be 
disrupted using the small molecule YK-4-279.  
AIM 2: Determine if disruption of the PDE4D7-DHX9 complex affects the 
proliferation of PC cells. Using the RTCA XCELLigence plate reader, the 
importance of PDE4D7-DHX9 complex will be assessed in order to 
understand if this interaction promotes or slow down PC cell growth.  
AIM 3: Determine if the disruption of the PDE4D7-DHX9 complex affects the 
ability of DHX9 to unwind nascent RNA structures in order to promote R-
loop formation. This will be assessed using ICC with confocal microscopy.  
AIM 4: Determine if changes in DHX9 expression result in changes to 
downstream signalling pathways using Reverse Phase Protein Array (RPPA) 
technology. DHX9 expression will be suppressed using siRNA technology, 
and changes to any downstream signalling pathways can be reviewed using 
RPPA technology.  
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5.3 Results 
5.3.1 siRNA-mediated knockdown of DHX9 leads to a decrease in 
cell proliferation in AS and CRPC cell lines 
5.3.1.1  DuCaP growth is reduced in cells treated with siDHX9 
The DuCap cell line was first established in 2001, DuCaP has since been used as a 
model for androgen sensitive PC (Lee et al., 2001) . Interestingly, this cell line 
also harbours the TMPRSS2-ERG gene fusion, which results in the androgen-
regulated expression of ERG (Pfeiffer, Mulders and Schalken, 2010). DuCaP were 
first derived from mouse SCID xenograft model (Sobel and Sadar, 2005) To 
determine if the cellular proliferation of prostate cancer cell lines is affected by 
decreased expression of DHX9, siRNA targeting DHX9 (and the controls GAPDH 
siRNA, and non-targeting siRNA) were transfected into DuCaP cells to check for 
siRNA efficiency. DuCaP cells were plated into six well plates, transfected with 
the appropriate siRNA the next day and left to incubate for 48 hours at 37˚C 
with 5% CO2. Cell lysate was extracted and proteins separated on an SDS-PAGE 
gel. Protein expression was then assessed by western blotting. DHX9 expression 
in all samples were normalised to loading control, then compared to cells 
treated with non-targeting siRNA (Figure 5.1) 
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Figure 5.1 siRNA mediated knockdown of DHX9 in DuCaP cells. A. DuCaP cells were 
transfected with either siDHX9, siGAPDH, or siNon-Targeting. Protein expression was assessed by 
SDS-PAGE with western blotting. Membranes were probed with antibody against DHX9 and α-
tubulin. B. DHX9 protein expression was normalised to α-tubulin, then normalised to the si Non-
Targetting. Data is presented as the mean ± SEM from two separate experiments. Significance 
was determined using a One-Way Anova where p<0.0001. This work was carried out by Jane 
Findlay. 
Transfection with the DHX9-specific siRNA led to a highly statistically significant 
50% decrease in protein expression (Figure 5.1B). This siRNA was then used to 
investigate whether the decreased expression of DHX9 leads to a change in 
DuCaP proliferation. 10 000 cells were seeded into each well of the 96 well E-
Plate and left to grow for 48 hours. They were then transfected with siRNA and 
left to grow for an additional five days (Figure 5.2). The cell growth of each 
condition was monitored using the RTCA software where cell growth is reported 
as the cell index (CI).  
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Figure 5.2 siRNA-mediated knockdown of DHX9 leads to a decrease in DuCaP cell 
proliferation. A. xCELLigence technology was used to measure proliferation of DuCaP cells 
transfected with siRNA against DHX9, GAPDH and Non-targeting. The cell index was normalised 
at the time of siRNA Transfection. Growth curves are represented as the mean ± SEM of three 
independent experiments. B. The maximum cell index for each growth curve was identified and 
represented as the mean ± SEM of three independent experiments. The maximum cell index was 
normalised to the cells-only condition and statistical significance was calculated using a One-Way 
Anova. C. The slope of each growth curve was calculated from the point of treatment to 100 hours. 
The slope is represented as the mean ± SEM of three independent experiments. The slope was 
normalised to the cells-only condition and statistical significance was calculated using a One-Way 
Anova. This work was carried out by Jane Findlay. 
During the first 48 hours of the experiment, the CI is seen to steadily increase 
due to the cells coming out of suspension and adhering to the bottom of the 
well. When transfected with non-targeting siRNA and siGAPDH, the cells are seen 
to continue to increase over the 5 days of the experiment, indicating that cell 
growth is unaffected by these transfections (Figure 5.2 A, red and green traces). 
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However, when transfected with siDHX9, the CI steadily decreases when 
compared to the other conditions, indicating that decreased expression of DHX9 
slows down DUCaP cell growth (Figure 5.2 A purple trace). Although in general, 
treatment with any siRNA reagents resulted in an overall reduction in cell 
growth (as assessed by the slope of exponential growth), growth of cells that 
were treated with siRNA specifically targeting DHX9 was significantly reduced 
when compared to the cells-only and siNon-Targeting conditions (Figure 5.2 C). A 
similar result was seen when the maximum cell index was evaluated (Figure 5.2 
B). The maximum cell index represents the timepoint at which the cells have 
reached their maximum attachment strength and confluency. The maximum cell 
index of cells treated with siRNA against DHX9 was significantly reduced when 
compared to the other treatments and cells-only. The data presented here 
shows that expression of DHX9 is crucial for PC cell growth and proliferation. 
Previous work by Lee et al (2014) demonstrated that suppression of DHX9 
expression in human fibroblast cells leads to an activation in the p53 pathway 
(Lee et al., 2014), which is potentially what is observed in the cell growth 
curves.  
5.3.1.2  LNCaP growth is reduced in cells treated with siDHX9 
In order to investigate if this effect was also seen in other AS cell lines, a pilot 
study with AS VCaP and LNCaP cells was carried out.. This was to determine the 
best cell density and cell line to use in future experiments. 40 000, 20 000, 10 
000 or 5 000 cells were plated into the 16 well E-P6ate, and their growth was 
monitored over 5 days (Figure 5.3). A pilot study was not conducted for the 
DuCaP experiments (Figure 5.2) as the optimum cell density was determined by 
previous members of the Baillie Lab. 
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Figure 5.3 AS cell line pilot study. In order to use the correct cell line and cell density for future 
experiments, LNCaP (A) and VCaP (B) were plated at different densities and growth was 
monitored using the RTCA cell analyser over five days. 
Based on the information obtained in Figure 5.3 A, I decided to use 5 000 LNCaP 
cells per well. This cell density provided three days of growth, giving us a large 
window of opportunity to study how growth can be affected by siRNA treatment. 
Although 10 000 and 20 000 LNCaP cells per well were able to show growth after 
seeding, they reached maximum cell index at 72 hours and 48 hours 
respectively. Unlike the other cell densities, when 40 000 LNCaP cells were 
seeded no growth was observed, potentially due to overcrowding of the well 
(Figure 5.3 A). VCaP cells were not chosen for any future experiments as most 
growth curves remained negative for 48 hours (Figure 5.3 B). Although VCaP 
have been used as a model for early stage PC, this cell line has a doubling time 
of 5-6 days (Cunningham and You, 2015), potentially explaining why it has taken 
them over 48 hours to recover from seeding. In order to use VCaP cells for future 
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xCELLigence experiments, more than 40 000 cells per well would be required in 
order to obtain an appropriate growth curve. Based on the information obtained 
in Figure 5.3 A, 5000 LNCaP cells per well was selected for future cell growth 
assays. siRNA transfection efficiency in LNCaP was then assessed by SDS-PAGE 
with western blotting (Figure 5.4) prior to starting xCELLigence experiments. 
 
 
Figure 5.4 siRNA transfection efficiency in LNCaP cells. A. Lysates from three independent 
siRNA transfection reactions were separated by SDS-PAGE, and protein expression was assessed 
by western blotting. B. DHX9 expression in siRNA-transfected cells were normalised to the β-actin 
loading control, then to the siNon-Targeting control. Statistical significance was determined using a 
One-Way Anova. p**=0.0046 and p**=0.0004 C. GAPDH expression in siRNA-transfected cells 
were normalised to β-actin loading control, then to the siNon-Targeting control. Statistical 
significance was determined using a One-Way Anova. 
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Transfection of LNCaP with siRNA directly targeting DHX9 expression led to a 
visible reduction in protein expression as shown in Figure 5.4 A. When probed for 
DHX9 (Figure 5.4 A top membrane) DHX9 expression is visibly significantly 
reduced. When quantified and normalised to cells treated with non-targeting 
siRNA, DHX9 expression was shown to be statistically significantly reduced by 
approximately 75%. Although not significant, transfection with siRNA targeting 
GAPDH led to a 25% reduction in expression when compared to cells treated with 
non-targeting siRNA. Interestingly, treatment of LNCaP with siGAPDH increased 
the expression of DHX9 (Figure 5.4 A and C). GAPDH is widely used as a 
housekeeping gene. These genes are essential endogenous regulatory genes that 
are involved in various processes in the cell, such as metabolism, transcription, 
and homeostasis. The expression levels of references genes should remain 
constant between the cells of different tissues and under different experimental 
conditions in order to normalise the expression of the gene or protein of interest 
(Zainuddin et al., 2010). Previous work by Phadke et al (2009) has shown that 
reduction of GAPDH protein in A549 human carcinoma cell lines arrested cell 
proliferation, and cells with reduced expressions of GAPDH accumulated in the 
G0/G1 phase of the cell cycle (Phadke et al., 2009). DHX9 expression may have 
increased during this experiment due to the accumulation of cells in the G0/G1 
phase. Work by Thacker et al (2020) has shown that DHX9 expression is required 
for the efficient progression of cells from G1 to S phase of the cell cycle 
(Thacker et al., 2020). Knockdown of GAPDH may have led to the increase in 
DHX9 expression due to its role in cell cycle progression. Using the information 
gained from figure 5.4, I can confidently say that the siDHX9 directly affects 
expression of the DHX9 protein (Figure 5.4 C). This siRNA was then used in a 
proliferation assay to investigate how the reduced expression of DHX9 affects 
LNCaP growth (Figure 5.5). 
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Figure 5.5 siRNA-mediated knockdown of DHX9 in LNCaP cells. A. xCELLigence technology 
was used to measure the proliferation of LNCaP cells transfected with siRNA against DHX9, Non-
targeting, and mock transfection. The cell index was normalised at the time of siRNA transfection. 
Growth curves are represented as the mean ± SEM of three independent experiments. B. The 
maximum cell index for each growth curve was identified and presented as the mean ± SEM of 
three independent experiments. The maximum cell index was normalised to the cells only condition 
and statistical significance was calculated using a One-Way Anova, where p***=0.0006 and 
p****<0.001 
Although I was able to achieve approximately 75% knockdown in DHX9 expression 
(Figure 5.4 B), siRNA treatment in this cell line led to an overall decrease in 
cellular growth. Treatment with the siRNA transfection reagent alone lead to a 
50% decrease in cell growth, which was shown to be very significant when 
compared to the cells only condition (Figure 5.5 B purple bar). When the cells 
were treated with both non-targeting and DHX9 specific siRNA, this led to very 
significant decrease in cell growth when compared to the cells-only condition 
(Figure 5.5 B red and green bars). In addition, there was no significant 
difference in growth between these two conditions, indicating that this 
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reduction in cell growth is due to the treatment rather than the decreased 
expression of DHX9. Although the initial data from the DuCaP growth assay 
indicated that the decreased expression of DHX9 leads to a significant decrease 
in cellular proliferation, this observation cannot be made in LNCaP despite 
showing that the same siRNA can reduce DHX9 expression by western blot 
(Figure 5.4 B).  
5.3.2 YK-4-279 inhibition of DHX9 leads to a decrease in PC cell 
proliferation 
Many cancers, such as PC, carry non-random chromosomal translocations 
encoding tumour-specific fusion transcription factors that are essential for 
disease progression. Ewing’s Sarcoma family tumours (ESFTs) express the EWS-
FL1 fusion protein, which is known to interact with DHX9. This binding is 
important for oncogenic function of DHX9 in ESFT cells, and disruption of this 
interaction using the small molecule YK-4-279 induces apoptosis (Erkizan et al., 
2009). Disruption of PPI using small molecule inhibitors is a rapidly evolving field 
(Bhalla et al., 2006) and disruption of the interactions of DHX9 with its 
interacting partners using disruptor peptides leads to a decrease in cell growth 
as demonstrated by Erzikan et al. (2009). YK-4-279 was initially identified from a 
library of over 3000 compounds after showing that it significantly reduced the 
interaction between the C-terminal end of DHX9 and EWS-FL1 without affecting 
expression levels of either protein. These authors also further showed that 
treatment of mouse ESFT xenograft models with 1.5 mg of YK-4-279 significantly 
reduced tumour growth when compared to PC3 prostate tumour xenografts that 
does no express EWS-FL1 protein. When tumours from DMSO- and YK-4-279-
treated mice were stained for caspase-3 by immunohistochemistry, tumours 
from YK-4-279 mice had a threefold increase in caspase-3 staining when 
compared to control mice. Not only did YK-4-279 inhibit tumour growth, but it 
also increased apoptosis in this xenograft model (Erkizan et al., 2009). 
Interestingly, this small molecule inhibitor is gaining the interest of PC 
researchers due to the fact that 40-70% of PC tumours have been shown to have 
gene rearrangements involving ETS transcription factors, with the most common 
of them being the TMPRSS2-ERG gene fusion (Rubin, 2012). Previous work by 
Rahim et al (2011) showed that growth of YK-4-279-treated LNCaP and VCaP PC 
cells was significantly reduced when compared with non-treated cells. 
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Furthermore, treatment with YK-4-279 reduced the invasive nature of LNCaP in a 
scratch assay (Rahim et al., 2011). In order to confirm this, further xCELLigence 
studies were carried out with this DHX9-specific inhibitor. 5 000 LNCaP cells 
were plated in each well of the 96 E-plate and left to grow overnight. The cells 
were then treated with YK-4-279 over a range of concentrations to establish a 
dose response curve and determine an IC50 for LNCaP growth.  
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Figure 5.6 Growth of LNCaP cells following treatment with YK-4-279. A. xCELLigence 
technology was used to monitor the growth of LNCaP cells over the course of three days. Cells 
were treated with YK-4-279 at the indicated concentrations after 24 hours, and all growth curves 
were normalised to growth at this point. Growth curves are represented as means of four 
independent experiments. B. The maximum cell index was plotted as a dose response curve, and 
the IC50 was calculated using a non-linear regression. Data is presented as the mean ± SEM from 
four independent experiments. 
YK-4-279 significantly reduced LNCaP cell growth at 10 µM and 1 µM after 
normalization when compared to the cells-only and DMSO controls (Figure 5.6 A). 
Interestingly, as the cells were exposed to lower concentrations of YK-4-279, the 
growth curve can be seen to increase up to basal levels in a dose-dependent 
manner (Figure 5.6 A). At 10 µM and 1 µM, we can assume that the treatment 
with YK-4-279 lead to the activation of caspase-3 as previously reported (Erkizan 
et al., 2009). The maximum cell index for each growth curve was identified and 
plotted as a dose response curve in order to calculate the IC50 of YK-4-279 in this 
cell line. Using log (inhibitor) vs response model on GraphPad Prism, a non-linear 
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regression was plotted in order to determine the concentration at which a 
response halfway between the maximum response and the maximally-inhibited 
response. The IC50 of YK-4-279 was found to be 0.46 µM in LNCaP cells (Figure 5.6 
B). Previous work by Sun et al (2017) showed that the IC50 of YK-4-279 in 
different neuroblastoma cells lines ranged from 0.218 µM to 2.255 µM (Sun et 
al., 2017). VCaP cells, although they are known to harbour the ERG gene 
rearrangement, has been shown to have an IC50 of 16 µM (M. S. Butler et al., 
2017). Such large differences in YK-4-279 can be explained by the difference in 
cell doubling time. LNCaP are known to have a doubling time of 28-60 hours, 
compared to 5-6 days for VCaPs (Cunningham and You, 2015). IC50 values are 
thought to decrease with increasing numbers of cell doublings during the 
incubation period (Baguley, Hicks and Wilson, 2002). Within the same day, 
LNCaP can go through more cell doublings than VCaPs, indicating that lower 
concentrations of YK-4-279 are required to inhibit growth.  
So far, I have been able to show that LNCaP growth is significantly affected by 
YK-4-279. We then investigated if growth of the AI cell line DU145 was affected 
by YK-4-279 . Previous work in our lab had determined that 10 000 cells per well 
is the most appropriate cell density for this cell line for xCELLigence 
experiments (Byrne, 2014). DU145 cells were seeded at the previously 
mentioned cell density and left to grow overnight. They were then treated with 
either 10 µM or1 µM of YK-4-279 or with DMSO vehicle control (Figure 5.7).  
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Figure 5.7 Treatment of DU145 cells with YK-4-279. A. xCELLigence technology was used to 
monitor the response of DU145 to YK-4-279. Cells were treated with either 10 µM or 1 µM of YK-4-
279 24 hours after seeding and this was the point to which the growth curves were normalised to. 
B. The maximum cell index of each growth curve was measured, then normalised to the DMSO 
vehicle control. Data presented is N=1. 
Unlike LNCaP cells, DU145 cells remained unaffected by the inhibitor. YK-4-279 
did not significantly decrease the proliferation of DU145 cells at either of the 
concentrations used (Figure 5.7). DU145 is an AI cell line that is most commonly 
used as a model for aggressive PC. However, this cell line does not naturally 
express ETS fusion protein (Swanson et al., 2011), explaining why this cell line 
remained unresponsive to the inhibitor. The data presented so far indicates that 
YK-4-279 is only able to target cells that express ETS fusion proteins that can 
bind to DHX9. Interruption of this DHX9-ETS interaction leads to an activation in 
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caspase-3 activity (Erkizan et al., 2009), which in turn leads to a significant 
decrease in cell growth (Figure 5.6). 
5.3.3 Disruption of the PDE4D7-DHX9 complex has no effect on 
cell proliferation  
My data has so far shown that disruption of the interaction between DHX9 and 
EWS-FL1 protein significantly reduces cell growth. Not only did this indicate that 
DHX9 is important for cell growth but also showed that by disrupting of the 
interaction between DHX9 and its partners negatively impacts growth. With this 
in mind, I then investigated if disruption of PDE4D7 and DHX9 complex in PC 
cells has similar effects as YK-4-279. The same proliferation assay as used in 
Figure 5.7 was repeated with our newly designed disruptor peptides previously 
described in chapter 3. These peptides were designed to recognise the binding 
sites between DHX9 and PDE4D7 from peptide array data. The UCR1 disruptor 
peptide inhibits DHX9 binding to PDE4D7, whereas the DHX9 disruptor peptide 
inhibits PDE4D7 binding to DHX9 (Figure 3.20). The cell-permeable disruptor 
peptide was shown to be effective in pull-down and PLA imaging assays (Figure 
3.21, Figure 3.22, and Figure 3.23). Therefore, I carried out these experiments 
to determine if disruption of this interaction by our newly synthesised peptides 
affected cell growth. 5000 LNCaP cells were seeded into each well of 96 well E-
Plate, and the cells were left to grow for 24 hours. The cells were then treated 
with DMSO, scrambled peptide, or our disruptor peptides (UCR1 or DHX9 
peptides), after which growth was monitored for 2 days (Figure 5.8).  
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Figure 5.8 Growth of LNCaP cells following treatment with disruptor peptides. A. Cells were 
treated with UCR1 disruptor peptide at concentrations ranging from 10uM to 10pM. B. Cells were 
treated with DHX9 disruptor peptide at the same concentration as in A. C. Cells were treated with 
scrambled peptide at the same concentrations as in A. All data is representative of N=4 and were 
normalised to the point of treatment.  
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During the first 21 hours of the experiment, the CI of all the different conditions 
was shown to rapidly increase as the cells settled and adhered to the bottom of 
the well (Figure 5.8 A-C). After the cells were treated with the different 
peptides, all cells continued to grow as shown by the steady increase in CI over 
the 2 days of the experiment (Figure 5.8 A-C). However, a small dip in the CI can 
be seen between the time of treatment and 26 hours. In order to investigate 
whether there was a dose-response effect in the growth curves, the growth 
between the 20 and 26 hours was plotted for further analysis. (Figure 5.9).  
 
Figure 5.9 LNCaP growth between 20 and 26 hours. A. Cells were treated with UCR1 disruptor 
peptide. B. Cells were treated with DHX9 disruptor peptide. C. Cells were treated with scrambled 
peptide. All data is representative of N=4 and were normalised to the point of treatment.  
Interestingly, cell growth can be seen to be briefly interrupted after the addition 
of the UCR1 and DHX9 disruptor peptides. During the first two hours of peptide 
incubation, all growth curves can be seen to decrease (Figure 5.9). 
Unfortunately, this decrease was not shown to be statistically different between 
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our two disruptor peptides and the scrambled peptide control, indicating that 
this effect may not be due to the disruption between PDE4D7 and DHX9 (Figure 
5.9). Furthermore, unlike with YK-4-279, treatment with our disruptor peptide 
did not lead to any significant decrease in cell growth when looking at the traces 
over the two-day peptide incubation. Instead, LNCaP cells can be seen to 
continue to grow after the 26 hour time point in all peptide treatments (Figure 
5.8 and Figure 5.9). Unfortunately, the disruption of the interaction between 
PDE4D7 and DHX9 does not affect long-term PC cell growth. This interaction, 
unlike the DHX9-EWS-FL1 interaction, may not be essential for cell growth and 
our disruptor peptides may not be a viable tool to slow disease progression. In 
order to evaluate the effects of peptides at early timepoints, the normalised cell 
index at the 24 hour “peak” was measured and normalised to the DMSO vehicle 
control (Figure 5.10). 
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Figure 5.10 Dose response of UCR1 and DHX9 disruptor peptides at the 24-hour peak. A+B. 
The cell index of LNCaP at the 24 hour peak was measured and compared to the scrambled 
peptide. The data presented here is the mean ± SEM of four independent experiments. Cell index 
of all points was normalised to the DMSO vehicle control-treated cells. Statistical significance was 
determined using a Two-Way Anova with multiple comparisons, where p****>0.0001. 
Unlike YK-4-279, both newly designed disruptor peptide significantly increased 
cell growth during the first two hours of treatment when compared to the 
scrambled peptide control (Figure 5.10). However, the cells were able to 
recover from peptide treatment as reflected by the increase in all growth curves 
after two hours of peptide treatment (Figure 5.8 and 5.10). In order to consider 
these peptides as “proof of concept” novel therapeutics, any changes in cell 
growth must be observed over a longer period of time. The ideal scenario in 
cancer drug development is to kill all tumour cells, while leaving the healthy 
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cells intact so that the patients survive treatment (Eastman, 2017). Additionally, 
measuring the potency of small molecule drugs is a critical step in the 
development of novel therapeutic agents (Niepel et al., 2017). Unfortunately, 
the disruptor peptide developed in this thesis did not have any long-term effects 
on the growth of PC cells. Although an initial decrease in growth can be 
observed during the first two hours of treatment, the cells eventually were able 
to overcome this and continue to grow over the three days of this experiment 
(Figure 5.8). Although I have shown that our disruptor peptides are able to 
disassemble the PDE4D7-DHX9 complex in an IP and PLA (Figure 3.21, Figure 
3.22,Figure 3.23), this does not lead to any changes in LNCaP cells growth. 
However, this assay does provide us with a platform to test other therapeutic 
agents that could potentially lead to a decrease in PC cell growth.  
5.3.4 Disruption of PDE4D7-DHX9 complex alters DHX9 activity 
The data in this thesis so far has shown that disruption of the PDE4D7-DHX9 
complex only leads to a short-term decrease in cell growth during the first two 
hours of peptide treatment. Although promising, this did not lead to any long-
term changes in LNCaP cell growth. However, I was interested to see if the 
disruption of this interaction could affect DHX9’s helicase activity. Previous 
peptide array data showed that PDE4D7 binds within the helicase domain of 
DHX9 (Figure 3.16), suggesting that it may play a role in regulating its activity.  
Recent work by Chakraborty et al (2018) has shown that DHX9 activity can be 
studied by looking at levels of specific DNA-RNA hybrids known as R-loops. R-
loops are three-stranded nucleic acid structures that include an RNA strand 
hybridized with the DNA template, leaving the non-template DNA single stranded 
(Figure 1.14). These structures occur naturally during transcription, however the 
prolonged formation of these structures can have deleterious effects on genome 
integrity (Skourti-Stathaki and Proudfoot, 2014). DHX9 has recently been shown 
to promote the formation of R-loops in cells that are deficient for the Splicing 
Factor Proline and Glutamine rich (SFPQ). In the absence of SFPQ, there is a 
prolonged interaction between DHX9 and RNA polymerase II (RNA pol II) leading 
to increased production of R-loops (Chakraborty, Huang and Hiom, 2018). In 
order to investigate if the activity of DHX9 is affected by dissociation from 
PDE4D7, the same R-Loop assay was repeated. In order to ensure that SFPQ 
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could be successfully knocked down in LNCaP cells, SFPQ protein expression was 
first assessed by western blotting after siRNA treatment (Figure 5.11). 
 
 
Figure 5.11 LNCaP siSFPQ treatment efficiency. A. SFPQ protein expression was assessed by 
SDS-PAGE with western blotting. B. SFPQ expression was normalised to β-actin loading control. 
Percentage knockdown was then determined by normalising protein expression to cells treated 
with non-targeting siRNA. Data is presented as the mean ± SEM of three independent 
experiments. C. GAPDH expression was normalised to β-actin loading control. Percentage 
knockdown was then determined by normalising protein expression to cells treated with non-
targeting siRNA. Data is presented as the mean ± SEM of three independent experiments. 
Statistical significance was determined using a One-Way Anova, where p*>0.01 and 
p****>0.00001. 
Transfection with siRNA targeting SFPQ expression led to a visible decrease in 
protein expression (Figure 5.11 A top membrane). When quantified and 
normalised to the loading control, SFPQ expression was significantly reduced by 
approximately 60% when compared to the non-targeting siRNA control (Figure 
5.11 B). Although GAPDH expression did not seem to be visible decreased (Figure 
5.11 last membrane), its expression was reduced by 15% when compared to the 
non-targeting siRNA control (Figure 5.11 C). As siRNA against SFPQ was so 
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efficient, I can then attribute any changes in R-loops formation to the reduction 
of expression of this specific splicing factor. LNCaPs were plated onto sterile 
glass coverslips and treated with siRNA against SFPQ alone, or in combination 
with siRNA against PDE4D7. siRNA PDE4D7 was previously designed by Dr Ashleigh 
Byrne and shown to significantly decrease its expression in PC cell lines (Byrne, 
2014). The cells treated with siSFPQ alone were then treated with either UCR1 
or DHX9 disruptor peptide, the scrambled control peptide, or DMSO vehicle 
control. Following fixing and blocking of the coverslips, the cells were stained 
for nucleolin and for DNA-RNA hybrids using the S9.6 antibody overnight. In 
recent years, the monoclonal S9.6 antibody has been used to purify, analyse and 
quantify R-loop structures in cells (König, Schubert and Längst, 2017). After 
counter staining with the appropriate secondary antibodies, the coverslips were 
mounted cell side down and imaged using a confocal microscope (Figure 5.12 
and Figure 5.12).  
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Figure 5.12 Staining for R-loops in LNCaP cells following treatment with siRNA and 
disruptor peptide. Representative images showing immunostaining for R-loops using the S96 
antibody (red) and nucleolin (green). LNCaP were transfected with siNon-targeting (A) or siSFPQ 
(B) as indicated. Certain cells were also transfected with siPDE4D7 (C), or treated with scrambled 
peptide (D), or disruptor peptide (E+F). S9.6 staining from 30 different individual cells were 
measured as described in Figure 5.13. This work was performed in collaboration with Prof Kevin 
Hiom, University of Dundee.  
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In order to measure the levels of R-loops formed directly due to DHX9 helicase 
activity, the S9.6 staining from the regions stained with anti-nucleolin was 
subtracted from the S9.6 staining in the nucleus, as described in Figure 5.13. 
 
Figure 5.13 Determining R-loop staining in the nucleus following siRNA and peptide 
treatment. In order to determine if there were any changes in formation of R-loops due to siRNA 
transfection or peptide treatment, the mean fluorescence intensity (MFI) of the nucleolin regions (B-
D) was subtracted from the total nuclear S9.6 staining (A). All data acquisition was performed on 
Image J and analysed using GrahphPad Prism 8. 
S9.6 staining from at least 30 individual cells was measured from each condition. 
The mean S9.6 staining was then plotted, and any statistical difference in 
staining was determined using a One-Way Anova with multiple comparisons 
(Figure 5.14). 
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Figure 5.14 Quantification of R-loop staining following siRNA and peptide treatment. R-loop 
staining in LNCaP cells following siRNA and disruptor peptide. Data is presented as the mean ± 
SEM of at least 30 individual cells per treatment. Statistical significance was determined using a 
One-Way Anova with multiple comparisons where p****>0.0001. This work was performed in 
collaboration with Prof Kevin Hiom, University of Dundee. 
When LNCaPs were treated with non-targeting siRNA, R-loop staining is low as 
splicing factors are still able to bind to nascent RNA structures, physically 
preventing R-loop formation (Figure 5.12 A and Figure 5.14). R-loop formation is 
normally protected by splicing factors which coat the nascent mRNA, which in 
turn allows for normal transcription to take place (Crossley, Bocek and Cimprich, 
2019). However, when treated with siSFPQ alone and siSFPQ with scrambled 
peptide, S9.6 staining in these cells increased significantly by three-fold and 
four-fold respectively (Figure 5.12 B+D and Figure 5.14). However, when LNCaP 
cells were treated with siSFPQ and the UCR1 disruptor peptide, this led to a 
significant decrease in R-loop detection when compared to the scrambled 
peptide control. Interestingly, levels of R-loops detected in these cells were not 
significantly different from those in cells treated with non-targeting siRNA, 
indicating that R-loop formation had returned to normal levels (Figure 5.12 E 
and 5.14). This same response was seen in cells transfected with siFPQ and 
siPDE4D7 (Figures 5.12 C and 5.14). My results suggest that the interaction 
between DHX9 and PDE4D7 is required for DHX9 to unwind nascent RNA 
structures within the nucleus. Loss of this interaction leaves DHX9 unable to 
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unwind nascent RNA structures, leading to a decrease in R-loop formation and 
detection. Interestingly treatment with siSFPQ and our DHX9 disruptor peptide 
also led to a significant decrease in R-loop detection when compared to the 
scrambled peptide treated cells (Figure 5.12 F and 5.14). However, there was 
still a two-fold increase in R-loops when compared to the non-targeting siRNA 
treated control. Although my DHX9 disruptor peptide was able to lower R-loop 
formation, it is possible that not all DHX9-PDE4D7 complexes were disrupted 
within the nucleus. This could lead to continued DHX9 helicase activity and R-
loop formation. The data presented here suggests that disruption of the 
interaction between PDE4D7 and DHX9 using our cell penetrating peptides 
inhibits DHX9’s ability to promote R-loop formation.  
5.3.5 Decreased expression of DHX9 leads to changes of 
downstream signalling pathways.  
Although DHX9 is known to be involved in multiple signalling pathways, such as 
the p53 pathway (Lee and Pelletier, 2017), little is known about how changes in 
DHX9 protein expression can alter different downstream signalling pathways. 
Reverse phase protein array (RPPA) is a high throughput antibody-based 
proteomic technique which enables the concomitant quantification of multiple 
proteins and post-translational modifications of these proteins in multiple 
samples. Proteins extracted from cultured cells are denatured by SDS treatment 
and spotted onto nitrocellulose-coated glass slides. Using over 60 highly 
validated antibodies (Figure 5.16), these slides can measure changes in levels of 
total or post translationally modified proteins from the whole proteome 
available in the cell lysate (Creighton and Huang, 2015; Macleod, Serrels and 
Carragher, 2017). In this instance, RPPA was used to investigate how the 
decreased expression of DHX9 can affect linked signalling cascades by looking at 
the total levels and phosphorylation state of signalling intermediates. In this 
way, novel roles for DHX9 can be identified in PC cells. AI cells (DU145) were 
treated with siRNA against DHX9, GAPDH, or non-targeting control. Protein 
expression was assessed by SDS-PAGE with western blotting in order to ensure 
decreased protein expression (Figure 5.15). DU145 cells were used for this 
experiment as they had the highest endogenous level of DHX9 expression out of 
the three PC cell lines used in this thesis (Figure 3.1). 
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Figure 5.15 DHX9 expression in DU145 for RPPA analysis. A. DHX9 protein expression was 
assessed by SDS-PAGE with western blotting. B. DHX9 expression was normalised to β-actin 
loading control. Percentage knockdown was then determined by normalising protein expression to 
cells treated with non-targeting siRNA. Data is presented as the mean ± SEM of three independent 
experiments. C. GAPDH expression was normalised to β-actin loading control. Percentage 
knockdown was then determined by normalising protein expression to cells treated with non-
targeting siRNA. Data is presented as the mean ± SEM of three independent experiments. 
Statistical significance was determined using a One-Way Anova, where p*>0.01 and 
p****>0.00001. 
When treated with siDHX9, this led to a visible decrease in DHX9 expression by 
western blotting (Figure 5.15 A, top membrane). When quantified and 
normalised against the non-targeting siRNA control, DHX9 expression was 
significantly decreased when transfected with siDHX9 (Figure 5.15 B). 
Furthermore, western blotting and densitometry analysis showed that GAPDH 
expression was significantly decreased after siRNA transfection (Figure 5.15 A, 
bottom membrane, and Figure 5.15 C). Knowing that DHX9 expression is 
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significantly decreased when treated with siDHX9, this sample, as well as the 
lysate treated with non-targeting siRNA, were sent to the Edinburgh Cancer 
Research Centre for RPPA analysis. Spot and initial data analysis was performed 
by Kenneth Macleod at the University of Edinburgh (Figure 5.16).  
 
  
Figure 5.16 RPPA data from DU145 cells treated with siNon-target or siDHX9. A+B. Over 60 
antibodies were tested. Arrays were scanned using a slide scanner and adjusted for maximal 
signal in order to avoid saturation. This data was generated by Kenneth Macleod at the University 
of Edinburgh. 
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Interestingly, the RPPA analysis revealed that the Mitogen-Activated Protein 
Kinase (MAPK) pathway (Figure 5.16 A) and the mTOR pathway (Figure 5.16 A 
and B) were altered after DHX9 knockdown. HSP27 pSer78, MEK1/2 pSer 217, 
MNK1 pThr197, Thr202 from the MAPK pathway, and 4E-BP1 P Ser65, p70 S6 
Kinase P Thr389, mTOR (7C10), from the mTOR pathway, were all shown to 
increase in expression following siDHX9 transfection. Interestingly, these two 
pathways are often associated with each other in prostate cancer. Work by 
Kinkade et al (2008) showed that inhibition of the mTOR pathway by rapamycin 
and inhibition of the MAPK pathway using MEK inhibitor significantly inhibits cell 
growth in PC cell lines and AI PC tumours in mouse models (Kinkade et al., 
2008). Furthermore, inhibition of the mTOR pathway has been shown to activate 
the MAPK pathway as compensation (D. E. Butler et al., 2017). The data here 
suggests that these two pathways may be reliant on DHX9 expression in order to 
successfully allow signalling via these pathways. In addition to the MAPK and 
mTOR pathways, phosphorylation of S6 Ribosomal protein P Ser235, Ser236 and 
S6 Ribosomal protein p Ser240, Ser244 expression increased following siDHX9 
transfection. The ribosomal protein is an important component of the 40S 
ribosomal subunit (Puighermanal et al., 2017) as it has the ability to bind to 
mRNA, tRNA, and initiation factors (Williams et al., 2003). Phosphorylation of 
this protein is known to promote mRNA translation (Williams et al., 2003) under 
the regulation of the mTOR pathway (Ruvinsky and Meyuhas, 2006). Initial RPPA 
analysis potentially suggests that knockdown of DHX9 expression can potentially 
affect the mTOR pathway, either by altering the phosphorylation of downstream 
proteins or by altering the translational activity of the cell. 
It should also be noted that the decrease in DHX9 expression also led to the 
decreased detection of Cofilin pSer 3. Cofilin is an F-actin severing protein 
required for the reorganization of the cytoskeleton, which in turn drives cell 
migration. Cytoskeletal rearrangement is regulated by the phosphorylation of 
cofilin at Ser 3 in response to growth factor stimulation (Collazo et al., 2014). 
The RPPA analysis presented here shows that total cofilin expression remains 
unchanged but cofilin pSer 3 expression decreases following siDHX9 transfection 
(Figure 5.16 B). Phosphorylation of cofilin abolishes its actin-binding activity, 
thereby reducing filament breakdown and promoting cell migration (Lee and 
Dominguez, 2010). This could indicate a role for DHX9 in regulating levels of 
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phosphorylated cofilin, thus regulating cellular migration and invasion. In 
addition to cofilin, DHX9 knockdown also led to a decrease in Chk1 P Ser345 and 
Chk2 P Thr68 detection. Chk1 and Chk2 are both kinases that play an important 
role in genome integrity and cell cycle control. Although these two proteins are 
structurally unrelated to each other, both play a role in relaying the checkpoint 
signals in response to DNA damage. Phosphorylation of these proteins promotes 
activation of DNA repair pathways (Bartek and Lukas, 2003). Interestingly, 
inhibition of CHK1 can promote tumour cell killing by different genotoxic agents 
(Smith et al., 2010). This could mean that by decreasing phosphorylation of 
these two proteins by suppressing DHX9 expression, we could potentially 
increase the potential for PC cells to succumb to different anti-cancer drugs.  
In order to further validate the RPPA analysis, the proteins presented in Figure 
5.17 were selected for western blot analysis. These proteins were selected as 
the initial RPPA analysis showed that their expression was altered following 
siDHX9 transfection. Unfortunately, I was unable to further validate the other 
proteins above due to antibody availability and time constraints.  
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Figure 5.17 RPPA proteins selected for further validation. DU145 cells were treated with either 
siNon-targeting or siDHX9 for 48 hours. Cells were then lysed and the lysates were spotted onto 
glass nitrocellulose slides. Lysates were serially diluted 1:2 four times from a starting concentration 
of 1.5 mg/mL, then spotted in triplicate. The data presented here is the representative spot images 
and the net intensity following normalisation to loading control and siNon-targeting control. Data is 
presented as the mean ± standard deviation of the triplicate data. N=1. A+B+C. S6 Ribosomal 
protein P Ser235,Ser236, S6 Ribosomal protein p Ser240,Ser244, and p70 S6 Kinase P Thr389 
expression increases following siDHX9 transfection. D. Cofilin pSer 3 expression decreases 
following siDHX9 transfection.  
As previously described, the expression S6 Ribosomal protein P Ser235, Ser236, 
S6 Ribosomal protein p Ser240, Ser244, and p70 S6 Kinase P Thr389 increased 
after siDHX9 transfection (Figure 5.17 A-C). This could suggest that decreased 
expression of DHX9 could lead to changes in mTOR signalling. Additionally, 
expression of cofilin pSer 3 decreased following siDHX9 transfection. DHX9 could 
potentially have a role in mediating its phosphorylation, in turn regulating cell 
migration (Figure 5.17 D). The expression of the proteins mentioned in Figure 
5.17 was then further validated by western blotting. DU145 cells were treated 
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with either siNon-targeting, siGAPDH, or siDHX9 for 48 hours, then lysed. The 
expression of the proteins of interest was then assessed by SDS-PAGE with 
western blotting (Figure 5.18) in order to validate the original RPPA analysis 
(Figure 5.16). 
 
Figure 5.18 Effects of DHX9 knockdown on the phosphorylation of downstream proteins. 
Western blot analysis of the levels of phosphorylated proteins in cells treated with siRNA against, 
DHX9, GAPDH, or non-targeting control. The data is presented as the mean ± SEM of three 
independent experiments. Statistical significance was determined using a One-Way Anova. 
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Unlike in Figure 5.17 A, the expression of S6 Ribosomal protein pSer 235 236 and 
cofilin pSer 3 do not significantly change following siDHX9 transfection (Figure 
5.18 A and D). However, S6 Ribosomal protein pSer 240 244 expression was 
increased following siDHX9 transfection (Figure 5.18 B). Interestingly, p70 S6 
Kinase P Thr389 expression doubled following siDHX9 transfection (Figure 5.18 
C), but it was not statistically significant due to high variability between 
experiments. Although these increases were not significant when compared to 
the non-targeting siRNA control, this data further validates the initial RPPA 
analysis from Figure 5.16 and 5.17. Interestingly, DHX9 has been shown to be an 
interactor of p70 S6 kinase (p70S6K) as well as a new possible target to regulate 
p70S6K activity (Pavan et al., 2016). Although I was only able to validate a 
handful of proteins from the initial 60 from the RPPA analysis, this novel 
interaction as well as its role in the mTOR pathway could be of interest in order 
to identify alternate signalling pathways that are dysregulated in PC.  
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5.4 Discussion 
5.4.1 Suppression of DHX9 leads to cell death 
Cancer cells are reliant on the cell’s transcriptional machinery for protein 
synthesis and translation of specific mRNA that promote tumour cell survival. 
Therefore, targeting this machinery has increasingly become a potential new 
target for cancer therapies. DHX9, as well as other members of the DEAD/H 
helicases, are involved in almost all steps of RNA metabolism and this process is 
thought to mediate oncogenic transformation of cancer cells (Heerma van Voss, 
van Diest and Raman, 2017). DHX9 thus may play a critical role in cellular 
metabolism and in cellular proliferation / neoplastic transformation (Fuller-
Pace, 2013).  
Part of this chapter’s aim was to understand how DHX9 influences the 
proliferation of PC cells. When expression of DHX9 was knocked down using 
siRNA in AS and AI PC cell lines, proliferation of these cells was significantly 
affected (Figure 5.2 and Figure 5.5). Interestingly, this effect was most 
significant in the AI cell line highlighting the importance of DHX9 in promoting 
oncogenic growth. The loss of cancer cell proliferation can be partially explained 
by the potential activation of p53. P53 is a nuclear transcription factor and is 
known to activate numerous target genes involved in the induction of cell cycle 
arrest and apoptosis. In conditions where DNA damage is detected, p53 is 
activated and induces the activation of the pro-apoptotic pathway (Ozaki and 
Nakagawara, 2011). Suppression of DHX9 has been shown to lead to changes in 
cell cycle and DNA damage response protein expression. Suppression of DHX9 in 
MRC-5 cells resulted in a moderate increase in p53 expression. Interestingly, 
senescence was not induced in MRC-5 cells where both DHX9 and p53 expression 
were suppressed (Lee et al., 2014). However, when repeated in p53 null mice 
and cell lines, DHX9 suppression led to cell death (Lee and Pelletier, 2017). 
Decreased proliferation of DUCaP and LNCaP cells in our experiments after 
knock-down of DHX9 may be due to the activation of the p53 pathway. Both 
DUCaP and LNCaP cells are known to express p53 (van Bokhoven et al., 2003; 
Chappell et al., 2012), providing a potential mechanism to explain why a 
decrease in cell proliferation was observed in PC cells. The DHX9-p53 “pathway” 
may be a potential new target for drug development. In cases where classic 
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chemotherapy targeting the p53 pathway is no longer a feasible option, p53-
deficient cells expressing functional DHX9 can be a possible new target to 
suppress tumour growth (Lee and Pelletier, 2017). In order to confirm that this 
was the case, expression levels of p53 could be investigated by western blotting. 
Previous work by Lee et al (2017) showed that the suppression of DHX9 led to an 
increase in expression of p53 as well as its downstream effector protein (Lee and 
Pelletier, 2017). 
5.4.2 YK-4-279 significantly inhibits cell growth in AS cell lines 
YK-4-279 has quickly emerged as a new small molecule drug that can specifically 
target the oncogenic fusion protein EWS-FL1. This fusion protein is only 
expressed after chromosomal translocation, making it specific to tumour cells 
and a potential new therapeutic target in Ewing’s Sarcoma. YK-4-279 can block 
the interaction of DHX9 and EWS-FL1 in ESFT cell lines, leading to a decrease in 
cell growth. Since its initial discovery in 2009, YK-4-279 has the potential to 
become a new therapeutic agent to target cancers that are known to express 
ERG fusion proteins, such as PC or Ewing’s Sarcoma (Erkizan et al., 2009). 50-
70% of prostate tumours are characterised by the expression of ETS gene fusion 
proteins, with the most common one being the TMPRSS2-ERG fusion which occurs 
in 50% of tumours. Fusion proteins involving other members of the ETS gene 
family, such as FL1, have only been identified in less than 2% of cases (Kedage et 
al., 2016). Currently, ETS transcription factors are grouped into four classes (I-
IV) according to their sequence homology (Poon and Kim, 2017). FL1 and ERG are 
both part of Class I ETS factors and share more than 80% homology in their amino 
acid sequences. In this chapter, I show that disruption of the interaction 
between DHX9 and EWS-FL1, using YK-4-279, leads to a significant decrease in 
LNCaP proliferation. At the highest concentrations (10 µM and 1µM), YK-4-279 
was shown to almost immediately alter cell growth (Figure 5.6). Although I did 
not investigate if LNCaP expresses the EWS-FL1 protein, YK-4-279 has previously 
been used to study how this drug can affect the efficacy of docetaxel in the 
treatment of PC (Yu et al., 2017). Treatment of these cells with 10 µM and 1µM 
of drug led to a 75% decrease in the maximum cell index. My data suggests that 
the interaction between EWS-FL1 and DHX9 is required for oncogenic cell growth 
in LNCaP cells, and disruption of this interaction retards cellular proliferation. 
When repeated in the AI cell line (DU145), growth was not affected (Figure 5.7) 
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as they do not naturally express ETS fusion proteins (Swanson et al., 2011). My 
data and conclusion are supported by the 2011 study by Rahim et al. who also 
looked at the effects of YK-4-279 on PC cells lines. YK-4-279 reduced the 
motility of PC lines in a scratch test as well as inhibiting the invasive nature of 
LNCaP cells. When the AI cell line PC3 was treated with YK-4-279, they remained 
unresponsive as they do not express ETS fusion proteins (Rahim et al., 2011). 
This result was very similar to that reported in my thesis as I provide more 
evidence showing how YK-4-279 is dependent on the expression of ETS fusions 
proteins and inhibits the growth of LNCaP cells (Figure XX?).  
YK-4-279 has the potential to become a new inhibitor of ETS-positive PC growth 
and metastasis. This small molecule has already been shown to be effective in 
slowing down the growth of primary tumours in mouse xenograft models (Rahim 
et al., 2011). Severe combined immunodeficient mice (SCID) were 
subcutaneously transplanted with ETS fusion positive LNCaP and fusion negative 
PC3. These animals were then treated with YK-4-279, and primary tumour 
growth was evaluated. Treatment with YK-4-279 resulted in a decrease in the 
growth of primary tumours only in LNCaP-transplanted mice. Interestingly, YK-4-
279 also inhibited metastasis to the lungs in these mice, indicating that this 
small molecule could be a powerful new therapeutic tool for treatment of PC at 
different stages of disease (Rahim et al., 2014). Interestingly, when YK-4-279 
was administered to SCID mice subcutaneously inoculated with lymphoma cells, 
this did not alter tumour volume, but the drug itself was well tolerated by all 
mice (Chung et al., 2017). Recent work by Yu et al (2017) suggested that YK-4-
279 can also be used as a combination therapy with docetaxel. The 
chemotherapeutic agent docetaxel is currently the first line treatment for CRPC 
patients. However, it is currently used as a monotherapy and is associated with 
high toxicity and resistance. Yu et al. has shown that YK-4-279 may have a 
synergistic effect with docetaxel. LNCaP cells were treated with low-dose 
docetaxel and YK-4-279, and the combination of these two drugs significantly 
decreased the expression of AR, PSA and ETV1. The use of YK-4-279 and 
docetaxel could permit the decrease in docetaxel dose necessary for patients 
with CRPC and lower its toxicity (Yu et al., 2017). However, this would limit the 
treatment to tumours that are known to express the EWS-FL1 fusion protein.  
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As YK-4-279 has the potential to become the next cell growth inhibitor, 
alternative PPI disruption strategies need to be investigated in order to find 
alternative targets to inhibit growth. This is clear from my data, which shows 
that DU145 cells did not react to YK-4-279 as there was no change in cell 
growth. Other protein complexes could be targeted to halt AI PC cell growth. 
5.4.3 Disruption of the PDE4D7-DHX9 complex does not change 
cell growth, but affects DHX9 activity 
Due to the success of YK-4-279, a small molecule PPI inhibitor, we were 
interested to determine if the interaction between PDE4D7-DHX9 is crucial for 
cell growth. Previous work by Henderson et al. (2014) showed that PDE4D7 
mediates the proliferation of PC cells. Using a dominant-negative approach, wild 
type PDE4D7 was displaced from endogenous anchoring sites and this resulted in 
an accumulation of cellular cAMP. Expression of the catalytically inactive 
PDE4D7 also led to an increase in cellular proliferation, a result that was 
confirmed using siRNA-mediated knockdown of global PDE4D7. Suppression of 
PDE4D7 was found to lead to an increase in the rate of proliferation. 
Interestingly, re-expression of PDE4D7 in AI PC3 cells lead to a significant 
decrease in proliferation (Henderson et al., 2014). In this chapter I show that 
displacement of PDE4D7 from DHX9 using our new cell penetrating peptides does 
not affect LNCaP proliferation (Figure 5.8). Both UCR1- and DHX9-directed 
peptides significantly increased the normalised cell index two hours after 
treatment when compared to the scrambled peptide (Figure 5.10), indicating 
that the disruption of this interaction leads to a short-term increase in 
proliferation when compared to the scrambled peptide control. However, this 
did not lead to a change in cellular proliferation over the following three days. 
Unlike YK-4-279, our new cell penetrating peptides did not lead to an overall 
change in cell growth suggesting that the interaction between PDE4D7-DHX9 is 
not crucial for cell growth. 
However, the disruption of the interaction between PDE4D7-DHX9 leads to a 
significant decrease in DHX9 activity as shown by the R-loop staining (Figure 5.12 
and Figure 5.14). R-loops are transient, reversible structures that form in many 
parts of the genome. These structures facilitate transcription by regulating DNA 
methylation, which then promotes or inhibits gene expression (Crossley, Bocek 
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and Cimprich, 2019; Hegazy, Fernando and Tran, 2019). R-loops are generally 
formed during transcription. As the RNA polymerase moves along the DNA double 
helix, the newly formed RNA strand threads back to hybridise with the 
transiently accessible template strand and this displaces the non-template 
strand, which can be between 100-200 base pairs in length (Figure 5.19) (Allison 
and Wang, 2019). R-loops are generally formed by RNA polymerase II transcribing 
a cytosine (C)-rich template so that a guanine (G)-rich transcript is generated, 
and initial formation of this structure is favoured by G clusters and DNA nicks 
downstream from the promoter of the non-template strand (Skourti-Stathaki and 
Proudfoot, 2014). Once formed, R-loops are thermodynamically stable due to 
the formation of G quadruplexes formed in the single-stranded exposed RNA 
strand (Skourti-Stathaki and Proudfoot, 2014). Currently, the most widely used 
antibody to detect and understand R-loops is the monoclonal hybrid-specific S9.6 
antibody (Boguslawski et al., 1986; Niehrs and Luke, 2020). Genomic instability 
remains one of the hallmarks of cancer with replication stress and genome 
instability contributing to cancer development. Inappropriate accumulation of R 
loops is thought to play a role in a number of human cancers (Richard and 
Manley, 2017).  
 
Figure 5.19 Model of R-loop formation and suppression. R-loops form during transcription 
when a nascent RNA hybridizes with DNA, generating and DNA-RNA hybrid. R-loops are 
suppressed by splicing factors which coat the nascent RNA structure, allowing for progression of 
transcription. Currently, DHX9 is thought to resolve these structures, releasing the nascent RNA for 
processing. (Figure taken from Crossley, Bocek and Cimprich, 2019).  
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Recent work by Chakrabortty et al (2018) showed that defects in the SFPQ 
splicing factor can cause R-loop formation and DNA replication stress. Defects in 
RNA splicing factors leads to an increase in genomic instability due to the 
formation of R-loops. Using siRNA technology, they observed that loss of SFPQ 
expression led to a significant increase in R-loops staining using the S9.6 
antibody. They then showed that expression of DHX9 is needed to promote the 
formation of R-loops. In cells that are defective for splicing factors, such as 
SFPQ, formation of R-loops is dependent on DHX9 as shown by the significant 
increase in S9.6 staining (Chakraborty, Huang and Hiom, 2018). However, this 
concept is directly opposed to that published by others in the field. Other 
researchers have proposed that DHX9 is required for the suppression of R-loops. 
Work by Cristini et al (2018) initially identified DHX9 as one of the main proteins 
involved in the suppression of R-loop formation. DHX9 was shown to interact 
with R-loops by IP, and this interaction was shown to be reduced following 
treatment with a transcriptional inhibitor. By using DNA/RNA IPs, they were able 
to investigate how this interaction could affect the transcription of the β-actin 
and γ-actin genes in HeLa cells following siRNA transfection. This experiment 
revealed that the loss of DHX9 expression lead to an accumulation of R-loops 
within the transcription termination region of each gene when compared to the 
control siRNA condition. They suggested that the normal expression of DHX9 
promotes the suppression of R-loops formed within the genome, allowing for 
successful gene transcription termination. Suppression of DHX9 within these cells 
also led to an accumulation of read-through transcripts, which results from 
continuous transcription of adjacent genes (Pintarelli et al., 2016), due to the 
increased presence of R-loops at the termination region (Cristini et al., 2018). 
Unlike Chakrabroty et al (2018), Cristini et al. (2018) conclude that DHX9 is 
needed to supress R-loop formation within the genome in order to limit R-loop 
associated DNA damage (Cristini et al., 2018). 
Using the newly developed method by the Hiom lab outlined above, we wanted 
to understand if the interaction between PDE4D7-DHX9 could modulate DHX9 R-
loop formation. This work was carried out in collaboration with Prof Kevin 
Hiom’s laboratory at the University of Dundee where I undertook a placement. 
My data (Figure 5.12 and Figure 5.14) showed that the disruption of PDE4D7-
DHX9 using our cell penetrating peptides resulted in a significant decrease in 
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DHX9 activity with respect to R-loop formation (Figure 5.14). My conclusion is 
that the interaction between DHX9-PDE4D7 is essential for DHX9 to resolve 
secondary structures in RNA. As such, when this interaction is interrupted by our 
custom peptides and with siRNA targeting PDE4D7, DHX9 is no longer able to 
resolve secondary structures in the nascent RNA, inhibiting R-loop formation. 
When LNCaP cells were treated with siRNA against SFPQ alone, this led to a 
significant increase in S9.6 staining in the nucleus as DHX9 is able to unwind 
abnormal RNA structures (Figure 5.12 B and Figure 5.20 B). However, when the 
cells were depleted for SFPQ and treated with the UCR1 cell penetrating 
disruptor peptide, S9.6 staining significantly decreased and was comparable to 
the level of staining in the non-targeting siRNA control (Figure 5.12 E and F, 
Figure 5.20 C). This effect was also observed in cells treated with the DHX9 
peptide and siRNA against PDE4D7 (Figure 5.12 C). My data further supports the 
idea that normal DHX9 expression is required in the formation to RNA-DNA 
hybrids as the protein can resolve secondary structures in the nascent RNA 
strand.  
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Figure 5.20 DHX9 promotes the generation of R-loops. A. Formation of R-loops in cells with 
impaired splicing factors can be due to a prolonged association of DHX9 with RNA Pol II during 
transcription. In normal cells, DHX9 can bind to RNA Pol II during the early phases of transcription, 
but this interaction in absent during elongation. The dissociation of DHX9 from RNA Pol II is 
dependent on the presence of SFPQ. SFPQ stabilizes the nascent RNA strand, preventing the 
formation of secondary structures. B. In the absence of these splicing factors, DHX9 remains 
bound to the transcription complex where it can then bind to the nascent RNA strand. These RNA 
strands are then able to invade DNA duplexes where it can form RNA-DNA hybrids. C. In cells 
deficient for splicing factors and decreased DHX9 activity, the nascent RNA remains in its 
secondary structures, leading to a decreased in RNA-DNA hybrid. Figure is adapted from 
Chakraborty, Huang and Hiom, 2018.  
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As previously mentioned, the role that DHX9 plays in R-loop formation is 
controversial as several groups have suggested that DHX9 promotes the 
suppression of R-loops in cells. Work by Cristinin et al. (2018) showed that DHX9 
directly binds to these DNA-RNA hybrids and promotes the suppression of R-
loops. DHX9 was also shown to be important in maintaining genome stability in 
response to camptothecin, a topoisomerase inhibitor, by preventing the 
accumulation of R-loops in the genome (Cristini et al., 2018). Additionally, DHX9 
has been identified as a protein that is involved in preventing and suppressing 
the formation of R-loops (Skourti-Stathaki and Proudfoot, 2014). Here we show 
that the interaction between PDE4D7-DHX9 is required in the formation of R-
loops as the loss of this interaction is detrimental to DHX9 activity. Although it 
was not investigated here, the R-loop assay developed by the Hiom lab would 
have allowed us to understand how the inhibition or activation of these different 
pathway could affect DHX9 activity. LNCaP could have been treated with an 
array of inhibitors or activators, such as enzalutamide or rapamycin, and DHX9 
activity could be assessed using this assay. This would have allowed us to 
understand how these different pathways can affect DHX9 activity. 
The assay developed by the Hiom Lab, although effective, also presents with its 
own limitations. The main limitation is the reliance on the levels of SFPQ 
expressed in the cells. Although we have been able to show that SFPQ expression 
can be reduced in LNCaPs, the expression of this protein was very low to start 
with. Furthermore, the relationship between DHX9 and R-loops remains 
controversial between lab groups. Therefore, other methods need to be used in 
order to determine whether or not PDE4D7 does in fact have a role in regulating 
DHX9 activity. One such assay is the helicase assay, which has been previously 
used to show that DHX9 unwinds triplex DNA. This assay requires full length 
purified DHX9 protein and DNA substrates that have the ability to form triplex 
structures. DHX9 activity can be measured by the extent of strand displacement 
from the triplex DNA substrates. Briefly, purified DHX9 protein is incubated with 
5 nM of specific DNA substrate in assay buffer containing DTT and ATP. The 
reaction is then placed in a temperature-controlled PCR machine at 32˚C for 20 
minutes. The products can then be resolved by DNA agarose gel electrophoresis 
(Jain et al., 2010, 2013). This method could potentially be modified in order to 
investigate if the interaction of PDE4D7 increases the helicase activity of DHX9. 
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We can also potentially hyper-phosphorylate DHX9 in order investigate how PKA 
phosphorylation alters its activity. Although this assay would be considered as an 
in vitro assay, it may be more accurate and reliable than the R-loop assay used 
in this chapter. The helicase assay was initially considered as a method to 
evaluate DHX9 activity in my thesis; however due to the complex nature of the 
purification of full length DHX9, we were unable to perform this assay. Full 
length protein is required for this assay as the HA2 region of DHX9 is required for 
helicase activity. Commercially available protein was therefore not an option as 
these only sold truncated versions of the protein.  
5.4.4 p70 S6 Kinase P Thr389 in prostate cancer 
RPPA based analysis has increasingly become a useful and highly efficient tool to 
quantify protein analytes with high precision, sensitivity, throughput and 
robustness. Due to its large antibody database, RPPA can assess a large number 
of proteins in many samples in a cost-effective and sensitive matter (Akbani et 
al., 2014). Recently, the Cancer Genome Atlas group has employed this 
technology to characterise patients samples across a broad range of cancers, 
generating expression data of over 200 total and phosphorylated protein markers 
in major signalling pathways (Li et al., 2017). Using RPPA, we were able to show 
that the levels of p70 S6 Kinase pThr 389 increases in DU145 cells with 
suppressed expression of DHX9. As total levels of p70 S6 kinase remained 
unchanged in the experiment, the data suggests that DHX9 may have a role in 
regulating p70 S6 kinase activity via its phosphorylation (Figure 5.17 and Figure 
5.18).  
p70S6K is a 85 kDa ribosomal protein that is a member of the AGC subfamily of 
serine/threonine protein kinases (Bahrami-B et al., 2014). AGC kinases include 
more than 60 proteins in the genome and this group is highly expressed in 
eukaryotic cells. AGC kinases are involved in diverse cellular functions and have 
become potential targets in human diseases such as cancer. The AGC kinase was 
named after 3 representative families: the cAMP dependent PKA, the cGMP 
dependent protein kinase G (PKG), and protein kinase C (PKC) (Arencibia et al., 
2013). For many AGC proteins, activation requires the phosphorylation of two 
highly conserved regulatory motifs. This includes the activation segment, which 
can be located in the protein’s catalytic domain, and the hydrophobic motif, 
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which is found in a non-catalytic region following the kinase domain (Pearce, 
Komander and Alessi, 2010) (Figure 5.21).  
 
Figure 5.21 Domain structures of p70 S6 Kinase. P70SK contains an acidic N-terminal region, a 
kinase domain, a linker region, and an acidic C-terminal region. Figure taken from Magnuson, Ekim 
and Fingar, 2011. 
In recent years, efforts have been made to map to the interactome of p70S6K 
involved in the regulation of multiple cellular processes. These newly identified 
interactors could represent new regulators or targets of p70S6K, furthering the 
understanding of this family of kinases. Such efforts have revealed that DHX9 is a 
novel interactor of p70S6K, and can potentially regulate its activity (Pavan et 
al., 2016). Our data suggests that DHX9 could play an important role in 
regulating the phosphorylation of p70SK. Knockdown of DHX9 using target 
specific siRNA revealed that levels of phosphorylation of p70S6K at Thr389 were 
increased in both our RPPA and western blot analysis. This is further supported 
by levels of total p70S6K remaining unchanged in the RPPA analysis after DHX9 
suppression. Interestingly, an increase in the levels of 4E-BP1 pSer 65 was also 
observed. These two proteins are both downstream effectors of the mammalian 
target of rapamycin (mTOR) complex 1 (mTORC1). Activation of mTORC1 results 
in the phosphorylation of 4E-BP1 and p70S6K which results in the initiation of 
protein synthesis (Choo et al., 2008). 
The mammalian target of rapamycin (mTOR) is a an evolutionarily conserved 
phosphatidylinositol 3-kinase (PI3K)-related Ser/Thr kinase that can integrate 
signals from nutrients, energy sufficiency, and growth factors to regulate cell 
growth as well as organ and body size. mTOR forms two distinct complexes, 
complex 1 which is rapamycin sensitive and complex 2 which is insensitive 
(Julien et al., 2010). Currently, the most accepted models is that mTOR complex 
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1 phosphorylates p70S6K hydrophobic motif at Thr 389, and the process can be 
reversed by rapamycin (Zhang et al., 2019) (Figure 5.22 panel A). P70S6K is one 
of the predominant effectors of the mTOR complex 1, and this pathway is known 
to play an important role in regulating protein synthesis, cell growth, 
metabolism, and aging (Laplante and Sabatini, 2009; Doscas et al., 2014).  
 
The mTORC1 substrate 4E-BP1, which is unrelated to p70S6K, inhibits translation 
by binding and sequestering the translation initiation factor eIF4E to prevent the 
formation of the eIF4F complex (Saxton and Sabatini, 2017). When 4E-BP1 is 
phosphorylated at serine 65 by mTOR complex 1, it no longer sequesters eIF4E, 
allowing formation of the eIF4F complex initiating cap-dependent translation. 
When mTORC1 is inhibited, 4E-BP1 becomes dephosphorylated, increasing its 
affinity for eIF4E (Sun et al., 2019). Interestingly, DHX9 has recently been shown 
to be recruited by mTOR to a 5’mRNA cap structure following its activation. 
DHX9 was shown to assist eIF4A in the unwinding of secondary structures with 
the 5’UTR of mRNAs (Nandagopal and Roux, 2015). In recent years, mTOR 
signalling has been shown to be dysregulated during disease progression. 
Upregulation of mTOR signalling can promote tumour growth and progression 
through multiple mechanisms (Hua et al., 2019). mTOR has specifically been 
implicated in PC metastasis via the regulation of HIFα and the inhibition of 
transforming growth factor β1 (TGFβ1) (Kremer et al., 2006). Furthermore, 
PDE4D has recently been shown to be regulate mTORC1 transcriptional activity 
via Rheb. mTORC1 is a direct substrate of Rheb, a small GTPase. The direct 
binding of Rheb and mTORC1 allows for the activation of mTORC1 and activates 
pathways that are downstream of this activation (Long et al., 2005). Under basal 
conditions, PDE4D binds to Rheb which in turn inhibits activation of the pathway. 
However, when cAMP levels are elevated, the interaction between PDE4D and 
Rheb is disrupted, inducing activation of mTORC1 and cap-dependent translation 
(Kim et al., 2010). This could potentially mean that in late stage disease, where 
global PDE4D expression is low, disease progression could be initiated through 
mTORC1-p70S6-RHEB1 pathway. Our data suggests that the suppression of DHX9 
in DU145 cells would potentially lead to an increase in translational activity via 
the mTORC1 pathway. Human mRNA translation requires DHX9 for folding / 
unfolding within their 5’UTR region. If these remain unresolved, the mRNA is 
unable to be read by ribosomal structures and inhibits the translation of 
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downstream open reading frames (Murat et al., 2018). It can therefore be 
proposed that the normal expression of DHX9 is required to maintain normal 
protein expression as well as PC progression. Suppression of DHX9 can then lead 
to the accumulation of mRNA structures leading to the formation of aggregates 
in the cell (Figure 5.22 panel B). These aggregates create stress granules, and 
can potentially initiate the apoptotic pathway and decrease cellular 
proliferation (Khong et al., 2017; Falcone and Mazzoni, 2018). 
 
Figure 5.22 Schematic diagram illustrating the proposed interaction between DHX9 and the 
mTOR pathway. A. Activation of mTOR pathway leads to the phosphorylation of p70 S6 Kinase at 
threonine 389 and of 4E-BP1 at serine 65. DHX9 is also recruited to the pathway, and these three 
proteins promote the initiation of translation, allowing for cell growth and proliferation. B. Here, we 
propose that the decreased expression of DHX9 leads to an increase in phosphorylation of p70 S6 
Kinase at threonine 389 and of 4E-BP1 at serine 65. Translation is still able to occurs, but due to 
the absence of DHX9, secondary RNA are not resolved and this leads to the accumulation of RNA 
that cannot be correctly translated into protein. This can then lead to the formation of stress 
granules and cell death. (Laplante and Sabatini, 2009; Pavan et al., 2016; Khong et al., 2017) 
Various in vitro models have been used in PC in order to understand the 
mechanisms that leads to treatment resistance and disease progression. DU145 
was once considered as the “gold standard” of PC cell lines. DU145 was first 
isolated from a brain metastatic prostate tumour, and no longer expresses mRNA 
or protein for AR or PSA. This observation has since cast doubts on this cell line 
as a true model for PC (Cunningham and You, 2015). Due to the absence of AR, 
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this cell line is most commonly used as an AR- control or to study AR singling by 
ectopic expression (Sampson et al., 2013). Most PC tumours still express AR, 
further supporting the idea that DU145 is not a true representation of late stage 
PC (Heinlein and Chang, 2004). As such, in order to ensure that the mTOR-DHX9 
signalling axis is worth investigating, this RPPA should be repeated in other PC 
cell lines such as VCaPs or PC3. If RPPA results in these other cell lines indicate 
that the same signalling axis is altered, then further work on how PDE4D7-DHX9 
is involved in this pathway should be carried out.  
Although RPPA remains a very useful tool in cancer biology, it can only look at 
changes in protein levels. However, DHX9 is involved in RNA processing, 
biogenesis and processing. Increasing evidence has shown that different RNA 
markers are differentially expressed in PC and such is the case with circular RNA 
(cRNA). cRNA are a novel type of non-coding RNA (ncRNA) which can regulate 
the function of microRNA (miRNA), and can play a key role in the development 
of drug resistance in PC (Greene et al., 2019). Furthermore, long-noncoding RNA 
(lncRNA) are known to bind to DHX9 and mediate cell invasion and angiogenesis 
of cervical cancer (Ding et al., 2019). These two types of ncRNA have important 
functional roles and are frequently dysregulated in PC. There is evidence 
showing that these RNAs are responsible for oncogenesis and tumour progression 
(Hua, Chen and He, 2019). It would be interesting to investigate if the 
suppression of DHX9 could also alter the levels of ncRNA or cRNA in PC cell lines 
or patient samples. These changes could indicate which ncRNA plays a critical 
role in the progression of PC, potentially revealing new drug targets of DHX9 
interactors. Unfortunately, RPPA does not have the ability to look at levels of 
RNA, therefore other approaches such as RNA-Sequencing could be used to look 
at changes in RNA levels due to decreased DHX9 expression.  
5.4.5 Chapter Summary  
The data presented in this chapter has provided further support to the current 
literature. I have shown that reduced expression of DHX9 in PC cell lines leads to 
a decrease in cellular proliferation. This supports the idea that DHX9 can be 
considered an oncogenic protein, and its increased expression in late-stage 
cancers further promotes disease progression. Disruption of the interaction 
between EWS-FL1-DHX9 also leads to very significant decrease in cell growth, 
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however this was not seen in the fusion negative cell line DU145. YK-4-279 has 
the potential to be a successful drug in treating fusion positive tumours and 
slowing the progression of disease. Unfortunately, our novel disruptor peptides 
targeting the interaction between PDE4D7-DHX9 did not have the same effect as 
YK-4-279, and instead showed that this interaction is not essential for cell 
growth or a viable target to slow down disease. Instead, this interaction has 
been shown to be important in DHX9’s helicase activity. Disruption of PDE4D7-
DHX9 interaction significantly reduced R-loop formation in cells that are 
deficient for splicing factors. This was also observed in cells that were co-
treated with siRNA against PDE4D7. In order to confirm that this was the case, 
alternative DHX9 helicase activity assays need to performed using purified 
protein. Our RPPA analysis confirmed that DHX9 plays an important role in the 
mTORC1 signalling pathway, and PDE4D isoforms plays a role in regulating the 
activation of this pathway. Increasing evidence has implicated this pathway in 
the progression of disease, and DHX9 is known to be recruited by mTOR to 
mediate 5’UTR cap dependent translation. However, further validation in AS cell 
lines is needed in order to confirm that the pathways affected in DU145 is also 
seen in either LNCaP or VCaP. If the mTOR pathway in both these cell models is 
affected by DHX9 knockdown, this could be a potentially new pathway to 
investigate.  
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Chapter 6 Final Discussion 
6.1 DNA/RNA helicases in PC 
RNA/DNA helicases are ubiquitous enzymes that are involved in many different 
aspects of nucleic acid function. They utilise energy, derived from the hydrolysis 
of ATP, to unwind abnormal DNA or RNA structures such as R-loops. Due to the 
importance of helicases in different cellular functions, mutations in these 
helicases are linked to hereditary diseases or associated with various cancers 
(Datta and Brosh, 2018). Changes in expression levels, mutations in human 
tumours, and roles in different signalling pathways that alter tumour growth are 
all ways in which cancerous cells utilise helicases in order to initiate disease 
(Robert and Pelletier, 2013).  
In recent years, members of the DExD/H and DEAD helicase family have emerged 
as having a role in the progression of PC. DDX5, also known as p68, has recently 
been shown to be a novel AR transcriptional co-activator that is overexpressed in 
PC (Clark et al., 2008). DDX5, like DHX9, is an RNA-dependent ATPase capable of 
unwinding abnormal RNA structures (Dai et al., 2014). DDX5 is thought to be 
involved in cellular proliferation and early organ maturation, as well as 
transcriptional regulation of multiple genes. Like DHX9, it is mainly expressed in 
the nucleus, but can be shuttled in and out of this compartment via RanGTPase-
dependent pathways (Wang et al., 2009). DDX5 was identified as a novel 
interactor of AR by yeast-two-hybrid screening by Clark et al. (2003). This 
interaction was further verified by ICC and IPs in LNCaP. Interestingly, DDX5 was 
found to contain the LXXLL motif that can be seen in cofactors that interact with 
hormone receptors. The LXXLL motif is a multifunctional binding sequence that 
participates in several protein-protein interactions between transcription factors 
and their cofactors. This binding sequence mediates these interactions in order 
to activate or repress the transcription of specific genes (Plevin, Mills and Ikura, 
2005). DDX5 was found to contain this motif between amino acid 146 and 150. 
Using chromatin-immunoprecipitation (ChIP) assays, DDX5 was shown to interact 
with AR at ARE within the promoter and enhancer regions of the PSA gene. This 
interaction at the ARE region was enhanced following prolonged activation of 
the AR by androgens. Suppression of DDX5 using siRNA technology reduced the 
expression of PSA and AR mRNA and protein, indicating the DDX5 is an important 
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co-activator of AR mediated gene expression. DDX5 expression was also seen to 
be increased when compared to benign tissue (Clark et al., 2008).  
In addition to DDX5, DHX15 is also known to be involved in PC. DHX15 is another 
member of the DExD/H helicase family and shares many of the same functions as 
DHX9. Additionally, DHX15 mediates the innate immune system in sensing of 
viral RNA (Murakami et al., 2017). DHX15 was identified as another AR co-
activator, and this interaction is required to regulate AR activity by modulation 
E3 ligase Siah2 AR ubiquitination (Jing et al., 2018). The E3 ligase Siah2 is 
thought to target chromatin-bound inactive AR, which in turn can regulate the 
expression of genes that control growth, survival, and tumorigenic abilities of PC 
cell (Qi et al., 2013). Work by Jing et al (2018) has shown that DHX15 promotes 
the binding of Siah2 to the AR, which in turn regulates its ubiquitination. DHX15 
was found to stabilize the interaction between Siah2 and AR, allowing for the 
activation of AR transcriptional activity (Jing et al., 2018). Furthermore, DHX15 
expression was found to be upregulated in CRPC samples. This increased 
expression was suggested to be protective towards these CRPC cells. Using a 
CRPC cell line model, the knockdown of DHX15 using siRNA technology reduced 
AR sensitivity to DHT and inhibited cell growth as well as increasing sensitivity to 
enzalutamide. Increased DHX15 could contribute to PC progression into CRPC (Xu 
et al., 2019).  
Many parallels between DDX5, DHX15, and DHX9 can be found. Data in this thesis 
has shown that the expression of DHX9 was increased in DU145 cells, which is 
currently used as a model for late stage disease (Figure 3.1). Multiple studies 
have shown that DHX9 is required for the appropriate expression of multiple 
genes via its interaction with different transcription factors (Lee and Pelletier, 
2016). Like DHX15, DHX9 could potentially play a role in regulating AR activity by 
modulating the interaction of AR with different co-activators. This could be the 
case with CBP. CBP is known to be a co-activator of AR, and this interaction is 
thought to play a role in prostate tumorigenesis. CBP alters chromatic 
structures, allowing for the binding of transcription factors such as AR (Debes et 
al., 2005). CBP is also known to form a complex with RNA polymerase II and 
DHX9 in order to mediate the targeting of genes activated by CREB (Nakajima, 
Uchida, Anderson, et al., 1997). It could be possible that these three proteins 
could form a complex within the nucleus in order to promote the expression of 
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different ARE genes that could promote the progression of disease. Increased 
expression of DHX9 could further promote such activities. Owing to the highly 
conserved nature of the DExD/H helicase family (Jankowsky, 2000), it can be 
proposed that DHX9 could potentially interact with AR. Interestingly, a study 
conducted by Heemers et al (2009) has identified DHX9 as a coregulator of AR 
activity. By using a cDNA-mediated annealing, selection, extension, and ligation 
(DASL) RNA profiling array, a tool designed to monitor gene expression from 
tissues or cells, they were able to identify DHX9 as a coregulator of AR in LNCaP 
cells. However, treatment with R1881, a synthetic form of androgens, did not 
change DHX9 expression after 48 hours (Heemers and Tindall, 2007). 
Furthermore, recent work by Chen et al (2020) has shown that although the AR 
has a role in regulating the expression of multiple RNA editing genes, AR was not 
reported to alter DHX9 mRNA expression in cells (Chen et al., 2020). Although 
these studies indicate that DHX9 can act as a coregulator of AR, no studies have 
further investigated whether DHX9 activity it required for AR’s transcriptional 
activity. DHX9 has often been described as a transcriptional coactivator that acts 
a bridging factor between transcription factors (Fuller-Pace, 2006). As DHX9 
expression increases at later stages of disease, it could potentially act as a co-
activator of AR transcription despite low levels of circulating androgens.  
6.2 PDE4D7 regulates DHX9 phosphorylation and helicase 
activity 
Experimental work reported in this thesis has provided extensive evidence that 
PDE4D7 and DHX9 are novel interactors in prostate cancer. By using extensive 
biochemical and peptide array techniques, not only was I able to show that the 
two proteins were interacting (Figure 3.6-3.9), but I was able to map where this 
interaction took place (Figure 3.11 and 3.16). DHX9 binds within the UCR1 
domain of PDE4D7, and this binding site contains the previously reported FLY 
PDE4 multi-docking site. On the other hand, PDE4D7 binds within the helicase 
core domain of DHX9, downstream of Ser449 that is readily phosphorylated by 
PKA (Figure 4.1). Treatment of HEK293 and PC cells with the UCR1 disruptor 
peptide led to a reduction in PDE4D7-DHX9 interaction (Figure 3.19 and 3.21). 
This interaction could potentially take place in the nucleus due to the expression 
of NLS in both proteins (Figure 3.5, Lee and Pelletier, 2016). Bioinformatic 
analysis showed that PDE4D7 potentially has a novel NLS sequence between its 
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linker and UCR2 domain (Figure 3.5), whereas DHX9 is known to have an NLS/NES 
sequence within its C-terminal domain (Lee and Pelletier, 2016; Ng et al., 2018). 
Interestingly, this loss of interaction also leads to an increase in DHX9 
phosphorylation by PKA under basal conditions (Figure 4.12) as well as a 
decrease in DHX9’s helicase activity (Figure 5.13). This could be due to the 
sequestering of phosphorylated DHX9 in the cytoplasm (Figure 4.10), inhibiting 
its ability to unwind nascent mRNA  that are found within the nuclear region, 
therefore decreasing R-loop formation. 
Modulation of RNA structures by members of the DExD/H family of helicases is a 
crucial step for many fundamental cellular processes (Sheng et al., 2006). In 
addition to their important cellular roles, subtle changes in their shape or 
activity can result in altered development, uncontrolled growth, or adaptation 
to environmental changes (Linder and Fuller-Pace, 2013). Therefore, it is 
important that these helicases are appropriately regulated via PTMs. Based on 
the data presented in this chapter, PKA phosphorylation of DHX9 could act as a 
negative regulator of its helicase activity within the nucleus owing to its 
translocation into the cytoplasm. It can be suggested that PKA phosphorylation 
has a role in modulating DHX9’s subcellular location and PDE4D7 prevents DHX9 
accumulation in the cytoplasm. Such protective interactions have been seen in 
the NF-κB signalling pathway. NF-κB is a family of transcription factors that 
plays an important role in inflammation, immunity, cellular proliferation, 
differentiation and survival. PKA is known to phosphorylate the NF-κB protein 
p65 in order to increase its transcriptional activity (Oeckinghaus and Ghosh, 
2009). However, PKA phosphorylation of NF-κB has also been shown to regulate 
its ability to translocate into the nucleus. Recent work by King et al (2011) has 
shown that the complex between A kinase interacting protein 1 (AKIP1), the 
catalytic PKA subunit (PKAc), and p65 regulates the rate at which p65 
translocates to the nucleus. P65 was found to be phosphorylated at Ser276, and 
inhibition of its ability to be phosphorylated by PKA by creation of a phospho-
null mutant lead to the accumulation of p65 in the nucleus. Furthermore, 
increased nuclear expression of p65 was observed when PKAc expression was 
suppressed using siRNA technology. This translocation was found to be mediated 
by AKIP1, where PKAc overexpression in cells resulted in increased expression of 
p65 in the nucleus. It was suggested AKIP1 protects p65 from PKA 
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phosphorylation, allowing p65 translocation into the nucleus and act as a 
transcription factor (King et al., 2011).  
Interestingly, the same observation was made in this thesis. The worked 
conducted in this thesis has shown that PKA phosphorylation directs the 
subcellular location of the proteins of DHX9. Conceptually, DHX9 phosphorylation 
by PKA should be “gated” by local PDE4D7 activity, allowing DHX9 to be mainly 
expressed in the nucleus. This interaction promotes DHX9’s helicase activity 
allowing it to unwind RNA secondary structures. This in turn increases R-loop 
formation as explained in Figure 5.20 B. However, disruption of this interaction 
either using our cell permeable peptides or by lowering PDE4D7 expression using 
siRNA, resulted in a significant loss in R-loop detection as well as an increase in 
the level of phosphorylated DHX9. Like AKIP1, PDE4D7 activity can protect DHX9 
phosphorylation and allow DHX9 to remain in the nucleus. PKA phosphorylation 
of DHX9 then leads to the translocation of DHX9 into the cytoplasm, which in 
turn leads to a decrease in its ability to unwind secondary RNA structures in the 
nucleus. Furthermore, phosphorylation of DHX9 could instead promote its 
translational activity. PKA phosphorylation not only promotes the enzymatic 
activity of certain proteins, but can also acts a molecular switch in order to 
promote other protein functions (Shwab et al., 2017). Modification of DHX9 by 
PKA phosphorylation could potentially act as a way of promoting its translational 
activity. Phosphorylation of translation initiation factors can help reduce the 
amount of energy required for this process and provides a rapid way to adapt to 
cellular changes (Pierrat et al., 2007). The majority of mRNA that exists in the 
cell are capped and polyadenylated, which requires unwinding prior to the 
initiation of translation (Marintchev, 2013). To date, the translation initiation 
factor eIF2 is the most well-known helicase to be recruited to these sites in 
order to unwind secondary structures, and failure to do so leads to inefficient 
translation initiation (Murat et al., 2018). DHX9 is emerging as an additional 
helicase that has a role in translation initiation. For example, DHX9 has been 
shown to be required in the efficient translation of Type I collagen by unwinding 
its unique 5’ stem-loop structure. siRNA mediated knockdown of DHX9 led to a 
significant loss in the synthesis of collagen protein, and has since been suggested 
to be an important factor in collagen synthesis in the human body (Manojlovic 
and Stefanovic, 2012). Therefore, the phosphorylation by PKA and loss of PDE4D7 
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could potentially promote DHX9’s translational activity and initiate the 
translation of certain mRNAs.  
6.3 DHX9 is involved in multiple signalling pathways 
Initial ADT treatment has proven to be successful in PC, but it is widely accepted 
that the majority of men treated with either surgical or chemical ADT will 
develop disease progression due to the propagation of androgen-independent PC 
cells (Perlmutter and Lepor, 2007). Increasing evidence has shown that ADT for 
the treatment of PC carries significant health risks and some side effects, which 
is generally tolerated by the men receiving treatment (Fang, Merrick and 
Wallner, 2008). Furthermore, the age at which the men are being treated can 
affect the overall effect of ADT. A retrospective study by Keating et al. (2019) 
has shown that younger patients had no significant difference in overall survival 
between patients receiving active surveillance and ADT (Keating et al., 2019). 
There is currently a need to find alternative therapies that could potentially be 
used in parallel with ADT in order to improve patient outcomes and limit the 
secondary effects associated with this course of treatment.  
Considering the data presented here and that in the literature it could be 
considered that DHX9 has the potential to be an alternate target for the 
treatment of PC. Suppression of DHX9 expression using siRNA resulted in a 
significant decrease in DuCaP growth (Figure 5.2). Work by Lee et al (2014) has 
shown that this significant change in cellular growth rate can be attributed to 
the activation of the p53 apoptotic pathway (Lee et al., 2014). However, using 
RPPA analysis, I was able to show that decreased expression of DHX9 by siRNA 
leads to an increase in p70 S6 Kinase phosphorylation at Thr389 and 4E-BP1 at 
Ser65 (Figure 5.15-17), both of which are known to be part of the mTOR signalling 
pathway. DHX9 has been shown to be recruited by mTOR to regulate the 
expression of specific mRNA (Nandagopal and Roux, 2015), and suppression of 
DHX9 could lead to the accumulation of these untranslated mRNA molecules. 
This in turn could potentially increase cellular stress, which could in turn 
activate pathways that activate cell death (Fulda et al., 2010). These two 
signalling pathways are not mutually exclusive from each other, and research 
has shown that the mTOR and p53 pathways are needed in order to regulate 
their respective pathways. Work by Feng et al (2005) demonstrated that the 
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activation of the p53 pathway leads to an inhibition of the mTOR pathway 
through the activation of AMP kinase (AMPK) (Feng et al., 2005). DHX9 could 
potentially act as protein that bridges these two signalling pathways in order to 
prevent the activation of the p53 pathway. In wild type cells, DHX9 could act as 
a negative regulator of p53 activation, which in turn allows for the activation of 
the mTOR pathway and translation of mRNA. However, when DHX9 is no longer 
expressed at normal levels, this leads to the activation of the p53 pathway and 
the inhibition of mTOR pathway. A potential way this can be studied is by 
looking at the expression of IGF-BP3, PTEN, TSC2, AMPK β1, Sestrin1, and 
Sestrin2. The expression of these proteins are only induced following p53 
activation and directly suppress the mTOR pathway (Feng, 2010). We could 
design an experiment where the expression of these protein changes following 
modulation of DHX9 expression using siRNA. It can by hypothesised that 
expression of IGF-BP3, PTEN, TSC2, AMPK β1, Sestrin1, and Sestrin2 increases 
following siDHX9 treatment due to the activation of the p53 pathway, which in 
turn can negatively regulate the mTOR pathway.  
6.4 Clinical trials involving mTOR and ERK signalling 
pathways 
Since the 1990s, great efforts have been made to increase the detections of 
prostate cancer while at the same time reducing the number of PC related 
deaths (Ahdoot et al., 2019). Although ADT has been the primary treatment of 
early and late-stage PC, patients ultimately progress to CRPC where the cancer 
becomes resistant to ADT. As such, these tumours develop ways to grow, 
decreasing the rate of survival (Ritch and Cookson, 2018). As such, alternative 
targets are currently being investigated in order to overcome these challenges.  
As previously discussed, the PI3K-mTOR signalling pathway is frequently altered 
in PC, facilitating tumour formation, disease progression and therapeutic 
resistance (Shorning et al., 2020). Drugs that target and inhibit the mTOR- PI3K 
activity is expected to therefore provide therapeutic value in a number of 
cancer types, including PC (Don and Zheng, 2011). Recent work by Statz et al 
(2017) evaluated the results of clinical trials investigating mTOR inhibition in 
CRPC, and predicted the clinical outcomes using the preclinical data. A total of 
14 studies were evaluated, all using mTOR inhibitors either as a monotherapy or 
Final Discussion 243 
in combination. Most studies showed that PSA levels declined during treatment, 
but often increased shortly after (Statz, Patterson and Mockus, 2017). 
Furthermore, the use of the mTOR kinase inhibitor voxtalisib showed limited 
clinical efficacy in the treatment of CRPC due to the dose reductions secondary 
to toxicity. Treatment of CRPC patients with this drug resulted in poor mTOR 
and signalling target inhibitions, which in turn led to increased AR Activation and 
PSA expression (Graham et al., 2018). Work by George et al (2020) have also 
shown that the treatment of CRPC with the FDA approved mTOR inhibitor 
Everolimus has no clinical effect on CRPC treatment. Out of 35 men enrolled in 
this phase 2 trial, no changes in PSA levels were observed while patients were 
taking everolimus. Instead, several patients had declines in PSA levels following 
cessation of everolimus treatment (George et al., 2020). Although promising, 
mTOR is still yet to become an effective drug target in PC. Despite mTOR 
inhibitors being used in the treatment of different cancers, such as pancreatic 
and breast cancer (Hua et al., 2019), mTOR inhibitors are yet to be used in the 
treatment of CRPC.  
In addition to the mTOR pathway, the ERK pathway is frequently altered in PC. 
In recent years, an increasing number of clinical trials are being performed on 
ERK inhibitors (Georgi et al., 2014). Recent work by Nickols et al (2019) has 
shown that the ERK pathway may be a viable treatment strategy for patients 
suffering from CRPC. They compared the differential phosphorylation of key 
downstream kinases between metastatic and localised CRPC, as well as the 
expression of mRNA, in order to infer differential ERK activity. From this study, 
32% of patients showed signs of amplified ERK pathway as well as increased 
levels of phosphorylated ERK1/2 when comparing CRPC to untreated primary PC 
(Nickols et al., 2019). Currently, the only approved ERK inhibitor is trametinib, 
which is commonly used for the treatment for metastatic melanoma showing 
favourable safety profile (Georgi et al., 2014). Work by Li et al (2019) has shown 
that inhibition of ERK using trametinib suppresses the growth of enzalutamide-
resistant CRPC (Li et al., 2019). Trametinib is currently in phase 2 clinical trial in 
order to study how this drug can help treat patients suffering from metastatic 
CRPC. Unfortunately, there is no data to date to indicate how efficacious 
trametinib was in treating these patients as the study is due to be completed in 
January 2022 (Retting, 2020).  
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6.5 DHX9 – A new druggable target? 
Although the disruption of the interaction between DHX9 and PDE4D7 using our 
cell permeable disruptor peptide did not lead to any long-term effects on cell 
growth (Figure 5.8-5.10), the YK-4-279 DHX9 inhibitor significantly decreased the 
growth of AS LNCaP cells (Figure 5.6). Disruption of the interaction between 
DHX9-EWS-FLI1 using this compound significantly decreased the growth of LNCaP 
cells, but not in DU145 cells (Figure 5.7). Treatment with YK-4-279 is selective 
for cells expressing the EWS-FL1 fusion protein (Erkizan et al., 2009) which is 
mainly detected in early stages of PC (Gierisch et al., 2016). Interestingly, YK-4-
279 is gaining clinical interest as this small molecule is currently being used in 
early-phase human trials for the treatment of Ewing Sarcoma (ES). Original work 
by Erkizan et al (2009) demonstrated that YK-4-279 was specific for ES due to 
the presence of the of the fusion protein (Erkizan et al., 2009). By using an oral 
formulation of YK-4-276, Lamhamedi-Cherradi et al (2015) were able to use this 
inhibitor in order to slow tumour growth. When murine models of ES were 
administered daily with the oral formulation of YK-4-279, this led to a significant 
delay in ES tumour growth when compared to mice receiving a placebo drug. 
Daily dosing with YK-4-279 was required in order to achieve tumour regression 
and slower growth rates. Interestingly, all 7 mice receiving this oral formulation 
showed no signs of toxicity or weight change, indicating that this drug regiment 
was well tolerated (Lamhamedi-Cherradi et al., 2015).  
Most of the work on YK-4-279 has mainly looked at its use in the treatment of 
Ewing’s Sarcoma and there is growing interest in using this small molecule drug 
in the treatment of other cancers that are known to be driven by ERG fusion 
proteins. Work by Winter et al (2017) showed that mouse xenograft models of 
ERG positive PC patient derived tumours were greatly affected by YK-4-279 
treatment. YK-4-279 was administered subcutaneously to these mice, which 
resulted in the reduction of tumour volume, decreased tumour progression, and 
decreased levels of PSA (Winters et al., 2017). Interestingly, work by Kollareddy 
et al. (2017) showed that YK-4-279 is able to overcome drug resistance in two 
different neuroblastoma cell lines (Kollareddy et al., 2017). Most patients who 
have progressed to the lethal CRPC phenotype have very little treatment options 
due drug resistance and clinical complications (Semenas et al., 2012). YK-4-279 
could be a potential new treatment for patients in the later stages of disease. 
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Due to its ability to only target cells expressing the fusion protein, and its ability 
to overcome drug resistance, YK-4-279 could potentially lead to decrease PC 
metastasis and could be considered as a putative curative treatment.  
6.6 Thesis limitations and future work 
Using a range of biochemical techniques, the work in this thesis has 
demonstrated that DHX9 is a novel interactor of PDE4D7 in PC cells. I was able to 
show that DHX9 binds within PDE4D7’s UCR1 region, and this interaction can be 
disrupted using a competing, custom-made, cell penetrating peptide. Although 
IPs are most commonly used technique in studying PPI, some may argue that this 
technique may force the interaction between two proteins when IPs are 
performed using tagged proteins. Therefore, other methods should have been 
used in order to provide stronger evidence of PDE4D7-DHX9 interaction. One 
such way that we could have studied PDE4D7-DHX9 interaction is through the use 
of Fluorescence Resonance Energy Transfer (FRET) imaging, a method that is 
routinely used in the Baillie lab (Di Benedetto et al., 2008). FRET is a distance-
dependent physical process by which energy is transferred from one fluorophore 
(the donor) to another fluorophore (the acceptor). This technique can measure 
the molecular proximity between two proteins that are within 3-6 nm of each 
other. FRET microscopy is also reliant on the ability to capture fluorescent 
signals from single living cells. If FRET occurs, the donor channel signal will be 
quenched, while the acceptor channel increases. Not only does this technique 
allow the user to visualise colocalization between the donor and acceptor 
labelled probes, but is also allows the user to verify the molecular association 
between two proteins (Sekar and Periasamy, 2003; Rainey and Patterson, 2019). 
Such approaches have already been used to study the interaction between the 
oestrogen receptor and transcription co-activators. Gunther et al (2009) were 
able to design a FRET assay where they were able to monitor ER interaction with 
steroid receptor coactivators. This assay was then used to identify small 
molecules inhibitors to disrupt this interaction (Gunther et al., 2009). Knowing 
that multiple FRET probes are available in the Baillie lab, we could potentially 
create FRET probes in order to study the interaction between PDE4D7 and DHX9 
in live cells. We can then also monitor the dissociation of this interaction 
following peptide treatment. Alternatively, surface plasmon resonance (SPR) 
could be another way to study PPI. SPR is a powerful tool to study PPI and 
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quantify binding affinities. SPR allows the use to investigate PPI without having 
to label the proteins of interest (Nikolovska-Coleska, 2015). SPR depends on the 
binding of a molecule to a bait molecule that is immobilised onto a thin metal 
film. Binding between these two molecules then leads to a change in the 
refractive index. This information can then be used to determine binding 
affinities in order to characterize PPIs (Drescher, Ramakrishnan and Drescher, 
2009). We could potentially immobilize PDE4D7 onto SPR metals film and 
investigate if DHX9 binds directly to it.  
Like in FRET, FP can also be used to find small molecules that can enhance or 
disrupt PPI (Hall et al., 2016). Although I attempted to establish an FP assay to 
study the PDE4D7 and DHX9 interaction, I was unable to unable to obtain 
proteins that were pure enough to obtain any binding information. In vast 
majority of cases, purified recombinant GST tagged proteins can be purified 
from bacterial lysates under non-denaturing conditions by affinity 
chromatography (Smith and Johnson, 1988). Although GST protein purification is 
a technique that is commonly used in the Baillie lab, successful GST protein 
purification relies on optimization of the methods and conditions for each 
protein (Harper and Speicher, 2011). Once the target protein has been cloned in 
the appropriate vectors, the optimization of protein expression conditions, such 
as E.Coli host strain, temperature, IPTG concentration, and length of induction 
should be optimized. (Harper and Speicher, 2011). Unfortunately, due to time 
constraints, I was unable to determine the optimal condition for the purification 
of GST tagged PDE4D-UCR1 or full length DHX9. Although I was able to purify this 
fragment, the eluate was highly degraded and of low yield (Figure 3.16). More 
time should have been invested in order to find the best conditions to purify this 
protein. Perhaps this would have enabled us to establish an FP assay that would 
have allowed me to determine the binding constant between PDE4D7 and DHX9.  
Using peptide array technology, IPs, and PLA technology, I was able to show that 
DHX9 is readily phosphorylated at Ser449. This information was used in order to 
generate a custom antibody which was able to specifically detect phospho-DHX9 
by western blotting and ICC. However, more effort should have been made to 
further validate the newly identified PKA phosphorylation site. Unfortunately, I 
was unable to make a phospho-null DHX9 construct where Ser449 could be 
substituted with an alanine. By substituting this serine with and alanine, we 
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would expect to see a significant decrease in DHX9 phosphorylation in PKA pull 
down assays. This approach has previously been used by Byrne et al (2015) in 
order to validate that Ser42 within the unique N-terminal region of PDE4D7 can 
be PKA phosphorylated. By creating a phospho-null mutant using site directed 
mutagenesis, they were able to demonstrate that the S42A mutant led to an 
ablation of PDE4D7 phosphorylation at this site (Byrne et al., 2015). 
Furthermore, most of the work relating to validating the newly synthesised 
phospho-DHX9 was performed in HEK293 cells. In recent years, HEK293 cell lines 
has been used as a tool to easily express a range of proteins (Chin et al., 2019). 
Ideally, the expression of phospho-DHX9 should have been studied in PC related 
cell lines in order to ensure that this antibody is able to detect phospho-DHX9 in 
disease related cells. The most commonly used cell line for this could be PC3, 
DU145, LNCaP, and VCaP cells (Wu et al., 2013). Additionally, expression of 
phospho-DHX9 and total DHX9 should also be investigated in non-tumour 
prostatic cell lines. These cells are models for normal prostate cell growth, and 
the prostatic intraepithelial neoplasia (PIN) is the most commonly used cell line 
to investigate oncogenic processes prior to disease formation (Cunningham and 
You, 2015). Ideally, the expression of phospho- and total-DHX9 should have been 
investigated in all these cell lines in order to see if expression of phospho-DHX9 
changes during the progression of disease. When phosphorylated, DHX9 is 
sequestered in the cytoplasm (Figure 4.13), suggesting that this PTM not only 
regulates the subcellular location of the helicase but potentially also its cellular 
function. DHX9 is known to be involved in the translation machinery by 
unwinding different RNA structures in the cytoplasm (Lai et al., 2011; Murat et 
al., 2018; Ding et al., 2019). Furthermore, the interaction between PDE4D7 and 
DHX9 was shown to be important in regulating the levels of DHX9 phosphorylated 
by PKA. Loss of this interaction led to an increase in DHX9 phosphorylation under 
basal conditions (Figure 4.15 and Figure 4.16). It would be interesting to 
investigate if the interaction, and phosphorylation of DHX9, is needed to 
promote DHX9’s translational activity. This could be investigated by looking at 
the change in mRNA expression using RNA-Sequencing. RNA sequencing is now a 
commonly used tool to analyse gene expression, allowing the user to identify any 
changes in RNA biogenesis and metabolism (Hrdlickova, Toloue and Tian, 2017).  
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One of the biggest limitations in this thesis is the lack of specificity testing of 
the newly synthesised phospho-DHX9 antibody. Although I was able to detect a 
band at the molecular weight representing DHX9 using this new antibody (Figure 
4.9), By BLASTing the antibody epitope without a phosphorylated serine 
(TQPRRISAVS) (https://blast.ncbi.nlm.nih.gov/) revealed that the epitope can 
be found in other members of the DExD/H helicase family such as DHX36, DHX57, 
and DHX16 (Figure 6.1). However, there is no information addressing whether 
these other isoforms can be phosphorylated by PKA. Interestingly, the BLAST 
sequence revealed that only DHX57 and DHX8 are similar in amino acid length 
when compared to DHX9 (Table 6.1). All other isoforms were less than 1000 
amino acids in length; therefore, we can assume that the band identified in our 
western blots were not these isoforms. 
Table 6.1 Amino Acid length of DHX57, DHX8 and DHX9. 
Protein Length (AA) 
DHX57_HUMAN 1,386 
DHX8_HUMAN 1,220 
DHX9_HUMAN 1,270 
 
 
 
Figure 6.1 BLAST of the phospho-DHX9 epitope. 
In order to confirm that the band seen in the western blots, and the signal 
detected in the ICC experiments, further siRNA experiments should be carried 
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out. Cells could be transfected with siDHX9, or other DExD/helicase isoforms, 
then treated with forskolin-IBMX for 3 minutes. In order to ensure that our new 
phospho-DHX9 antibody is detecting its unique antigen, we would only expect to 
see a decrease in phospho-DHX9 detection only in cells transfected with siDHX9. 
Furthermore, peptide arrays against other members of the DExD/H helicase 
family could have been synthesised and incubated with the phospho-DHX9 
antibody. If this antibody could only specifically detect phosphorylated DHX9, 
we would not expect to see any spots in these other peptide arrays.  
 
In addition to confirming that these two proteins are novel interactors, my thesis 
has also provided some information on how this interaction can influence DHX9’s 
activity. By adapting the R-loop assay from the Hiom lab, I was able to 
demonstrate that the loss of PDE4D7-DHX9 interaction, either by decreasing 
PDE4D7 expression using siRNA or using our newly synthesised disruptor peptide, 
significantly decreased DHX9’s ability to unwind the nascent RNA structure. 
However, for this assay to work correctly, it is reliant on the knockdown of SFPQ 
using siRNA. Unfortunately, theirs is no way of ensuring that the expression of 
this protein is sufficiently decreased before proceeding with ICC staining and 
confocal microscopy. Alternative assay should have been performed in order to 
further determine how PDE4D7 binding can affect DHX9 activity. Previous studies 
by Jain et al (2010) have used helicase assay in order to study DHX9 activity. 
This assay relies on the purification of recombinant DHX9, which is then 
incubated with DNA substrates and ATP. The reaction mix is then run on a DNA 
agarose gel to visualise how DHX9 can displace a strand of DNA (Jain et al., 
2010). Alternatively, other groups have used ATPase assays to study helicase 
activity. DHX9, like other members of the DExD/H helicase family, are ATPase 
dependent helicases and this is has been shown to be important in helicase 
activity (Ng et al., 2018). ATPase assays have been used to characterize the 
helicase activity of UAP56, which is also a member of the DExD/H helicase 
family (Shen, Zhang and Zhao, 2007). ATPase assays rely on the incubation of the 
purified recombinant ATPase proteins with ATP, which in turn leads to the 
release of inorganic phosphate. The amount of phosphate released due to 
ATPase activity can be quantified using a colorimetric assay (Rule, Patrick and 
Sandkvist, 2016). Unfortunately, I was not able to use either of these two 
methods as I was unable to purify DHX9 from bacterial cells. Although I was able 
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to express the N-terminal and helicase fragments of DHX9, these remained stuck 
to the beads (Figure 3.14 D) and therefore not suitable for these assays. Future 
work for this project needs to include the optimization of the purification of 
GST-tagged DHX9. Not only would I be able to use this protein for helicase and 
ATPase assay, but we would be able to study how the interaction between 
PDE4D7 and DHX9 can affect DHX9’s helicase activity. Furthermore, PDE4D7 and 
DHX9 purified protein can be used to further validate PDE4D7-DHX9 interaction 
by performing pure-protein IPs. The information collected from all these assays 
could provide us with invaluable information on how the interaction between 
PDE4D7 and DHX9 is important in the progression of disease.  
6.7 Thesis conclusion 
To conclude, the data presented in this thesis has shown that DHX9 is a novel 
interacting partner for PDE4D7 in vitro. DHX9 binds to PDE4D7 within its UCR1 
domain, while PDE4D7 binding to DHX9 within its helicase domain. This 
interaction can be disrupted using the newly designed cell permeable disruptor 
peptides, which enabled me to confirm where the binding sites were. 
Interestingly, peptide array analysis revealed that DHX9 is readily 
phosphorylated by PKA at Ser449, which can be found upstream of the PDE4D7 
binding sequence. Disruption of the PDE4D7-DHX9 complex leads to the increase 
in the phosphorylation of DHX9 under basal conditions, suggesting that PDE4D7 
plays an important role in regulating the phosphorylation of DHX9. The 
interaction between PDE4D7 and DHX9 was shown to be needed in order to 
unwind nascent RNAs when studied using an R-loop assay. Finally, using RPPA 
analysis, I was able to show that DHX9 is potentially part of the mTOR pathway. 
Research into DHX9, and other DExD/H helicases, is crucial in order to 
understand how this large family of proteins contributes to disease progression. 
My thesis has only scratched the surface on how DHX9 is involved in PC.  
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